Record,Field,User,Datetime,Comment
1,ve_infant_vax_n,cdugdale.mgh.harvard.edu,"2025-07-25 20:26:57","Using this first set of fields for 90 day RSV-MA-LRTI"
1,ve_infant_vax_n_2,cdugdale.mgh.harvard.edu,"2025-07-25 20:30:57","These fields are for 180 day RSV-MA-LRTI"
1,ve_infant_vax_n_3,cdugdale.mgh.harvard.edu,"2025-07-25 20:33:30","These fields are for 90 day hospitalization"
1,ve_infant_vax_n_4,cdugdale.mgh.harvard.edu,"2025-07-25 20:35:03","These fields are for 180 day hospitalization"
1,ve_other_vax_n,cdugdale.mgh.harvard.edu,"2025-07-25 20:29:07","These fields are 240 day RSV-MA-LRTI"
1,ve_other_vax_n,cdugdale.mgh.harvard.edu,"2025-07-25 20:31:27",Updated
1,ve_other_vax_n_2,cdugdale.mgh.harvard.edu,"2025-07-25 20:32:26","These fields are for 360d RSV-MA-LRTI"
1,ve_other_vax_n_3,cdugdale.mgh.harvard.edu,"2025-07-25 20:34:16","These fields are for 360 day hospitalization"
5,domain,scottja.stanford.edu,"2025-07-27 21:53:21","Eric had checked AE and VE but I think the paper only covers VE."
5,nos_cc_4,ulric063,"2025-09-25 20:41:49","changed to no history of disease to align with guidance"
6,nos_coh_1,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 12:23:22","US military service members"
6,nos_coh_5,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 12:23:52","baseline characteristics and SARS-CoV-2 infection in pregnancy"
6,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 12:52:41","also SGA"
8,nos_coh_1,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 12:43:51","pregnant persons, though this sampled those receiving their care at Kaiser Permanente Northern California"
8,nos_coh_5,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 12:44:49","conditional logistic regression adjusting for infant sex, race, ethnicity, maternal age group, trimester of vaccination, comorbidities, BMI"
8,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 12:30:58","also: small for gestational age, stillbirth, placental abruption, congenital defects, preterm birth (< 37 weeks)"
10,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-07-26 15:25:07","propensity score"
10,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-07-26 15:23:25","Propensity score"
10,ae_outcome1_em_type_3,emeyerowit.montefiore.org,"2025-07-26 15:25:22","propensity score"
10,ae_outcome1_em_type_4,emeyerowit.montefiore.org,"2025-07-26 15:26:54","propensity score"
10,ae_outcome1_em_type_5,emeyerowit.montefiore.org,"2025-07-26 15:27:56","propensity score"
10,ae_outcome1_em_type_6,emeyerowit.montefiore.org,"2025-07-26 15:28:48","propensity score"
12,nos_cc_4,ulric063,"2025-09-25 20:44:44","Updated to no history of disease to align with guidance"
16,ae_incidence_yn,emeyerowit.montefiore.org,"2025-07-26 16:39:28","2 cases"
16,ae_incidence_yn_2,emeyerowit.montefiore.org,"2025-07-26 16:40:02","2 cases"
16,ae_incidence_yn_3,emeyerowit.montefiore.org,"2025-07-26 16:40:20","27 cases"
16,ae_incidence_yn_4,emeyerowit.montefiore.org,"2025-07-26 16:40:40","2 cases"
16,ae_incidence_yn_5,emeyerowit.montefiore.org,"2025-07-26 16:41:12","1 case"
16,ae_incidence_yn_6,emeyerowit.montefiore.org,"2025-07-26 16:41:34","1 case"
19,ae_outcome,scottja.stanford.edu,"2025-07-26 18:03:13","Outcome is Large for Gestational Age, but the preset list doesn't include LGA; no free‑text option available."
19,ae_outcome1_em_type,ncmccann.bu.edu,"2025-07-28 13:16:31","The odds ratio refers to comparison between COVID and flu- so not reported for flu vs. no vax."
19,ae_vax_type,ncmccann.bu.edu,"2025-07-28 13:42:53","Influenza vaccines, not specified"
19,domain_ae_include_vax,scottja.stanford.edu,"2025-07-27 20:32:27","unspecified influenza vaccine"
19,domain_ae_num,scottja.stanford.edu,"2025-07-27 20:36:46","The study compared events in the mRNA group to those who received influenza (comparator)."
19,domain_ae_num,ncmccann.bu.edu,"2025-07-28 12:43:54","Because mRNA is not disaggregated, I don't think we can use those results. But we can use the flu vax data"
19,virus,ncmccann.bu.edu,"2025-07-28 13:05:16","This paper collects COVID vax data, but we are excluding it because it does not disaggregate by product."
20,ae_incidence_yn,scottja.stanford.edu,"2025-08-05 01:22:59","This is a case-control study. Counts represent sampled cases and controls, not population-level incidence rates."
20,ae_incidence_yn_v2,scottja.stanford.edu,"2025-08-05 01:24:14","This is a case-control study. Counts represent sampled cases and controls, not population-level incidence rates"
21,nos_coh_1,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 13:02:09","individuals with two successive singleton live-birth pregnancies within integrated health organizations participating in Vaccine Safety Datalink which covers large insured US population"
21,nos_coh_5,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 13:04:28","adjusted for relevant covariates including age, race/ethnicity, behavioral factors, maternal comorbidities, history of adverse perinatal outcomes, timing of conception, calendar year of pregnancy, educational level, etc; adjusted for these in Poisson regression model to estimate RR"
21,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 12:58:18","also: placental abruption, prematurity, SGA"
22,ae_outcome1_em_type,scottja.stanford.edu,"2025-07-26 19:53:11","prevalence ratio"
22,ae_outcome1_em_value,ncmccann.bu.edu,"2025-07-28 14:01:43","Adjusted: 0.91, CI: 0.80-1.04"
22,ae_outcome1_em_value_v2,ncmccann.bu.edu,"2025-07-28 14:11:00","Adjusted: 0.88 (0.65 to 1.21)"
22,ae_outcome1_otherinfo_yn,scottja.stanford.edu,"2025-07-26 19:54:26","organ‑system sub‑analyses"
24,ae_outcome,emeyerowit.montefiore.org,"2025-07-26 20:40:53","Pregnancy loss - composite outcome including spontaneous miscarriage, death in utero, medical termination of pregnancy"
24,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-07-26 20:39:20","82.2% of 938"
24,ae_outcome1_vax_n_v2,emeyerowit.montefiore.org,"2025-07-26 20:41:53","11.6% of 938"
24,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 13:25:55","also: congenital defects, stillbirth, miscarriage"
25,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-07-26 20:53:52","Relative Odds Ratio"
25,domain_ae_include_yn,emeyerowit.montefiore.org,"2025-07-26 20:49:50","Note that the study also reports rates of myocarditis for influenza vaccines"
25,nos_xs_1,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 13:42:07","no structured sampling strategy; the database is basically derived from spontaneous adverse event reports submitted to the WHO pharmacovigilance database, probably subject to reporting bias, underreporting, differential reporting by region, vaccine type, demographic factors, etc."
27,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-07-26 21:17:04","Odds ratio is for spina bifida - other odds ratios are available for some of the other defects"
27,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-07-26 21:16:37","195+2033 = 2228 with defects. (4.1% vax = 91 defects)
1333 + 1360 = 2693 controls. (4.5% vax = 121 controls)"
27,nos_cc_6,ejholmes,"2025-08-29 14:57:49","Data on outcome (BD) medically abstracted and reviewed; Cases/controls are also interviewed (blinded)"
27,nos_cc_6,calba1.mgh.harvard.edu,"2025-09-03 12:54:13","Structured, blinded interview - leaving designation as is since one point is assigned regardless of (a) or (b) selection here"
27,nos_cc_8,ejholmes,"2025-08-29 15:02:45","BD-STEPS response rates reported similar between case-controls via NIH: https://pmc.ncbi.nlm.nih.gov/articles/PMC4537667/#:~:text=The%20birth%20population%20encompassed%20within,or%20after%20January%201%2C%202014."
27,nos_cc_8,calba1.mgh.harvard.edu,"2025-09-03 12:56:31","Unable to determine exposure for 4/210 cases (1.9%) and 112/1538 controls (7.2%)."
29,nos_coh_2,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 14:29:31","there was no comparator group?"
29,rob_outcome_epi,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 14:26:16","the study examined prevalence of post-acute sequelae of COVID after infection during pregnancy; ""seroprevalence"" is the closest term to prevalence that I found here"
30,ae_outcome1_otherinfo_yn,cdugdale.mgh.harvard.edu,"2025-07-26 20:29:02","Weighted HR: 0.83 (0.47-1.47)"
30,ae_outcome1_otherinfo_yn_2,cdugdale.mgh.harvard.edu,"2025-07-25 21:23:41","Weighted HR: 0.61 (0.50, 0.74)"
30,ae_outcome1_otherinfo_yn_3,cdugdale.mgh.harvard.edu,"2025-07-25 21:25:41","Weighted HR: 0.99 (0.76, 1.30)"
30,ae_outcome1_unvax_n,cdugdale.mgh.harvard.edu,"2025-07-26 20:28:02","Back calculated based on data in Table 2 on cumulative incidence and # events"
30,ae_outcome1_unvax_y_2,cdugdale.mgh.harvard.edu,"2025-07-25 21:23:02","Calculated from % in Table 2"
30,ae_outcome1_vax_n,cdugdale.mgh.harvard.edu,"2025-07-26 20:27:49","Back calculated based on data in Table 2 on cumulative incidence and # events"
30,ae_outcome1_vax_yes_2,cdugdale.mgh.harvard.edu,"2025-07-25 21:22:32","Calculated from % in table 2"
31,ae_outcome1_otherinfo_yn_2,cdugdale.mgh.harvard.edu,"2025-07-26 20:11:59","Weighted HR: 0.61 (0.50, 0.74)"
31,ae_outcome1_otherinfo_yn_3,cdugdale.mgh.harvard.edu,"2025-07-26 20:13:02","Weighted HR: 0.99 (0.76, 1.30)"
31,ae_outcome1_unvax_y_2,cdugdale.mgh.harvard.edu,"2025-07-26 20:11:32","Calculated from % in Table 2"
31,ae_outcome1_vax_yes_2,cdugdale.mgh.harvard.edu,"2025-07-26 20:11:12","Calculated from % in table 2"
32,ae_outcome1_em_type,scottja.stanford.edu,"2025-07-26 23:42:21","prevalence ratio"
32,domain_ae_num,scottja.stanford.edu,"2025-07-26 23:33:53","Study includes both BNT162b2 and mRNA‑1273, but primary safety analysis 
pools the two brands (no separate counts vs unvaccinated)."
33,ae_outcome1_em_type,scottja.stanford.edu,"2025-07-27 01:21:44","they compared to background rates"
33,ae_outcome1_em_value,scottja.stanford.edu,"2025-07-27 01:25:07","Registry prevalence of any major structural birth defect: 3.8 % (750/19 931 live births). Authors compare to pre-pandemic baseline;
no internal unvaccinated comparator; therefore no ratio entered."
33,ae_outcome1_otherinfo_yn,scottja.stanford.edu,"2025-07-27 01:26:05","Tthey stratified by < 14 vs >= 14 weeks vaccination"
33,domain_ae_num,scottja.stanford.edu,"2025-07-27 01:10:25","Pfizer‑BioNTech, Moderna, and Janssen - but products are pooled."
34,ae_incidence_yn,cdugdale.mgh.harvard.edu,"2025-07-25 21:06:08","Cannot calculate overall incidence from case-control design."
34,ae_incidence_yn_v2,cdugdale.mgh.harvard.edu,"2025-07-25 21:05:30","Cannot calculate overall incidence from a case-control study design."
34,ae_outcome,cdugdale.mgh.harvard.edu,"2025-07-25 20:54:47","Miscarriage/spontaneous abortion"
34,ae_outcome1_em_value,cdugdale.mgh.harvard.edu,"2025-07-25 21:01:46","Also has aOR: 0.97 (0.57-1.66)"
34,ae_outcome1_otherinfo_yn,cdugdale.mgh.harvard.edu,"2025-07-25 21:02:16","aOR 0.97 (0.57-1.66)"
34,ae_outcome1_otherinfo_yn_v2,cdugdale.mgh.harvard.edu,"2025-07-25 21:05:12","Crude OR: 0.69 (0.37-1.31)
aOR: 0.59 (0.29-1.19)"
34,date_end_month,cdugdale.mgh.harvard.edu,"2025-07-25 20:52:59","Exact month chosen based on spontaneous abortion dates rather than LMP"
34,nos_cc_8,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 14:10:56","Not explicitly described but it draws all cases and controls from electronic health records"
34,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 14:01:09","cases identified as those with spontaneous abortions"
35,ae_outcome1_disagg,scottja.stanford.edu,"2025-07-27 01:53:31","While the study disaggregates outcomes by age groups and also disaggregates by vaccine type (Pfizer/mRNA vs. AstraZeneca/viral-vector), it does not explicitly provide a table or specific numerical results for the Pfizer (BNT162b2) vaccine's outcomes further disaggregated by age group in the main text or figures."
35,ae_outcome1_otherinfo_yn,scottja.stanford.edu,"2025-07-27 01:51:44","The study further classified preterm birth into ""extremely and very preterm (24-31 wks)"" and ""moderate to late preterm (32-36 wks)"
35,domain_ae_num,scottja.stanford.edu,"2025-07-27 01:39:33","The study included data on ChAdOx1-S and BNT162b2; since we're not reviewing ChAdOx1-S data, I selected ""1"" product to only extract data for the BNT162b2 vaccine."
35,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 13:51:06","also: SGA, stillbirth; venous thromboembolism as well though this is not listed as an adverse event of interest in RedCap"
38,rob2_result1,nebasta,"2025-09-05 21:23:15","Authors called this a ""post-hoc exploratory analysis"""
38,ve_outcome_prime,stodd046,"2025-07-28 18:13:33","Should this be medically-attended infection instead of other?"
38,ve_overall_em,harleen.k.marwah.gmail.com,"2025-07-26 23:09:51","The cumulative incidence of RSV infections from swabs collected due to suspected LRTI was lower with nirsevimab versus placebo at day 151 (Δ −5.6; Figure 1A); this difference increased slightly at day 361 (Δ −5.9) and day 511 (Δ −6.4)."
39,ae_outcome1_vax_y,emeyerowit.montefiore.org,"2025-08-04 21:35:23","Note 1 ""cardiac disorder"" noted in part 2 group in supplement, but they say 0 cases of myocarditis identified in the study overall so must have been deemed to not be myocarditis"
39,ae_vax_type,emeyerowit.montefiore.org,"2025-08-04 21:34:41","technically mRNA-1273.214 vaccine which was for BA1 variant"
39,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-07-26 23:45:17",mRNA-1273.214
40,rob_reviewer1,ulric063,"2025-09-27 07:30:13","Automatically marked as high risk based on no comparator"
41,rob2_interv2,ulric063,"2025-09-19 16:52:21","Single blind study - no specific information regarding who was unblinded"
41,rob2_interv6,ulric063,"2025-09-19 16:54:20","""All the subjects who were administered the vaccine were considered for the safety evaluation."" Each of the two study arms received vaccine."
43,rob_screen2,nebasta,"2025-09-05 22:22:18","randomized phase I trial"
43,rob2_interv6,nebasta,"2025-09-05 22:27:23","Guidance indicates: ""nd 'as treated' analyses (in which trial participants are grouped according to the intervention that they received, rather than according to their assigned intervention) should be considered inappropriate."" Study reports ""Safety analyses were conducted using the as-treated population, which included all randomized participants who received nirsevimab or placebo; participants were analyzed based on the actual treatment received."""
43,rob2_random3,nebasta,"2025-09-05 22:24:01","sample size is very small (n=24), so some imbalance even with randomization"
44,rob2_msmt3,nebasta,"2025-09-06 11:29:55","Since the outcome is hospitalization and the authors state that the treating physicians weren't aware of assignment, selecting no here"
44,ve_maternalvax,emeyerowit.montefiore.org,"2025-07-27 08:30:02","Ended Feb 2023, likely before maternal RSV vaccination available"
45,rob_domain_aensi_other,nebasta,"2025-09-06 11:45:25","Table 5 lists all solicited AEs, picked one of many for this assessment"
45,rob2_interv6,nebasta,"2025-09-06 11:47:44","per protocol analysis, but only 1 participant not administered as randomly assigned and 1 LTFU"
45,rob2_interv8,nebasta,"2025-09-06 11:49:38","guidance suggests ""some concerns"" given pattern of responses, but does not seem warranted given small number of participants affected by analysis choices (2)"
45,rob2_msmt1,nebasta,"2025-09-06 11:50:03","solicited AEs, parental report"
46,rob2_interv6,nebasta,"2025-09-06 12:03:33","figure 1, safety row"
47,rob2_interv6,nebasta,"2025-09-06 12:19:10","analysis included ""safety analysis set"""
47,rob2_random3,nebasta,"2025-09-06 12:17:18","Table 1 columns 1 and 2 is for the ""per protocol set"" not the ""safety analysis set"" - there are no concerning imbalances here, but no direct comparison specific to the safety analysis set"
49,rob_screen1,moat0011,"2025-09-03 13:40:39","pre-N vs post-N"
49,rob_screen2,moat0011,"2025-09-03 14:08:14","Compares demographic/clinical/microbio data across comparison groups, but does not adjust/control for these variables. Stat. analysis is chi-squared and Mann-Whitney U test which don't inherently control for confounding. Eligibility also not restricted."
49,ve_comparator1,emeyerowit.montefiore.org,"2025-07-27 09:10:40","6.6% of all in pre-N seasons received palivizumab (vast majority unimmunized)"
49,ve_overall_unvax_n,emeyerowit.montefiore.org,"2025-07-27 09:21:02","377 RSV PICU admissions pre N * 100/9 = 4189 total PICU admissions"
49,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-07-27 09:20:22","31 RSV PICU admissions post N *100/4.3 = 721 total admissions"
50,epi_ifr_covid,emeyerowit.montefiore.org,"2025-07-27 09:28:13","In hospital mortality"
50,epi_ifr_flu,emeyerowit.montefiore.org,"2025-07-27 09:30:32","In hospital mortality"
50,epi_ifr_rsv,emeyerowit.montefiore.org,"2025-07-27 09:29:40","in hospital mortality"
50,nos_coh_2,nebasta,"2025-09-03 21:04:47","This study is comparing outcomes among children hospitalized with RSV to those hospitalized with COVID-19 and to those hospitalized with flu. With this design, there is not technically a ""non-exposed cohort"", though one could consider the COVID-19 and influenza patients ""non-exposed"" to RSV"
50,nos_coh_2,nebasta,"2025-09-03 21:11:07","Either way, it is not possible to determine if the non-RSV cohorts are ""drawn from the same community"" without knowing the epidemiology of these pathogens in this region. Results suggest the cohorts are drawn from entirely different populations."
50,nos_coh_4,nebasta,"2025-09-03 21:05:58","The outcome of interest is the clinical outcomes. I considered (ICU) admission the primary outcome."
51,ve_overall_em,emeyerowit.montefiore.org,"2025-07-27 09:40:33","Also has VE of 82.0%, 95% CI 655.6-90.2%"
52,ve_infant_em,emeyerowit.montefiore.org,"2025-07-27 09:55:14","Data is disaggregated by follow up month (time since N immunization) not by age group of interest in Table 3"
53,rob_outcome_ae,ejholmes,"2025-08-29 15:45:42","Multiple AEs studied; Most reported are reactogenicity (fever, fatigue, tenderness, etc)"
53,rob_screen1,nebasta,"2025-09-03 21:23:46","This is a follow up cohort of KIDCOVE trial participants who received an optional booster. Th AEs are reported for those who received the booster in descriptive analyses. There is no comparison group."
54,rob_screen2,nebasta,"2025-09-03 21:32:06","Described as an ecological analysis, no attempt to control for confounding."
55,date_start_month,harleen.k.marwah.gmail.com,"2025-08-12 10:40:28","out of date range"
55,epi_hospitalization_rsv,emeyerowit.montefiore.org,"2025-07-27 17:30:15","Of total cohort"
57,nos_cc_3,stodd046,"2025-09-03 14:57:56","Our study included all infants aged 12 months or younger who attended the paediatric emergency department between Oct 14, 2023, and Feb 29, 2024, and
whose nirsevimab status was known. Those without bronchiolitis or upper
respiratory tract infections were classed as controls."
57,nos_cc_3,calba1.mgh.harvard.edu,"2025-09-05 11:56:28","Anyone from community could present to ED so treating as community controls - not selected from a hospitalized population. Discussed with Clare Stoddart and Nicole Basta on 9/4 via email."
57,nos_cc_8,stodd046,"2025-09-03 15:11:22","response rate not described"
57,rob_outcome_ve,stodd046,"2025-09-03 14:35:39","effectiveness of nirsevimab against paediatric emergency department visits for all-cause bronchiolitis during the 2023-24 RSV season"
58,nos_xs_1,ejholmes,"2025-09-02 12:29:41","20% of 1 Australian state (seeking med care)"
58,nos_xs_2,ejholmes,"2025-09-02 12:33:00","ideal sample size not mentioned; ; 28% response rate"
58,nos_xs_3,ejholmes,"2025-09-02 12:33:58","parent self-report, no validation (eg med record)"
59,domain,harleen.k.marwah.gmail.com,"2025-08-01 10:07:50","""Safety and infectious outcomes in pediatric kidney transplant  recipients"" - Described as safety, though also looks at VE for this population (not within our VE date window, however)"
59,population_disagg,harleen.k.marwah.gmail.com,"2025-08-01 10:10:14","Per patient"
59,rob_reviewer1,ulric063,"2025-09-27 07:55:08","Marked as no control for confounding and subsequently high risk"
61,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 15:05:10","also: ITP, GBS"
62,nos_coh_6,calba1.mgh.harvard.edu,"2025-09-05 12:21:49","I think independent blind assessment is more appropriate as the neonatologist and study nurses were ""blinded to any interventions or complications experienced during the initial NICU stay"" and used the ""same equipment and instruments...for all assessments"", not ICD linkage - actually measured at study visit. Not changing given A and B both assign 1 point anyway."
62,ve_outcome_prime_other,emeyerowit.montefiore.org,"2025-07-27 20:09:34","Bronchitis episodes as reported in follow-up parental questionnaire regarding the last 12 months before 5-6-year follow-up examination."
62,ve_overall_vax_y,emeyerowit.montefiore.org,"2025-07-27 20:08:45","Calculated from data on page 12, section 3.5"
66,nos_xs_3,nebasta,"2025-09-05 23:31:28","""For this analysis, a case of IAE was defined as the marking of the encephalopathy or encephalitis checkbox on the case report form"""
70,rob_screen1,nebasta,"2025-09-27 21:05:45","58 patients with cancer, all vaccinated, % of AEs reported, no comparator group, no control of confounding in assessment of AEs)"
72,nos_cc_4,ulric063,"2025-09-25 20:49:09","Updating to no history of disease to align with guidance"
72,nos_cc_5,moat0011,"2025-09-03 13:29:12","We used conditional lo-
gistic regression models to estimate conditional odds ratios for influenza
positivity by vaccination status, adjusting for age (quadratic term), sex,
prior year's vaccination status and the presence of underlying medical
conditions, matched by two-week periods of calendar time."
72,nos_cc_6,moat0011,"2025-09-03 13:31:41",". Information on
influenza vaccination status was collected by interviewing parents or
legal guardians using a standard questionnaire, and cross-checking re-
sponses with medical records."
73,ae_outcome1_vax_y,ncmccann.bu.edu,"2025-07-27 21:43:34","this is less than 6"
74,nos_cc_4,ulric063,"2025-09-25 20:50:44","Updated to 'no history of disease' to align with guidance"
75,rob_screen2,nebasta,"2025-09-07 20:01:40","Study was not randomized (participants were enrolled and all given the same intervention, divided by past flu vaccine history and then the two groups defined by past vaccination were compared. AEs were reported descriptively."
78,nos_xs_2,ejholmes,"2025-09-02 15:39:24","Ideal sample size not described"
78,nos_xs_3,ejholmes,"2025-09-02 15:40:23","Self-report without independent validation"
79,nos_cc_2,stodd046,"2025-09-03 14:28:48","There are quite a few factors associated with the authors' third group: unknown vax status"
79,nos_cc_2,calba1.mgh.harvard.edu,"2025-09-07 15:40:49","Unknown vax status is in regards to exposure not cases and controls. Discussed with CS to switch to representative series."
79,nos_cc_4,stodd046,"2025-09-03 14:26:19","authors control for history of bronch. but these patients are still included "
79,nos_cc_6,calba1.mgh.harvard.edu,"2025-09-07 15:42:53","Large unknown vaccination status cohort which was imputed (further described in appendix). In the guidance, it says to select c or d if ""some participants may have been categorized as vaccinated even though they were not or vice versa"" which applies in this case. They did perform a complete-case sensitivity analysis using only the 531 infants with known nirsevimab status and claim they found ""similar results for the primary outcome."" However, the extracted VE estimate is from the imputed population (n = 739) from Figure 2, so I think our ROB assessment should reflect the imputed approach."
79,rob_outcome_ve,stodd046,"2025-09-03 14:11:08","Hospitalization after ED visits"
79,ve_infant_em_adj,calba1.mgh.harvard.edu,"2025-07-29 20:40:51","(adjusted VE 95%CI: 34.1-67.3)"
80,rob_screen1,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 15:30:28","considered the comparator group to be the patients themselves given comparison of relapse rates pre- and post-vaccination"
80,rob_type,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 15:34:29","the study is described as a retrospective cohort study rather than case series, which I agreed with"
81,nos_cc_4,stodd046,"2025-09-03 14:01:50","test negative design- controls are the negatives"
81,population_premature,emeyerowit.montefiore.org,"2025-07-28 15:21:50","Among the 1286 children included aged < 2 years"
81,ve_infant_em_adj,emeyerowit.montefiore.org,"2025-07-28 15:29:48","CI 79-94"
81,ve_infant_em_ci,emeyerowit.montefiore.org,"2025-07-28 15:29:34",unadjusted
81,ve_infant_vax_n,emeyerowit.montefiore.org,"2025-07-28 15:28:47","supplementary table eTable 8"
81,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-07-28 15:31:53","CI 79-94"
81,ve_overall_em_adj_2,emeyerowit.montefiore.org,"2025-07-28 15:32:38","CI 82-97"
81,ve_overall_em_ci,emeyerowit.montefiore.org,"2025-07-28 15:31:44",unadjusted
81,ve_overall_em_ci_2,emeyerowit.montefiore.org,"2025-07-28 15:32:29",unadjusted
81,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-07-28 15:32:54","Data in supplementary table eTable 8"
82,domain_ae_include_list,harleen.k.marwah.gmail.com,"2025-07-29 18:47:23","4 common post-vaccination symptom categories such as local, general, musculoskeletal symptoms and fever"
83,nos_cc_3,stodd046,"2025-09-03 13:19:19","controls born in the same hospital network but not hospitalized for illness during the study period"
83,population_premature,harleen.k.marwah.gmail.com,"2025-07-28 16:40:31","Calculated from Table 1A"
83,population_premature,ncmccann.bu.edu,"2025-07-29 20:25:51","Confirmed calculation"
83,ve_em_type,ncmccann.bu.edu,"2025-07-30 07:49:37","They don't explicitly state their definition, it seems most likely 1-OR * 100 since they used logistic regression (which typically produces odds ratios unless otherwise specified), but since they don't state it, leave as ""other."""
83,ve_overall_em,harleen.k.marwah.gmail.com,"2025-07-28 16:51:26","Pragmatic estimates of effectiveness (95% CI) were obtained from conditional logistic models based on the actual immunisation status at  the matching date and adjusting for sex, gestational age, birth weight, multiple pregnancy, previous non-RSV hospitalisation, and previous  comorbidities up to that date. Analyses were based on cases and controls with complete covariate information"
83,ve_overall_em,ncmccann.bu.edu,"2025-07-30 07:47:52","Given that they used a logistic regression I would guess this is adjusted, (1-OR)*100, but they don't explicitly state that, so leaving as ""other""."
83,ve_overall_vax_n,harleen.k.marwah.gmail.com,"2025-07-28 16:50:43","Calculated looking at table 2"
85,rob_screen2,stodd046,"2025-08-28 16:05:50","The primary outcome of the paper was nirsimivab acceptance (for which they controlled for confounders with MV regression) but that is outside of our scope. The primary outcome I'm assessing is AEs for which I did not see strong evidence of confounder control."
86,ve_overall_em,harleen.k.marwah.gmail.com,"2025-07-28 17:32:48","for at birth immunization"
86,ve_overall_vax_n,harleen.k.marwah.gmail.com,"2025-07-28 17:29:47","# of hospitalized RSV cases"
86,ve_overall_vax_y,harleen.k.marwah.gmail.com,"2025-07-28 17:30:14","# vaccinated (calculated from %'s in Table)"
87,epi_sample_rsv,emeyerowit.montefiore.org,"2025-07-29 06:34:28","Total RSV hospitalizations during study period"
87,nos_coh_1,stodd046,"2025-08-29 12:48:52","Authors do not actually confirm whether the hospitalized individuals in the subgroups from both time cohorts received immunization: 
Hospitalization rates for three groups with varying eligibility for RSV prevention products were analyzed: 1) infants aged 0-7 months eligible for protection through maternal RSV vaccine or nirsevimab, overall and in prespecified subgroups of infants aged 0-2 months, who are at highest risk for
RSV-associated hospitalization (1) and infants aged 3-7 months; 2) children aged 8-19 months entering their second RSV season,
some of whom might have been nirsevimab-eligible based on risk conditions; and 3) children aged 20-59 months, who were ineligible for either product."
87,nos_coh_1,stodd046,"2025-08-29 12:50:41","The two cohorts they use cover a lot of ground, especially RSV-NET 
RSV-NET: 300 hospitals in 161 counties
across 13 states
NVSN - seven U.S. medical centers"
87,nos_coh_2,stodd046,"2025-08-29 12:56:11","All three groups are drawn from the same surveillance networks"
87,nos_coh_3,stodd046,"2025-08-29 13:11:35","dates from the hospital records"
87,nos_coh_4,stodd046,"2025-08-29 13:13:53","Patients could have already been hospitalized when they tested positive for RSV: ""RSV-associated hospitalizations are defined as those among persons who have received a positive RSV reverse transcription-polymerase chain reaction
(RT-PCR) or rapid antigen detection test result ≤14 days before or after hospital admission."""
87,nos_coh_5,stodd046,"2025-08-29 13:17:14","RSV-NET rates were adjusted to account for RSV underdetection related to testing practices and test sensitivity using an established multiplier approach. NVSN rates were adjusted for enrollment rates, weeks with < 7 surveillance days, test sensitivity, and hospital market share"
87,nos_xs_1,stodd046,"2025-08-31 16:44:30","The two cohorts they use cover a lot of ground, especially RSV-NET
RSV-NET: 300 hospitals in 161 counties
across 13 states
NVSN - seven U.S. medical centers

But authors do not actually confirm whether the hospitalized individuals in the subgroups from both time cohorts received immunization."
87,nos_xs_2,stodd046,"2025-08-31 16:46:54","Overall, 18,389 RSV-associated hospitalizations (15,405 in RSV-NET and 2,984 in NVSN) were identified among children aged < 5 years; these included 11,681 during 2018-20 and 6,708 during 2024-25."
87,nos_xs_3,stodd046,"2025-08-31 16:49:20","RT-PCR confirmed RSV infection among hospitalized patients"
87,rob_type,stodd046,"2025-08-29 12:40:00","From active surveillance networks (RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN)), authors form 3 subgroups of patients to compare hospitalization rates from 2 different time points - 2018-20 and 2024-25 seasons. "
88,ve_infant_unvax_y,ncmccann.bu.edu,"2025-07-30 09:14:37","Conversely, in the control group, we observed 10 hospital emer-
gency visits, 34 hospital admissions and 14 ICU admissions"
88,ve_infant_vax_y,ncmccann.bu.edu,"2025-07-30 09:14:11","""Among infants immunized with nirsevimab, there were 56 
hospital emergency visits for RSV-associated bronchiolitis, 109 
hospital admissions and 25 ICU admissions"
89,date_start_month,emeyerowit.montefiore.org,"2025-07-29 06:53:59","Non-continuous study period."
89,nos_coh_1,stodd046,"2025-09-02 17:12:26","exposed and unexposed cohorts are comprised of children under 24 months who attended the ED in 6 different study locations. Exposed is after nirsimivab introduction and unexposed is the time before introduction."
89,nos_coh_5,stodd046,"2025-09-02 17:18:22","stratified by age"
89,nos_coh_7,stodd046,"2025-09-02 17:22:13","Since we dont know when or if the participants received nirsimivab, we don't know whether f/u time was sufficient"
89,nos_xs_2,stodd046,"2025-09-02 17:28:19","large data sets pulled from ED visits and admissions at 6 different sites"
89,nos_xs_3,stodd046,"2025-09-02 17:28:59","Diagnosis codes, which allows for some variability"
89,rob_outcome_ve,stodd046,"2025-09-02 16:55:42","Emergency department attendances and admissions"
89,rob_screen2,stodd046,"2025-09-02 17:02:21","Authors stratified results by age groups"
89,rob_type,stodd046,"2025-09-02 17:25:51","Authors describe this study as a cohort but it is really just surveillance data with no individual level factors matched (besides age and hospital of admission) and no exposure confirmation"
89,ve_child_vax_n,ncmccann.bu.edu,"2025-07-30 09:32:53","summed the 2 older age groups"
92,population,ncmccann.bu.edu,"2025-07-30 12:00:29","< 21 years"
94,nos_coh_6,moat0011,"2025-09-03 15:42:03","Influenza/ILI episodes were identified using an artificial intelligence-
driven algorithm. This algorithm incorporated both structured clinical
diagnoses (ICD-9-CM codes: 487, 487.0, 487.1, 487.8) and unstructured
free text from medical charts. A custom-developed and validated Natural
Language Processing (NLP) algorithm, trained on a comprehensive,
gold-standard labeled dataset, was employed to ensure accurate case
identification within our study population. The algorithm demonstrated
excellent performance, achieving an accuracy of approximately 99 %"
94,ve_child_em_adj,emeyerowit.montefiore.org,"2025-07-29 14:46:12","Adjusted for sex, age at the start of each influenza season, Italian region of birth, deprivation index, comorbidities, and influenza vaccination status, number of influenza/ILI episodes, antibiotic therapies, and primary care visits in the preceding season of interest"
94,ve_child_em_adj_v2,emeyerowit.montefiore.org,"2025-07-29 14:48:47","adjusted in same way as before"
94,ve_child_em_ci,emeyerowit.montefiore.org,"2025-07-29 14:45:10",adjusted
94,ve_child_em_ci_v2,emeyerowit.montefiore.org,"2025-07-29 14:48:51",adjusted
95,population,emeyerowit.montefiore.org,"2025-07-30 08:59:41","Note according to Table 6, 28/32 are < 6 months"
95,ve_infant_vax_n,emeyerowit.montefiore.org,"2025-07-30 09:05:03","Table 6 - total number cases < 6 months"
95,ve_maternalvax,emeyerowit.montefiore.org,"2025-07-30 08:45:49","Note from page 2: "" It is important to note that a maternal immunisation programme against RSV had not yet been implemented in Spain at the time of this study"""
95,ve_overall_unvax_n,emeyerowit.montefiore.org,"2025-07-30 09:04:25","Table 6 - total controls"
95,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-07-30 08:57:36","Table 6 - total number cases"
97,rob2_msmt2,nebasta,"2025-09-07 20:49:14","participants knew their intervention group and their past vaccination status, such knowledge could affect reporting of AEs"
97,rob2_random3,nebasta,"2025-09-07 20:47:06","group 3 mean age is higher (prior vaccination group)"
97,rob2_result4,nebasta,"2025-09-07 20:51:34","Some concerns based on no information regarding analysis plan/unblinded trial"
98,nos_cc_4,ulric063,"2025-09-25 21:08:24","Updating to 'no history of disease' to align with guidance"
98,nos_cc_5,moat0011,"2025-09-03 14:54:33","E was adjusted for sex, age, comorbidity, area,
month of onset, and diagnostic methods, as analyzed previously ["
98,nos_cc_6,moat0011,"2025-09-03 14:54:48","To
determine vaccine status, we queried guardians and/or confirmed using
the Maternal and Child Health Handbook provided by local govern-
ments"
98,nos_cc_8,moat0011,"2025-09-03 14:56:06","For statistical analysis, 52 cases were excluded from further adjusted
analysis: 39 had received their first dose of the vaccine within 2 weeks
prior to onset, and 13 had unknown immunization status."
99,nos_cc_2,ulric063,"2025-09-08 16:26:23","Children immunized with only one dose within 2 weeks before onset were excluded.  Children who had taken anti-influenza drugs before the visit were excluded."
99,nos_cc_4,ulric063,"2025-09-25 21:10:58","Updating to 'no history of disease' to align with guidance"
99,ve_vax_type,emeyerowit.montefiore.org,"2025-07-30 09:22:05","Note 16 received LAIV, but were excluded from analysis"
100,nos_coh_4,flemi644,"2025-09-03 17:10:10","paper does not state myocarditis/pericarditis were ruled out at baseline"
100,nos_coh_8,flemi644,"2025-09-03 17:12:34","Low survey completion rate. non-response may bias follow-up"
101,nos_cc_5,flemi644,"2025-08-28 12:39:18","Adjusted models; key confounders include age and comorbidity burden.

Sex, race/ethnicity, BMI, prior documented infection, health-care utilization, influenza vaccination, etc"
101,ve_child_vax_n,emeyerowit.montefiore.org,"2025-07-30 10:46:55","Use supplementary figure 1 for next sections"
101,ve_overall_vax_n_2,emeyerowit.montefiore.org,"2025-07-30 10:37:24","Includes hospitalization and ED/urgent care visits"
101,ve_overall_vax_n_2_v2_v3,emeyerowit.montefiore.org,"2025-07-30 10:46:30","Calculated from supplementary Figure 1"
101,ve_vax_type,emeyerowit.montefiore.org,"2025-07-30 10:39:35","For ages 5-11"
102,author,emeyerowit.montefiore.org,"2025-07-30 11:35:48","Note - article in COVIDENCE is wrong. Need to pull it up either in Zotero or online from CID"
102,nos_cc_5,flemi644,"2025-08-29 11:07:36","notable that underlying conditions were captured but not included in the primary adjustment set"
102,ve_adult_vax_n_3,emeyerowit.montefiore.org,"2025-07-30 11:33:56","Note this is for ages >/= to 18. Not disaggregated by age >65"
103,ae_incidence_yn,harleen.k.marwah.gmail.com,"2025-07-28 17:45:49","Provides information on number of myocarditis cases w/ COVID vaccine but not otherwise in the population. ""Among 168 confirmed cases, 73 (43%) were COVID-19 mRNA vaccine-proximate cases, 47 (28%) were remotely vaccinated, 39 (23%) were unvaccinated, and 9 (5%) had unknown vaccination status"""
103,ae_vax_type,harleen.k.marwah.gmail.com,"2025-07-28 17:43:57","""mRNA COVID vaccines"""
103,nos_coh_1,flemi644,"2025-08-29 11:25:40","cases only at tertiary pediatric IMPACT centers (not population-based), so vaccinated ""cohort"" members seeking non-tertiary/outpatient care are underrepresented."
103,nos_xs_1,flemi644,"2025-08-29 11:38:48","ascertainment of hospitalized/ED cases, but the network is not population-based, potentially biasing toward more severe presentations; milder outpatient cases are not captured"
103,nos_xs_2,flemi644,"2025-08-29 11:54:13","prospective surveillance with descriptive analyses and no hypothesis testing/power statement reported (captured all eligible cases over the period)"
104,date_start_month,emeyerowit.montefiore.org,"2025-07-29 15:55:51","Included RSV seasons 2019, 2022, and 2024 (non-continuous study period)"
104,nos_coh_5,flemi644,"2025-08-29 12:06:58","Note: No clear adjustment for socio-economic/health-care-seeking proxies"
104,ve_outcome_prime_txt,emeyerowit.montefiore.org,"2025-07-29 16:07:38","In Supplementary Table 5"
104,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-07-29 16:13:48","""The effectiveness of nirsevimab was estimated using the stratified Cox proportional hazards model with time-variant covariates, including age, sex, wga, region and rurality in the stratification"""
105,date_end_month,emeyerowit.montefiore.org,"2025-07-30 12:59:26","day 56"
105,rob_screen2,flemi644,"2025-08-29 12:32:54","A bit on the fence, the only comparator was patients who had not previously received an Influenza vaccination, but all AE subjects received at least one vaccination."
105,rob2_data1,flemi644,"2025-08-29 12:43:58","all 240 received ≥1 dose and were in the safety analysis), but diary completeness not quantified"
105,rob2_interv1,flemi644,"2025-08-29 12:38:51","open-label; self-report"
105,rob2_interv6,flemi644,"2025-08-29 12:40:20","included all vaccinated participants"
105,rob2_msmt5,flemi644,"2025-08-29 12:46:39","subjective pain"
105,rob2_random1,flemi644,"2025-08-29 12:37:18","Non-randomized; participants were grouped by prior vaccination history, and all received IIV4"
105,rob2_random2,flemi644,"2025-08-29 12:37:43","Open-label, non-randomized"
105,rob2_random4,ulric063,"2025-09-20 12:40:38","This was a non-randomized Phase IV study"
105,rob2_result2,flemi644,"2025-08-29 12:57:05","pre-specified solicited local AE set"
106,domain,harleen.k.marwah.gmail.com,"2025-08-01 09:41:11","VE on long COVID"
106,nos_coh_1,flemi644,"2025-08-29 13:23:49","academic pediatric network across many U.S. centers"
106,ve_em_type,harleen.k.marwah.gmail.com,"2025-08-01 09:44:28","effectiveness was reported as (1-relative risk)*100 and mediating effects were reported as relative risks"
106,ve_overall_em,harleen.k.marwah.gmail.com,"2025-08-01 09:48:53","During the Delta variant phase, the BNT162b2 vaccine exhibited an estimated overall vaccine effectiveness against long COVID of 95.4% (95% CI: 90.9%-97.7%) among adolescents."
106,ve_overall_em_2,harleen.k.marwah.gmail.com,"2025-08-01 09:50:02","During the Omicron phase, the estimated overall vaccine effectiveness against long COVID was 60.2% (95% CI: 40.3%-73.5%) for children"
106,ve_overall_em_3,harleen.k.marwah.gmail.com,"2025-08-01 09:50:56","For adolescents, it was 75.1% (95% CI: 50.4%-87.5%)"
106,ve_overall_vax_n_2,harleen.k.marwah.gmail.com,"2025-08-01 09:53:10","Table 2"
106,ve_overall_vax_n_3,harleen.k.marwah.gmail.com,"2025-08-01 09:53:04","Table 2"
106,ve_vax_type,harleen.k.marwah.gmail.com,"2025-08-01 09:43:30","VE on long COVID"
107,nos_cc_1,flemi644,"2025-08-29 15:17:45","defined via post-infection survey; guardian-reported; no blinded clinical adjudication."
107,nos_cc_5,flemi644,"2025-08-29 15:19:09","Age and acute illness severity

also sex, baseline health, time from infection to survey"
107,nos_cc_6,flemi644,"2025-08-29 15:20:44","Secure record when available (vaccine cards uploaded; registry/medical record verification); otherwise self-report. Overall mixed but largely record-verified."
107,nos_cc_8,flemi644,"2025-08-29 15:22:11","equivalence by case/control status not established. >10% lost to follow-up; characteristics of non-responders compared, but PCC status among non-responders is unknown"
107,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-08-27 19:22:30","AdjustedORestimatedusinglogisticregressionwithunvaccinatedasreferentgroupadjustedforsex,ageatinfection,numberofsymptomsexperiencedduringinfection,self-rated
 health at baseline, and time betweeninfection andsurveycompletion."
107,ve_overall_em_ci,emeyerowit.montefiore.org,"2025-08-27 19:22:37","adjusted CI"
109,ae_outcome1_vax_n,harleen.k.marwah.gmail.com,"2025-07-29 12:33:36","# of doses (not # of vaccinated)"
111,nos_coh_4,calba1.mgh.harvard.edu,"2025-09-08 12:57:56","Depends on outcome. For analyses assessing new-onset thyroid dysfunction, they required no ICD-10 relevant codes/medications in prior 12 months to classify as ""new-onset"" - leaving as ""No"" because there is chance for inappropriate classification with this approach AND other outcomes do not specifically require that outcome was not present at start of observation period."
111,rob_type,nebasta,"2025-09-27 21:10:17","Authors note ""We performed a self-controlled case series (SCCS) analysis to assess the association between COVID-19 vaccination and thyroid-related outcomes in various subgroup populations."""
112,ae_incidence_yn,harleen.k.marwah.gmail.com,"2025-07-29 17:57:23","one case of nonserious, moderate, probable acute myocarditis resolved by 8 days from symptom onset"
112,ae_outcome,harleen.k.marwah.gmail.com,"2025-07-29 17:58:05","An independent cardiac event adjudication committee (CEAC) reviewed suspected cases of myocarditis and pericarditis to determine if they met Centers for Disease Control and Prevention (CDC) criteria of ""probable"" or ""confirmed"" events"
112,ae_outcome1_longterm_yn,harleen.k.marwah.gmail.com,"2025-07-29 17:58:35","One AE of chest pain was adjudicated as probable myocarditis; this event was mild and self-limited, with no evidence of sequelae, which is consistent with most cases of myocarditis postvaccination."
112,rob_outcome_ae,nebasta,"2025-09-06 14:27:00","Authors note this is ""probable acute myocarditis"""
112,rob_screen1,nebasta,"2025-09-06 14:24:30","The authors note ""Long-term analyses of safety, immunogenicity, and COVID-19 incidence endpoints were summarized descriptively by treatment without comparing the placebo-mRNA-1273 and mRNA-1273 groups."" 

Based on this info, selected no comparator group for this study.

All other TeenCOVE studies were assessed as having no comparator group via the AE-NSI list. This decision is consistent with that assessment."
113,domain_ae_include_yn,harleen.k.marwah.gmail.com,"2025-07-29 15:10:07","The study has a category called ""Adverse events of special interest."" In the supplementary materials (available online), Appendix 4/Table 17/page 192 lists out the AESIs and includes Guillain-Barre Syndrome on the list. However, there is no disaggregation of AESIs so cannot draw any conclusions about the specific AEs listed."
114,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-07-29 13:16:13","booster dose"
116,ae_vax_type,harleen.k.marwah.gmail.com,"2025-07-28 13:49:45","About Pfizer BA.1 or BA.4/5 vaccine"
116,nos_xs_1,ejholmes,"2025-09-02 12:54:01","Low response rate (< 3%)"
116,nos_xs_2,ejholmes,"2025-09-02 12:54:17","No ideal sample size mentioned"
116,nos_xs_3,ejholmes,"2025-09-02 12:54:41","Attempts to confirm reported AESIs via independent validation"
116,rob_screen2,ejholmes,"2025-09-02 12:53:00","Results stratified by age/sex"
117,nos_coh_1,ejholmes,"2025-09-03 14:28:05","Small sample of adolescents recruited"
121,nos_coh_1,flemi644,"2025-09-03 17:41:41","single hospital network"
121,nos_coh_5,flemi644,"2025-09-03 17:44:32","seasonal before/after rate comparisons are vulnerable to time-varying confounding (RSV circulation intensity, testing practices, healthcare-seeking, residual COVID-era effects, etc) that are not fully controlled in the study"
121,ve_infant_em,harleen.k.marwah.gmail.com,"2025-07-29 14:44:46","Among infants under 3 months of age, hospitalizations decreased by 79.3% (IRR: 0.21, 95% CI: 0.12-0.34). In infants aged 3 to 6 months, there was a 66.9% reduction (IRR: 0.33, 95% CI: 0.15-0.64)."
121,ve_infant_em,harleen.k.marwah.gmail.com,"2025-07-29 14:45:05","Reported by 0-3 mo and 3-6 mo"
121,ve_infant_em_2,harleen.k.marwah.gmail.com,"2025-07-29 14:49:00","Reported as < 3 months and 3-6 months (Table 3)"
122,rob2_interv2,flemi644,"2025-09-03 22:46:26","unblinded study nurses who administered the vaccines played no further role in the study; participants and laboratory personnel were blinded to vaccine administered."
122,rob2_interv6,ulric063,"2025-09-20 12:52:42","Safety set used for safety analysis"
123,rob_screen1,flemi644,"2025-09-03 23:01:37","coadmin vs sequential"
123,rob2_interv6,ulric063,"2025-09-20 12:56:02","Primary analyses pre-specified, An exploratory subgroup analysis of the primary immunogenicity endpoints stratified by age (65‒74 years and ≥75
years) was also conducted."
124,coadmin_pop1_n,emeyerowit.montefiore.org,"2025-07-30 13:27:00","Fig 1 - only those who received BNT162b2"
124,rob2_data1,flemi644,"2025-09-03 23:24:37","IGA data no. Stage 2 of the trial was not triggered."
124,rob2_interv1,flemi644,"2025-09-03 23:17:06","Not explicitly stated, but I assume so based on the RCT study design."
124,rob2_interv1,ulric063,"2025-09-09 16:23:56","Participants were randomised 1:1 to receive an influenza vaccine or saline placebo alongside their second dose of COVID-19
vaccine at day 0 (D0). At D21 those who received an influenza vaccine at D0 received placebo, and vice versa."
124,rob2_interv2,ulric063,"2025-09-20 13:41:05","From previously published methods: ""Participants, clinicians assessing causality of adverse events, and laboratory staff were masked to the treatment allocation. Vaccines were prepared out of sight of the participant, and masking was maintained by asking participants to look away during the injection and applying a masking label over the vaccine syringe. Trial staff who administered the vaccines and entered these data were not masked."""
124,rob2_interv6,ulric063,"2025-09-20 13:43:57","Data were analysed by intention to treat following a pre-specified plan"
124,rob2_msmt4,flemi644,"2025-09-03 23:25:43","Automated plate-based readouts and fixed QC/thresholds limit subjectivity"
124,rob2_random1,flemi644,"2025-09-03 23:19:20","Nothing mentioned in the text beyond that it was randomized."
124,rob2_random1,ulric063,"2025-09-20 13:39:38","From previously published ComFluCOV study: ""At day 0, participants were randomly assigned (1:1) to receive either an age-appropriate influenza vaccine or a placebo injection, alongside their second dose of a COVID-19 vaccine homologous to their first dose, using a secure internet-based system to ensure allocation concealment. The randomisation schedule was stratified by cohort, with blocks of varying size. The sequence was generated by a statistician who was not otherwise involved in the trial.""

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02329-1/fulltext"
125,nos_coh_1,flemi644,"2025-09-03 23:46:23","Single-center; adult community attendees, but one region only"
125,nos_coh_1,ulric063,"2025-09-09 16:36:38","Attendees at a Vaccination Center"
125,nos_coh_5,flemi644,"2025-09-03 23:48:36","Study stratified by dose and compared vaccine-dose pairs, but did not adjust for age/sex/calendar time in multivariable models. Also, policy change restricting Spikevax to ≥30 y likely biased manufacturer contrasts. Participants usually stayed with the same brand for follow-up doses."
125,nos_coh_6,flemi644,"2025-09-03 23:49:44","Self-report via standardized questionnaire. Susceptible to expectation/reporting differences by vaccine brand"
125,nos_coh_8,flemi644,"2025-09-03 23:50:47","also no responder/non-responder analysis"
125,rob2_interv1,flemi644,"2025-09-03 23:35:12","participants necessarily experienced the concise vs in-depth briefing, so awareness of received intervention is unavoidable"
126,rob2_interv6,flemi644,"2025-09-04 00:05:44","Follow-up limited to 28 days post-dose. Myocarditis events beyond this window (rarer) would not be captured."
126,rob2_msmt1,flemi644,"2025-09-04 00:02:12","while specific diagnostic adjudication criteria aren't detailed, the approach is standard for RCT safety surveillance"
126,rob2_msmt1,flemi644,"2025-09-04 00:05:11","Follow-up limited to 28 days post-dose. Myocarditis events beyond this window (rarer) would not be captured."
126,rob2_random2,flemi644,"2025-09-04 00:00:22","concealment isn;t detailed, but it is an observer-blinded multi-arm RCT with central ethics approval and clincaltrials.gov registry. adequate concealment likely."
127,rob_screen1,flemi644,"2025-09-04 15:39:42","Placebo for 3rd dose"
127,rob2_data1,flemi644,"2025-09-04 15:42:16",>95%
127,rob2_interv2,flemi644,"2025-09-04 15:41:27","only pharm techs were unblinded but had no role in assessments"
127,rob2_interv6,ulric063,"2025-09-20 13:59:21","The safety analysis set consisted of all randomised participants
who received ≥1 dose of study vaccine."
128,rob_screen1,flemi644,"2025-09-04 15:46:23",sequential
128,rob2_data1,flemi644,"2025-09-04 15:58:31","PPS 87% included"
128,rob2_data2,flemi644,"2025-09-04 15:59:55","ES and PPS were consistent; withdrawals were low (5%) and mainly unrelated to AEs"
128,rob2_interv1,flemi644,"2025-09-04 15:52:38","open label"
128,rob2_interv6,flemi644,"2025-09-04 15:55:54","primary analysis was PPS."
128,rob2_interv7,flemi644,"2025-09-04 15:56:26","PPS included ~87% and ES results were concordant"
128,rob2_msmt3,flemi644,"2025-09-04 16:00:35","blinding of lab not stated"
128,rob2_random3,ulric063,"2025-09-15 14:45:57","Slightly higher proportion of males in control group"
129,date_explain,harleen.k.marwah.gmail.com,"2025-08-04 12:10:26","Interim safety and immunogenicity 29 days after vaccination are reported."
129,date_explain,harleen.k.marwah.gmail.com,"2025-08-04 12:10:50","Interim 15- and 29-day analysis results are reported."
129,date_start_month,harleen.k.marwah.gmail.com,"2025-08-04 12:12:08","April 2023"
129,domain_ae_inc_other,harleen.k.marwah.gmail.com,"2025-08-04 12:12:51","local and systemic reactions (Figure 2)"
129,rob_screen1,flemi644,"2025-09-04 16:07:00","monovalent vs bivalent boosters"
129,rob2_interv1,flemi644,"2025-09-04 16:09:15","open label"
129,rob2_interv8,flemi644,"2025-09-04 16:10:40","limited detail on possible deviations"
129,rob2_msmt2,flemi644,"2025-09-04 16:12:33","self-report in an open label study"
129,rob2_msmt6,flemi644,"2025-09-04 16:13:20","unblinded, self-reported subjective outcomes"
129,rob2_random1,flemi644,"2025-09-04 16:07:51","Randomization sequence not detailed."
129,rob2_random3,ulric063,"2025-09-20 16:26:38","Higher proportion age 65+ in the monovalent compared to bivalent arm (22% vs 13%); prevalence of SARS-CoV-2 prior infection higher in monovalent arm"
129,rob2_random4,flemi644,"2025-09-04 16:09:00","lack of detail on sequence generation/concealment despite randomization"
129,rob2_result1,flemi644,"2025-09-04 16:14:16","registered clinicaltrials.gov study"
129,setting,harleen.k.marwah.gmail.com,"2025-08-04 12:11:08","The trial is being conducted across 9 US sites"
130,rob_screen1,flemi644,"2025-09-04 16:20:17",sequential
130,rob2_data1,flemi644,"2025-09-04 16:25:32",94.6%
130,rob2_interv1,flemi644,"2025-09-04 16:21:53","open label"
130,rob2_interv6,flemi644,"2025-09-04 16:23:30","PPS. Results were said to be consistent on the Exposed Set, but an ITT analysis was not described"
130,rob2_interv7,flemi644,"2025-09-04 16:24:32","Exclusions were largely administrative (out-of-window, missed assessment) or protocol-forbidden medications"
130,rob2_msmt2,flemi644,"2025-09-04 16:27:05","even though open-label, laboratory analyses are standardized and objective"
130,rob2_random1,flemi644,"2025-09-04 16:21:37","randomization methods in Supplementary Methods"
131,coadmin_pop1_n,emeyerowit.montefiore.org,"2025-07-31 06:35:48","Only study part B was co-admin"
131,rob2_data1,flemi644,"2025-09-04 16:36:16",~91-92%
131,rob2_interv2,flemi644,"2025-09-04 16:35:36","single-blind for immunogenicity and safety. Implies some study staff awareness."
131,rob2_msmt3,flemi644,"2025-09-04 16:37:43","supplemental methods"
131,rob2_msmt4,flemi644,"2025-09-04 16:39:34","objective lab titers."
131,rob2_random1,flemi644,"2025-09-04 16:33:46","sequence detailed in supplementary methods"
131,rob2_result3,flemi644,"2025-09-04 16:40:54","Use of different analysis sets/adjustments possible; H1N1 objective priority changed during program; minor concern for selective emphasis"
132,coadmin_sero_other,emeyerowit.montefiore.org,"2025-07-31 06:51:42","Unclear clinical significance"
132,coadmin_sero_other,emeyerowit.montefiore.org,"2025-07-31 07:01:00","Second trial with this finding"
132,rob_screen1,flemi644,"2025-09-04 16:44:00",sequential
132,rob2_data1,flemi644,"2025-09-04 16:48:29","Per-protocol immunogenicity sets were 471/523 (Co-Ad) vs 400/522 (Control)"
132,rob2_data1,ulric063,"2025-09-15 21:43:29","Authors state: ""baseline characteristics remained balanced between groups in the per-protocol sets, and immunogenicity
analyses in the exposed set showed similar results as in the per protocol set, indicating that the eliminations  due to protocol
deviations did not impact our conclusions"""
132,rob2_interv1,flemi644,"2025-09-04 16:47:39","open label"
132,rob2_interv6,ulric063,"2025-09-15 21:40:16","PPS analysis"
132,rob2_random1,flemi644,"2025-09-04 16:45:08","supp methods"
133,design,abersm.gmail.com,"2025-07-30 14:00:19","Secondary analysis of previously reported RCT"
134,rob2_random2,flemi644,"2025-09-04 16:59:19","double blind with matched placebo"
135,coadmin_ae_yn,emeyerowit.montefiore.org,"2025-07-31 07:12:08","Relative risk of AEs (reactogenicity) not significantly different comparing coadmin to COVID booster only group."
135,rob2_msmt4,flemi644,"2025-09-04 17:09:35","objective lab titers."
136,rob2_interv1,flemi644,"2025-09-05 11:34:45","60+ cohort was open-label"
136,rob2_interv2,flemi644,"2025-09-05 11:36:45","same comment"
136,rob2_interv6,ulric063,"2025-09-15 21:58:07","Per protocol set"
136,rob2_random1,flemi644,"2025-09-05 11:34:02","supp methods"
136,rob2_random2,flemi644,"2025-09-05 11:33:53","supp methods"
137,rob_screen1,flemi644,"2025-09-05 11:42:32","lot to lot comparison"
138,ae_outcome,emeyerowit.montefiore.org,"2025-07-31 08:57:39","1 case of myocarditis in the mRNA-1273 group reported, see Table S16 in supplementary material"
138,ae_outcome1_vax_n,scottja.stanford.edu,"2025-08-08 02:53:10","I changed that it does provide incidence data and added 1 out of 374 with myocarditis. P10, table 3"
138,domain_ae_num,scottja.stanford.edu,"2025-08-08 02:45:35","I changed this from 1 to 3"
138,population_disagg,scottja.stanford.edu,"2025-08-08 02:42:43","Figure 2F  shows neutralizing antibody titers by disease cohort. The logistic regression analyses  identify factors (including age, disease cohort, and treatments) contributing to the likelihood of immune responses. Serious adverse events are split by treatment group and disease group in the appendix"
138,rob2_interv1,flemi644,"2025-09-05 11:51:39","Open label"
138,rob2_interv6,ulric063,"2025-09-15 23:09:32","Unintentional data change - changed back to correct response: ""yes"""
138,rob2_msmt1,flemi644,"2025-09-05 11:58:20","No prespecified myocarditis case definition or active surveillance (e.g., troponin/ECG screening). SAEs only collected to day 28."
138,rob2_msmt2,flemi644,"2025-09-05 11:58:45","open-label knowledge"
138,rob2_msmt6,flemi644,"2025-09-05 11:59:40","Subjective, unblinded ascertainment with no standardized case definition and short surveillance window"
138,rob2_result4,flemi644,"2025-09-05 12:01:01","AE windows (21 vs 28 days), seriousness, and varying definitions could allow multiple choices."
139,rob2_interv2,flemi644,"2025-09-05 12:35:33","designated unmasked site personnel who did not participate in any clinical study evaluations"
139,rob2_interv4,flemi644,"2025-09-05 12:36:39","only 2 participants in the RSV+placebo group who mistakenly received mRNA-1273 on Day 1"
139,rob2_random3,flemi644,"2025-09-05 12:33:29","Age imbalance due to randomization error for Part A of the study."
140,rob2_data1,flemi644,"2025-09-05 12:48:33","75% completed the trial; withdrawals/loss to follow-up were sizable but similar across groups"
140,rob2_interv2,flemi644,"2025-09-05 12:43:39","A protocol amendment removed the planned season-3 dose; a minority received dose 3 before the amendment, but analyses censored appropriately"
140,rob2_interv6,flemi644,"2025-09-05 12:46:16","analyses were performed ""based on the administered intervention,"" not explicitly ITT"
140,rob2_interv7,flemi644,"2025-09-05 12:47:03","Given masking, centralized randomization, and on-site dosing"
140,rob2_result2,flemi644,"2025-09-05 12:50:26","Multiple related endpoints (e.g., ARI overall vs medically attended ARI [post hoc]) and season-specific cuts"
140,rob2_result3,flemi644,"2025-09-05 12:51:58","Primary model adjusted for age/region/season with an additional post-hoc model omitting season; didn't correct for multiple comparisons. "
141,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-08-02 15:41:16","Ad26/protein preF RSV"
141,population_disagg,harleen.k.marwah.gmail.com,"2025-08-02 15:43:34","Disaggregated by further age groups (18-45, 46-59, 65-74, 75-84, 85+)"
141,rob2_interv1,flemi644,"2025-09-05 13:05:02","double blind, placebo-controlled"
142,rob2_interv1,flemi644,"2025-09-05 13:12:00","double blind, placebo-controlled"
143,rob2_interv2,flemi644,"2025-09-05 13:22:51","Designated unblinded site personnel handled dose prep/administration only"
143,rob2_interv6,flemi644,"2025-09-05 13:23:49","P302 was PPS. P301 was ITT"
143,rob2_interv7,flemi644,"2025-09-05 13:24:14","PP exclusions in P302 relate to early discontinuation/major deviations"
143,rob2_random1,flemi644,"2025-09-05 13:21:26","supp methods"
143,ve_overall_em_adj,ncmccann.bu.edu,"2025-08-03 11:18:14","Note that this is the VE for what we are specifying as the comparator."
144,rob2_interv1,flemi644,"2025-09-05 13:33:51","double blind, placebo-controlled"
145,date_start_month,harleen.k.marwah.gmail.com,"2025-08-04 13:47:51","in supplementary materials"
145,rob_screen1,flemi644,"2025-09-05 13:41:21","meningococcal vaccine"
145,rob2_data1,flemi644,"2025-09-05 13:43:50","denominators consistent with high diary return, though explicit completion rates are not provided"
145,rob2_random2,flemi644,"2025-09-05 13:42:08","concealment is strongly implied though not detailed."
147,design,ncmccann.bu.edu,"2025-08-11 12:25:15","participants randomized, but not really described as a trial"
147,rob_screen1,flemi644,"2025-09-05 16:59:54","single vs. double dose"
147,rob2_interv1,flemi644,"2025-09-05 17:01:39","open label and two shots vs one"
147,rob2_msmt2,flemi644,"2025-09-05 17:03:56","Open-label plus inherently different administration (two injections vs one) could influence perception/reporting. Should have used a placebo for the second shot in the 1-shot group."
147,rob2_msmt3,flemi644,"2025-09-05 17:04:38","Self-report/clinic follow-up without blinding."
147,rob2_msmt4,flemi644,"2025-09-05 17:05:35","subjective symptoms"
147,rob2_msmt5,flemi644,"2025-09-05 17:05:55","Subjective outcomes in unblinded setting"
147,rob2_msmt6,flemi644,"2025-09-05 17:06:11","non-blinded measurement of subjective outcomes"
147,rob2_random1,flemi644,"2025-09-05 17:00:35","no method described"
147,rob2_random3,ulric063,"2025-09-20 14:05:48","Small sample size, but slight imbalance in gender: 43% (10/23) of men received 2 doses; 55% (15/27) of women received 2 doses"
148,rob2_interv1,flemi644,"2025-09-05 17:13:04","double blind"
148,rob2_interv6,ulric063,"2025-09-20 14:18:00","Participants who received a
booster were included in the safety analyses."
148,rob2_random3,ulric063,"2025-09-20 14:16:43","However, within each priming group, randomised arms
demonstrated similar distributions of age, sex (determined through a structured questionnaire as biological
sex), the highest level of education, comorbidities, and
baseline symptoms (Supplementary Tables S1-S3). This
was consistent when considering the analysis groups on
day 21-60 and day 21-35 (Supplementary Table S4)."
149,rob2_data1,flemi644,"2025-09-05 17:21:44","PPS required post-vaccination samples and protocol adherence; thus not all randomized participants contributed to the immunogenicity analysis"
149,rob2_data2,flemi644,"2025-09-05 17:22:24","conlcusions replicated in broader ES set."
149,rob2_interv1,flemi644,"2025-09-05 17:18:52","open label"
149,rob2_interv6,flemi644,"2025-09-05 17:19:51","PPS only (no ITT)"
149,rob2_interv6,ulric063,"2025-09-20 14:21:04","The assessment of immunogenicity was conducted using the Per-Protocol Set (PPS)."
149,rob2_interv7,flemi644,"2025-09-05 17:20:41","non-inferiority for QIV HI titers was also demonstrated in the ES analysis"
149,rob2_msmt4,flemi644,"2025-09-05 17:23:24","objective lab titers."
150,rob2_interv2,flemi644,"2025-09-05 17:30:17","vaccinators were unmasked but had no further role"
150,rob2_interv6,ulric063,"2025-09-20 14:27:53","Descriptive analyses of safety endpoints were done in
the safety set, which comprised all participants who
received a study vaccine and who had post-vaccination
safety data and no substantial deviations from Good Clinical Practice standards"
150,rob2_msmt1,flemi644,"2025-09-05 17:32:18","featured symptoms with Brighton adjudication. no troponin/ECG screening, so sub-clinical events could be missed."
150,rob2_msmt1,ulric063,"2025-09-20 14:35:54","Changing from ""probably yes"" to ""probably no"" as Brighton Collaboration Case Definition for myocarditis includes testing and imaging studies for suspected cases"
151,rob2_interv2,flemi644,"2025-09-05 17:38:37","A single unblinded study nurse prepared/administered vaccines"
152,rob2_interv2,flemi644,"2025-09-05 17:46:39","An unblinded study nurse administered injections"
152,rob2_interv2,ulric063,"2025-09-20 14:48:23","Research staff involved in the safety and reactogenicity follow-up
were blinded to the group assignment of participants."
152,rob2_interv3,flemi644,"2025-09-05 17:47:18","two participants developed COVID-19 and was withdrawn (minor)"
153,rob2_random1,ulric063,"2025-09-20 14:53:10","in a 1:1 ratio using interactive response technology by a centralized randomization procedure to receive mRNA-1083
plus placebo (henceforth referred to as mRNA-1083) or active comparator vaccines for seasonal influenza and COVID-19."
153,rob2_result1,flemi644,"2025-09-05 18:04:24","supp methods"
154,rob2_interv2,nebasta,"2025-09-07 22:32:35","staff administering the vaccine were aware, but did not participate in any other aspect of the trial"
155,rob_type,nebasta,"2025-09-07 21:19:21","This is a cross-over/booster RCT following up from a prior trial"
155,rob2_interv2,nebasta,"2025-09-07 21:19:59","those delivering intervention were unblinded"
156,domain_ae_include_yn,ncmccann.bu.edu,"2025-08-05 20:46:40","USED CLINICALTRIALS.GOV TO GET SPECIFIC AES. There were serious AEs reported, but not stated which kind in the publication, so went to the clinical trial website. https://clinicaltrials.gov/study/NCT05827978?tab=results#adverse-events"
156,rob2_interv1,nebasta,"2025-09-07 21:02:31","From supplement "" Neither the
participant, nor the investigator, nor clinic staff responsible for study assessments/safety had
access to the vaccine assignment during the conduct of the study."""
156,rob2_interv2,nebasta,"2025-09-07 21:03:10","staff administering the intervention were aware, but they were not involved in any other element of the trial"
157,rob2_data1,mehr0035,"2025-09-07 10:29:49","See pages 5 & 6 for #s completing study treatment/participation. Chose ""probably no"" because info detailed but below 95%."
157,rob2_interv7,ulric063,"2025-09-20 15:10:39","Differential follow-up by randomization arm; differential proportion excluded from PPS for reason ""COVID-19 vaccine/treatment"""
158,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-08-02 16:02:39","Ad26.RSV.preF/RSV preF protein vaccine"
159,coadmin_pop1_n,emeyerowit.montefiore.org,"2025-08-03 16:02:26","Not disaggregated by mRNA vaccine brand"
159,rob2_interv1,ulric063,"2025-09-20 15:18:14","Vaccine and placebo
were administered by unblinded study staff who did not participate in outcome measurements.
Participants and remaining study staff were blinded to treatment allocation."
159,rob2_interv2,ulric063,"2025-09-20 15:18:21","Vaccine and placebo
were administered by unblinded study staff who did not participate in outcome measurements.
Participants and remaining study staff were blinded to treatment allocation."
159,rob2_random1,ulric063,"2025-09-20 15:17:21","Randomization detailed in supplemental materials https://cdn-jamanetwork-com.ezp3.lib.umn.edu/ama/content_public/journal/jamanetworkopen/939484/zoi241236supp1_prod_1730219476.43754.pdf?Expires=1761422952&Signature=WOJh3rH5HHLmt81kvvTqBGcb0O9UGCCn3wQCrYtX4-R8NhD-iBAV1OIkOpV-oBB7aE0pJ-W-I0VpJh~i4am4ge7NrfzBocT4vPLCTUeCgiedvt4SA2Q-NaZewN9kJxaHY2ffsLNi-F5Mfa~TReLd6FUCeZy-CuPVpGi~LLJnwUdRBhrM3z88-xUChjoBMlqH2HOKQnVBgAPoRKE4sff~aOMuzc6qGWSIfLdNjxPt9zyA2PMAbwrEh4fuuy1qikBdKEoQMKzNILF0P45ge0nqHhDstyG1yhd3u28foHMQQaMveSLrbExSANsqs9Bah1Im-mz7HC73PAxu~jg9u4tEvw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
165,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-03 16:21:48","The study included a cohort of individuals with preexisting ITP."
167,ae_outcome,abersm.gmail.com,"2025-07-29 20:29:58","Data are for ischemic stroke"
167,ae_outcome1_otherinfo_yn,stodd046,"2025-08-06 11:27:33","This study reports IRR for ""cerebro-vascular"" events which includes stroke but does not disaggregate"
167,design,stodd046,"2025-08-06 10:51:37","I switched this designation from ""Other"" to ""Observational"" based on 8/5 meeting discussion"
169,ve_outcome_prime_txt,emeyerowit.montefiore.org,"2025-08-05 20:00:32","Supplementary eTable3"
169,ve_timeline,emeyerowit.montefiore.org,"2025-08-05 20:04:53","Model 4 is in table 2"
170,rob_outcome_ve,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-03 22:44:05","also hospitalization for influenza and/or pneumonia"
170,ve_outcome_prime,emeyerowit.montefiore.org,"2025-08-05 20:31:17","Table 2"
170,ve_overall_vax_n_2,emeyerowit.montefiore.org,"2025-08-05 20:32:37","Table 1"
172,nos_xs_2,ejholmes,"2025-09-02 14:55:16","Ideal sample size not described"
173,date_start_year,stodd046,"2025-08-06 11:42:52","""from the inception of the VAERS"""
177,nos_xs_1,nebasta,"2025-09-27 13:39:11","says ""random sampling"" but no information given, only those who had medical records of CA included"
178,domain_ae_include_list,abersm.gmail.com,"2025-07-31 17:11:20","Other heme parameters not disaggregated by vaccine"
181,virus,abersm.gmail.com,"2025-07-31 17:05:28","No disaggregation by specific COVID vaccine. No disaggregation by specific influenza vaccine"
182,immunocomp_describe,harleen.k.marwah.gmail.com,"2025-08-04 13:52:29","1) solid organ transplant recipients (including heart, lung, liver, or
kidney) who received their transplant at least 3 months before enrollment and with no
acute rejection episodes within the previous 2 months; (2) individuals receiving active
immunomodulator therapy for an autoimmune inflammatory disorder at a stable dose
(i.e., receiving the same dose for at least 3 months with no changes in the 28 days before
enrollment); (3) individuals with advanced non-small cell lung cancer who received initial
or maintenance chemotherapy for at least 2 weeks before enrollment, individuals who are
treatment-naive and not expected to receive chemotherapy within at least 2 weeks after
study vaccinations, or those who received checkpoint inhibitor treatment or targeted drug
therapy (i.e., tyrosine kinase inhibitors, including epidermal growth factor receptor [EGFR],
anaplastic lymphoma kinase [ALK], c-ros oncogene 1 [ROS1], v-raf murine sarcoma viral
oncogene homolog B1 [BRAF], rearranged during transfection [RET], and neurotrophic
tyrosine receptor kinase [NTRK] inhibitors) for at least one treatment cycle before enroll-
ment; and (4) individuals on maintenance hemodialysis treatment secondary to end-stage
renal disease."
182,rob_screen1,nebasta,"2025-09-06 14:41:34","""Single-Arm Study"""
184,ae_vax_type,stodd046,"2025-08-08 11:33:52","Evaluating NVX-CoV2601"
184,rob_screen1,nebasta,"2025-09-06 14:44:16","""Single Arm Study"""
185,ae_vax_type,stodd046,"2025-08-08 11:50:00",NVX-CoV2601
185,rob_screen1,nebasta,"2025-09-06 14:50:58","""Single-arm study"" - but authors are comparing those previously vaccinated to those not previously vaccinated, so will consider this ""comparator"" groups"
185,rob_screen2,nebasta,"2025-09-06 14:54:38","Trial was previously randomized, but this analysis is of a subset of those participants who were later enrolled in a single-arm study, so this analysis does not benefit from the prior randomization. In the AE assessment, no additional attempts to control of confounding in this analysis is reported."
188,domain_ae_include_vax,stodd046,"2025-08-11 10:43:27","mRNA-1273.214 or BA.1-adapted BNT162b2"
189,ve_adult_vax_n,stodd046,"2025-08-08 12:01:37","Please see note in general info- authors include this population but report VE in a strange way. 18 and over is reported in this form as ""Overall Population"""
199,nos_coh_1,calba1.mgh.harvard.edu,"2025-09-09 09:08:13","Unclear how exposed population was selected (longitudinal cohort) - they are referred to as ""volunteers"" so would consider downgrading to ""Selected group"" but this would not change the overall risk of bias assessment, so leaving as is."
199,nos_coh_1,ulric063,"2025-09-21 17:37:17","AKU - downgrading to ""selected group"""
199,nos_coh_3,ulric063,"2025-09-21 17:40:05","""Vaccines were administered as part of the standard of care"" - unclear if and how receipt of vaccination was documented."
199,nos_coh_4,calba1.mgh.harvard.edu,"2025-09-09 09:17:27","They collect baseline antibody levels and report separately results among those without pre-existing immunity before vaccination with, aside from H3N2, no significant differences between flu, flu+COVID (same arm), and flu+COVID (different arms) - the overall takeaway of the paper."
204,rob2_random1,mehr0035,"2025-09-07 13:47:52","Have ""probably no"" for now and put a ? into the WhatsApp group. 

For reference: https://cdn.clinicaltrials.gov/large-docs/39/NCT02860039/SAP_001.pdf

See Fig 1 of study.

QUESTION: The parent study was an RCT. The 65 participating in this study are repeaters drawn from the original RCT. Their assignment of SD-QIV or HD-TIV was based on parent study randomization, not this study specifically. Does this still count as being a RCT or should it be cohort? "
205,ve_overall_vax_n,harleen.k.marwah.gmail.com,"2025-08-04 16:41:42","Table #3 has this listed by events/person-years"
206,date_start_year,harleen.k.marwah.gmail.com,"2025-08-04 17:37:26","They also had a cohort from 22-23 season, but just looking at the 23-24 season for this extraction"
206,epi_other_covid,harleen.k.marwah.gmail.com,"2025-08-04 17:39:05","During the 2023 to 2024 season, the 30-day risk of hospitalization was similar for COVID-19 (16.2%) and influenza (16.3%) but lower for RSV at 14.3% (RD for COVID-19 vs RSV, 1.9% [95% CI, 0.9%-2.9%]; RD for influenza vs RSV, 2.0% [95% CI, 0.8%-3.3%]). The 30-day risk of death during the 2022 to 2023 season was slightly higher for COVID-19 (1.0%) compared with influenza (0.7%) (RD, 0.4% [95% CI, 0.1%-0.6%]) or RSV (0.7%) (RD, 0.4% [95% CI, 0.1%-0.6%]) but similar during the 2023 to 2024 season. Mortality risk at 180 days was higher for COVID-19 during both seasons (2023-2024 RD for COVID-19 vs influenza, 0.8% [95% CI, 0.3%-1.2%]; RD for COVID-19 vs RSV, 0.6% [95% CI, 0.1%-1.1%])."
206,rob_outcome_epi,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-04 12:52:27","also: 30-day hospitalization, death with laboratory-confirmed COVID, influenza, or RSV infection"
207,nos_coh_1,ejholmes,"2025-09-10 13:24:31","Some early attrition; unknown comparison of baseline characteristics of NMD greater population to sample used here"
207,nos_coh_8,ejholmes,"2025-09-10 13:25:12","Close (high 70%)"
207,nos_coh_8,calba1.mgh.harvard.edu,"2025-09-10 14:44:36","According to Figure 1, 1311 people were initially consented but ultimately only 1020 were included in the AE analysis (78% of initial included group) without comment on how characteristics compared between the included and excluded groups. Once included, study mentions patients were followed up for 12 months, but unsure if that included 100% retention. Decided to downgrade to ""Follow up rate < 80% and no description of those lost"" in agreement with EH via email on 9/10."
208,nos_coh_1,ulric063,"2025-09-25 21:16:39","health care workers
who received the bivalent COVID-19 mRNA booster and the
seasonal influenza vaccine on the same day or different days."
208,nos_coh_3,ulric063,"2025-09-25 21:17:55","No detail"
208,nos_coh_4,ulric063,"2025-09-25 21:21:04","no baseline"
208,rob_type,ulric063,"2025-09-25 21:15:36","Changing to cohort study: Participants were enrolled as a part of the Massachusetts
Consortium on Pathogen Readiness with informed consent. 
Individuals were divided into participants who received an influenza vaccine on the same day as the bivalent COVID-19
mRNA vaccine or those who received the 2 vaccines on different days within 4 weeks. "
210,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-08-10 12:30:45","sum IC + matched groups"
210,nos_coh_4,and05081,"2025-09-02 15:35:53","""For each ADR, information on time to onset (TTO), outcome, duration of symptoms (if recovered), severity/impact
of the symptoms (including medical assistance & hospitalisation) was collected."""
210,nos_coh_8,calba1.mgh.harvard.edu,"2025-09-11 17:17:11","Extracted data was AE stroke among immunocompromised+non-immunocompromised after first dose. Fig 1 shows significant attrition among immunocompromised and matched cohort."
211,population,abersm.gmail.com,"2025-07-31 17:21:00","Immunocompromised not specifically mentioned as inclusion criteria but study includes patients on chemo, XRT, target/endocrine therapy"
213,coadmin_ae_yn,harleen.k.marwah.gmail.com,"2025-08-01 10:38:16","Not reported"
213,coadmin_vax_num,harleen.k.marwah.gmail.com,"2025-08-01 10:36:48","Patients were managed as outpatients and simultaneously intramuscularly vaccinated against influenza (Vaxigrip Tetra, season 2023/ 2024, Sanofi, pre-filled syringe, batch number: X3E895V) (right arm) and RSV (Arexvy, GSK, batch number: 3X5K3) (left arm) from the 15th of September 2023 to the 17th of November 2023."
213,population,harleen.k.marwah.gmail.com,"2025-08-01 10:36:05","High Risk Heart Failure"
213,rob_screen1,stodd046,"2025-09-04 15:48:19","This is an RCT but authors ONLY give information about one arm. There is no comparative statistics, only frequency of the outcomes in participants who were administered RSV and flu simultaneously."
213,rob2_random3,stodd046,"2025-09-04 15:37:11","This study has two groups: coadmin and standard of care. Authors only report on the coadmin group and do not provide any explicity information about the SOC group."
214,design,abersm.gmail.com,"2025-07-29 21:19:08","Propensity matched"
214,domain_ae_include_vax,harleen.k.marwah.gmail.com,"2025-08-04 18:05:59","Likely RSVpreF3 and RSVpreF given that is what is mentioned in the introduction"
214,population,abersm.gmail.com,"2025-07-29 21:19:17","Age >= 60"
214,setting,harleen.k.marwah.gmail.com,"2025-08-04 18:04:03","look at records of 108 million patients from 66 healthcare organizations, representing 27% of the US population from all 50 states"
215,ae_outcome1_otherinfo_yn,emeyerowit.montefiore.org,"2025-08-10 12:48:34","Has details about clinical presentation"
215,nos_cc_1,ejholmes,"2025-09-03 14:10:19","Case def'n for myocarditis is thorough; Definition for ""vaccine-related"" myocarditis is only temporal (within 15 days of receiving vaccine)"
215,nos_cc_8,ejholmes,"2025-09-03 14:14:19","Table 1, baseline characteristics similar"
215,nos_coh_1,ejholmes,"2025-09-10 13:52:01","Small sample, 13 sites in Italy, seeking care in ER and consenting"
215,nos_coh_5,ejholmes,"2025-09-10 15:52:21","Minimal controls beyond exclusion criteria and stratification"
215,nos_coh_8,ejholmes,"2025-09-10 15:53:37","No description; retrospective cohort limits LTFU potential"
216,nos_cc_3,calba1.mgh.harvard.edu,"2025-09-09 16:29:29","Data are from RELAB, community-based laboratories, NOT hospitalized patients. Study only assessed PCR-proven infection not medically-attended visits (e.g., clinic visits, ED presentation, hospitalization, etc.)"
216,nos_cc_4,ulric063,"2025-09-25 21:26:36","Updating to 'no history of disease' to align with guidance"
216,nos_cc_5,moat0011,"2025-09-03 19:14:09","We fitted a logistic (binomial) linear model to
test result (negative/positive), as a function of sex, age
category, PCR technique, week, and vaccination status,
age and week being the most important confounders."
216,nos_cc_6,moat0011,"2025-09-03 19:14:56","self reported"
216,ve_elder_unvax_n,abersm.gmail.com,"2025-07-29 22:07:44","Calculated from Table 3"
216,ve_elder_unvax_y,abersm.gmail.com,"2025-07-29 22:07:51","Calculated from Table 3"
216,ve_elder_vax_n,abersm.gmail.com,"2025-07-29 22:07:31","Calculated from Table 3"
216,ve_elder_vax_y,abersm.gmail.com,"2025-07-29 22:07:39","Calculated from Table 2"
216,ve_em_type,abersm.gmail.com,"2025-07-29 22:15:01","Article states OR is used but after calculating their raw data, it's clear that (1-OR)*100 was used"
216,ve_other_unvax_n,abersm.gmail.com,"2025-07-30 16:31:51","Age 0-64"
216,ve_other_unvax_n_2,abersm.gmail.com,"2025-07-30 16:39:38","Age 0-64"
216,ve_other_unvax_y,abersm.gmail.com,"2025-07-30 16:31:55","Age 0-64"
216,ve_other_unvax_y_2,abersm.gmail.com,"2025-07-30 16:39:43","Age 0-64"
216,ve_other_vax_n,abersm.gmail.com,"2025-07-30 16:31:33","Age 0-64"
216,ve_other_vax_n_2,abersm.gmail.com,"2025-07-30 16:39:28","Age 0-64"
216,ve_other_vax_y,abersm.gmail.com,"2025-07-30 16:31:46","Age 0-64"
216,ve_other_vax_y_2,abersm.gmail.com,"2025-07-30 16:39:33","Age 0-64"
219,domain_ae_include_vax,moat0011,"2025-08-06 17:23:47","Vaccine products not specified"
220,epi_sample_rsv,harleen.k.marwah.gmail.com,"2025-08-04 18:21:54","27 withdrew during season 1, 77 between seasons 1 and 2, and 129 during season 2 and were censored at the time of withdrawal"
222,domain_ae_include_vax,stodd046,"2025-08-11 12:31:42","In our analysis, the cases were the AEFI reports for
which mRNA COVID-19 vaccines elasomeran-Spikevax® (Moderna) and tozinameran-Comirnaty® (Pfzer
& BioNTech), were suspected, while non-cases were AEFI
reports for which all other vaccines listed in Supplementary Table 1 (excluding non-mRNA COVID-19 vaccines)
were suspected"
223,domain,stodd046,"2025-08-11 13:01:41","EXCLUDE STUDY: SWITCHING TO VE SINCE THERE ARE NO AEs"
227,nos_cc_3,calba1.mgh.harvard.edu,"2025-09-09 16:45:59","Changed from hospital to community controls. Inclusion was presentation for acute respiratory illness to ED, urgent care, or outpatient setting - NOT among a hospitalized population."
227,nos_cc_4,ulric063,"2025-09-25 21:29:00","Updating to 'no history of disease' to align with guidance"
228,nos_cc_2,calba1.mgh.harvard.edu,"2025-09-10 14:27:15","Cases were specifically selected from hospitalized population, whereas controls could have been community or hospitalized (I.e., different settings and possibly different symptom burdens) - suggesting reduced TND study quality. Changing to ""Potential for selection bias"" - discussed with LM on 9/10."
228,nos_cc_3,calba1.mgh.harvard.edu,"2025-09-10 14:33:25","Controls must've test negative but could have been hospitalized or not. Discussed with LM and keeping as ""hospital controls"" as the deviance from standard TND norms to ensure selection cases and controls should not warrant an additional point for study quality in this case."
228,ve_comparator_vax_v2,flemi644,"2025-08-07 16:42:08","All non-xbb vaccinated + unvaccinated: listed as ""non-xbb vaccinated"" in table 2, with overall case and control totals matching table 1"
235,nos_cc_1,ejholmes,"2025-08-29 16:09:54","Yes; does only captures strokes leading to hospital admission"
235,nos_cc_8,ejholmes,"2025-08-29 16:14:51","No nonresponse since pulling from national database"
235,population_disagg,abersm.gmail.com,"2025-07-31 09:46:56","Age data not disaggregated by specific vaccine."
236,nos_coh_1,stodd046,"2025-09-04 16:18:08","I am treating BNT/pfizer as exposed and 1273/moderna as unexposed"
236,ve_overall_em_ci_2,emeyerowit.montefiore.org,"2025-08-10 07:31:20",adjusted
238,population_disagg,abersm.gmail.com,"2025-07-30 17:14:46","Individual patient data provided"
239,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-10 09:03:24","There were too few myocarditis events to disaggregate - listed as < 5 for multiple vaccines."
239,ae_incidence_yn,stodd046,"2025-08-12 10:41:53","After third dose of vaccine (multiple brands aggregated)"
239,ae_incidence_yn_2,emeyerowit.montefiore.org,"2025-08-10 09:04:03","Too few GBS events"
239,ae_outcome_v2,emeyerowit.montefiore.org,"2025-08-10 09:13:16","""any stroke + TIA"""
239,ae_outcome1_vax_n_3,emeyerowit.montefiore.org,"2025-08-10 09:11:25","Sum of 239030 + 232,765 + 414,077 for total BNT162b2 doses given for doses 1,2,3, from Table 1"
239,ae_outcome1_vax_n_4,emeyerowit.montefiore.org,"2025-08-10 09:10:53","Sum of 239030 + 232,765 + 414,077 for total BNT162b2 doses given for doses 1,2,3"
239,ae_outcome1_vax_n_v2,emeyerowit.montefiore.org,"2025-08-10 09:14:13","Number of 3rd dose mRNA-1273 vaccines"
239,ae_outcome1_vax_y_3,emeyerowit.montefiore.org,"2025-08-10 09:06:17","Sum of 48 + 41 + 37 for all events across all 3 doses of BNT162b2"
239,ae_outcome1_vax_y_3,stodd046,"2025-08-12 10:50:33","This information is found in supplementary figures S12-S14"
239,ae_outcome1_vax_y_4,emeyerowit.montefiore.org,"2025-08-10 09:05:39","Sum of 159 + 179  + 235 for all events across all 3 doses of BNT162b2"
239,domain,stodd046,"2025-08-12 10:32:29","Also has VE but out of date range"
240,nos_cc_8,ejholmes,"2025-09-02 09:55:24","National registry"
240,rob_domain_aensi_other,ejholmes,"2025-09-02 09:44:52","flu vaccine + use of statins"
240,rob_type,ejholmes,"2025-09-02 09:47:10",""" Case-centred analysis is similar to a
case-control study without sampling, in which all matched to all available subjects (or reference set) with the same age and sex on the event date of the case, from the entire population"""
241,nos_xs_1,moat0011,"2025-09-10 12:19:34","Rep of transplant pop'n"
241,rob_domain_aensi_other,stodd046,"2025-09-04 16:23:57","Reactivation of the latent varicella-zoster virus can cause herpes zoster (HZ) infection, and renal
transplant recipients undergoing immunosuppressive therapy are particularly susceptible to this condition. This
study aims to evaluate the potential increase in HZ incidence following influenza vaccination among this specific
patient population"
241,rob_screen2,nebasta,"2025-09-27 20:43:43","self-controlled case series automatically controls for confounding"
243,nos_coh_1,ejholmes,"2025-09-04 09:27:17","Very large sample; would not capture uninsured adults/those that do not seek HC"
243,nos_coh_7,ejholmes,"2025-09-04 09:28:28","12 months"
244,domain_ae_include_vax,moat0011,"2025-08-12 13:54:14","Also included AZ, SInovac, and SInopharm"
245,domain_ae_include_vax,abersm.gmail.com,"2025-07-30 14:25:47","Article did not explicitly state influenza vaccine product. They only said that IIV is provided free of charge in Korea"
246,rob_screen1,nebasta,"2025-09-06 17:16:41","Would consider these Vigibase/EudraVigilance/VAERS/other AE-case report-only database analyses not to have a comparator group because there is no [valid] comparator group in the sample, even if the authors subset the sample and compare between two vaccines within the AE database. 

It could also be valid to choose ""yes"" to comparison group, to list study type  as ""case series with comparator group"" and fill in cross-sectional checklist. Both paths lead to the same high risk of bias assessment."
246,virus,scottja.stanford.edu,"2025-08-13 23:20:21","COVID vaccines are included too but not disaggregated."
247,rob2_data1,and05081,"2025-09-05 10:13:40","Data was available for nearly all participants, but no randomization."
247,rob2_msmt2,and05081,"2025-09-05 10:25:50","Selected response for immunogenicity component of study; Response would likely differ for AE component, which involved self-reporting"
248,nos_cc_2,ulric063,"2025-09-25 21:36:44",", we included patients who visited the emergency department or
outpatient clinic with ILI and those who were hospitalized with either laboratory-confirmed
influenza or with symptoms consistent with ILI. The attending
physician performed an influenza rapid antigen test (RAT) or real-time reverse-transcription
polymerase chain reaction (RT-PCR) according to the standard protocols. Patients who
tested positive for influenza RAT or RT-PCR were defined as influenza cases, whereas those
with negative results were regarded as controls."
248,nos_cc_4,ulric063,"2025-09-25 21:37:07","Updating to 'no history of disease' to align with guidance"
249,ae_incidence_yn,flemi644,"2025-08-08 11:14:46","Number of administered doses"
249,ae_outcome_2,flemi644,"2025-08-08 12:28:00","""acute cardiovascular injury"" = ""myocarditis, pericarditis, and others;"" not disaggregated by vaccine brand"
249,ae_outcome_2_v2,flemi644,"2025-08-08 12:30:14","""acute cardiovascular injury"" = ""myocarditis, pericarditis, and others;"" not disaggregated by vaccine brand"
249,nos_xs_1,ejholmes,"2025-09-03 15:23:48","Unsure how representative their passive surveillance system is (guidance doc is in Korean)"
249,nos_xs_2,ejholmes,"2025-09-03 15:55:23","Large sample"
249,nos_xs_3,ejholmes,"2025-09-03 15:55:57","Some outcome reports are self-report & unverified"
249,nos_xs_3,calba1.mgh.harvard.edu,"2025-09-11 08:34:03","Agreed, especially for the text message surveys. Even the COVID-19 vaccination management system (which was the one specifically used to assess myocarditis/pericarditis), is described as: ""AEs reported to the CVMS are suspected cases and do not necessarily indicate a medically confirmed diagnosis."""
250,nos_cc_2,ulric063,"2025-09-25 21:44:08","We conducted an influenza rapid antigen test (RAT) or real-time reverse-transcription
polymerase chain reaction (RT-PCR) according to the standard protocols. RAT is performed
more frequently in Korea than PCR tests for cost and rapidity considerations. Because
RAT is known to be less sensitive, we limited this test to patients who underwent testing
within 48 h of symptom onset"
250,nos_cc_4,ulric063,"2025-09-25 21:43:26","Updated to 'no history of disease' to align with guidance"
250,nos_cc_6,moat0011,"2025-09-03 19:49:37","The history of vaccination was collected
through individual questionnaires, medical records, and the national immunization registry
of the Korea Disease Control and Prevention Agency (KDCA)."
251,rob_outcome_epi,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-04 20:36:34","also in-hospital mortality"
252,rob_outcome_ve,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-04 21:40:23","also medically-attended infection and emergency department visits"
253,nos_cc_4,ulric063,"2025-09-25 22:03:30","Updating to 'no history of disease' to align with guidance"
253,nos_cc_6,moat0011,"2025-09-03 19:55:29","Trained staff interviewed participants or their parent/guardian to
obtain demographic and clinical information and inquired about
receipt of current season influenza vaccination"
253,nos_cc_6,moat0011,"2025-09-03 19:55:58","I considered this ""less rigorously"" assessed"
253,ve_adult_vax_n_3,emeyerowit.montefiore.org,"2025-08-10 13:50:02","Note: age 18-49"
253,ve_adult_vax_n_4,emeyerowit.montefiore.org,"2025-08-10 13:55:12","18-49 years"
253,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-10 13:53:22","8 months-17 years"
253,ve_child_vax_n_2,emeyerowit.montefiore.org,"2025-08-10 13:53:10","8 months - 17 years"
253,ve_child_vax_n_3,emeyerowit.montefiore.org,"2025-08-10 13:52:00","8 months-17 years"
253,ve_child_vax_n_4,emeyerowit.montefiore.org,"2025-08-10 13:57:07","8 months to 17 years"
253,ve_elder_vax_n_3,emeyerowit.montefiore.org,"2025-08-10 13:49:07","Note this is for >50"
253,ve_elder_vax_n_4,emeyerowit.montefiore.org,"2025-08-10 13:54:34",">50 years"
254,ae_incidence_yn,flemi644,"2025-08-08 13:04:47","Incidence is per-dose rates per 100,000 doses"
254,ae_outcome1_vax_n,flemi644,"2025-08-08 13:05:00",doses
254,ae_outcome1_vax_n_2,flemi644,"2025-08-08 13:08:50",doses
254,ae_outcome1_vax_y,flemi644,"2025-08-08 13:08:11","Myocarditis vs Pericarditis differentiated in the text (page 6). Myo + peri = 25"
254,ae_outcome1_vax_yes_2,flemi644,"2025-08-08 13:09:28","Specified in the text."
254,nos_xs_1,ejholmes,"2025-09-03 16:02:32","Non-random, large sample of 2 states"
254,nos_xs_3,ejholmes,"2025-09-03 16:01:28","Mix of voluntary/mandatory reporting; Mix of med record and self-report; Temporal association of outcome only (not causal)"
254,rob_screen1,nebasta,"2025-09-27 11:32:55","NEB: Study is based on Aus AE Reporting System Reports (RR reported is ""Reporting Rate"" not ""Relative Risk"" - no comparator group to assess reports against."
255,nos_cc_4,ulric063,"2025-09-25 22:05:07","Updating to 'no history of disease' to align with guidance"
255,ve_adult_vax_n,emeyerowit.montefiore.org,"2025-08-10 14:07:14","age 15-64"
255,ve_child_em_ci,emeyerowit.montefiore.org,"2025-08-10 14:07:02","adjusted CI"
255,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-10 14:05:16","7 months to 14 years"
255,ve_overall_em_ci,emeyerowit.montefiore.org,"2025-08-10 14:10:37","adjusted CI"
259,nos_coh_8,ejholmes,"2025-09-04 14:51:53","States criteria for LTFU, but not detailed characteristics of those lost"
261,date_start_month,abersm.gmail.com,"2025-08-04 13:11:12","Specific time period not mentioned. Authors state, ""March 2023, at the time this study was 
conducted"" in first line of discussion section."
263,nos_coh_1,ejholmes,"2025-09-04 15:10:31","Large registry + Medicare claims"
263,nos_coh_3,ejholmes,"2025-09-04 15:15:47","Vaccination data relied on Medicare claims info; Potential for exposure misclassification depending on how individuals received vaccine (eg community events vs PCP)"
263,nos_coh_6,ejholmes,"2025-09-04 15:14:38","Claims data + cardiac monitoring data"
263,nos_coh_8,ejholmes,"2025-09-04 15:16:18","All ppts followed in registry"
265,ve_overall_em_ci,emeyerowit.montefiore.org,"2025-08-10 14:24:53","adjusted CI"
269,title,emeyerowit.montefiore.org,"2025-08-10 14:31:48","Vaccine in study: SK's Inactivated Quadrivalent Seasonal 
Influenza Vaccine (Fluarix Tetra)"
271,date_end_month,abersm.gmail.com,"2025-08-02 09:36:48","Last vaccination 7/2023"
271,nos_coh_1,ejholmes,"2025-09-04 15:24:10","Natl registry"
271,nos_coh_2,ulric063,"2025-09-22 12:10:35","The general population pre-pandemic comparator cohort
consisted of the population of Danish residents aged ⩾5 years who were alive and residing in Denmark on 1 January 2017"
271,nos_coh_4,ulric063,"2025-09-22 12:19:34","Outcome of interest may have been present for control group"
271,nos_coh_5,ulric063,"2025-09-22 12:12:45","Adjusted for sex"
274,domain_ae_include_vax,abersm.gmail.com,"2025-08-02 09:49:39","98% of vaccinations were Pfizer"
275,population,abersm.gmail.com,"2025-08-02 09:54:43","Age criteria not explicitly stated."
275,population_disagg,abersm.gmail.com,"2025-08-02 09:55:26","Age not disaggregated for each type of vaccine"
276,rob_outcome_ve,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-04 22:13:12","also hospitalizations"
276,ve_comparator1,abersm.gmail.com,"2025-08-02 10:07:14","Note that P values in table 2 compare VE to standard dose QIV. However, VE calculated by comparing to unvaccinated."
276,ve_overall_vax_n,abersm.gmail.com,"2025-08-02 10:18:05","Data from table 2"
276,ve_overall_vax_n_2,abersm.gmail.com,"2025-08-02 10:18:29","Data from table 2"
276,ve_overall_vax_n_2_v2,abersm.gmail.com,"2025-08-02 10:25:54","Data from table 2"
276,ve_overall_vax_n_2_v2_v3,abersm.gmail.com,"2025-08-02 10:30:16","Data from table 2"
276,ve_overall_vax_n_3,abersm.gmail.com,"2025-08-02 10:18:35","Data from table 2"
276,ve_overall_vax_n_3_v2,abersm.gmail.com,"2025-08-02 10:25:48","Data from table 2"
276,ve_overall_vax_n_3_v2_v3,abersm.gmail.com,"2025-08-02 10:30:21","Data from table 2"
276,ve_overall_vax_n_v2,abersm.gmail.com,"2025-08-02 10:26:00","Data from table 2"
276,ve_overall_vax_n_v2_v3,abersm.gmail.com,"2025-08-02 10:30:10","Data from table 2"
276,ve_vax_type_v2_v3,abersm.gmail.com,"2025-08-02 10:28:04","QIV (Influvac Tetra or Vaxigrip Tetra). Standard dose."
276,ve_vax1_other_v2,abersm.gmail.com,"2025-08-02 10:22:30","All patients were age >= 70"
278,nos_cc_4,ulric063,"2025-09-25 22:06:06","Updating to 'no history of disease' to align with guidance"
278,nos_cc_6,moat0011,"2025-09-03 20:02:48","self-reported on questionnaire, recall bias possible"
278,population,abersm.gmail.com,"2025-08-03 16:23:06","NOTE: Age ranges in study do not match definitions here exactly. See next form for details"
278,ve_adult_vax_n,abersm.gmail.com,"2025-08-03 16:38:57","Actual age range in study: 18-59 years"
278,ve_adult_vax_n_2,abersm.gmail.com,"2025-08-03 16:52:01","Age 18-59"
278,ve_adult_vax_n_3,abersm.gmail.com,"2025-08-03 16:51:54","Age 18-59"
278,ve_adult_vax_n_7,abersm.gmail.com,"2025-08-03 16:44:23","Age 18-59"
278,ve_child_vax_n,abersm.gmail.com,"2025-08-03 16:38:23","Actual age range in study: 0-17 years"
278,ve_child_vax_n_2,abersm.gmail.com,"2025-08-03 16:50:49","Age 0-17"
278,ve_child_vax_n_3,abersm.gmail.com,"2025-08-03 16:50:57","Age 0-17"
278,ve_elder_vax_n,abersm.gmail.com,"2025-08-03 16:39:09","Actual age range in study: >= 60 years"
278,ve_elder_vax_n_2,abersm.gmail.com,"2025-08-03 16:50:25","Age >= 60"
278,ve_elder_vax_n_3,abersm.gmail.com,"2025-08-03 16:50:17","Age >= 60"
278,ve_elder_vax_n_6,abersm.gmail.com,"2025-08-03 16:49:49","Age >= 60"
278,ve_elder_vax_n_7,abersm.gmail.com,"2025-08-03 17:02:17","Age >= 60"
279,nos_coh_1,ejholmes,"2025-09-04 15:32:52","Very large EHR dataset"
279,nos_coh_4,ulric063,"2025-09-22 12:27:18","Women
were excluded from the study if they had a diagnosis of any menstrual disorder prior to
COVID-19 vaccination and/or were pregnant and/or breastfeeding."
279,nos_coh_8,ejholmes,"2025-09-04 15:35:03","Only subjects with complete f/u data included"
279,population_disagg,abersm.gmail.com,"2025-08-03 16:11:20","Age not disaggregated by vaccine type"
280,ae_outcome,emeyerowit.montefiore.org,"2025-08-10 14:50:57","2 cases reported in study"
280,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-04 22:38:24","examines myocarditis (rare event in this study) in the context of a broad category of immune-related adverse events"
281,nos_coh_1,ulric063,"2025-09-22 12:32:07","The EULAR COVAX physician-reported registry (https://www.
eular.org/eular-covax-registry) was an observational registry of
patients with a pre-existing I-RMD or non-I-RMD who received
one or more doses of any vaccine against SARS-CoV-2. Providers were asked to report as many cases as possible of patients with RMDs vaccinated against SARS-CoV-2, with or without flares."
281,nos_coh_2,ulric063,"2025-09-22 12:33:08","When reporting only a subset of
patients from, for example, a full clinic list, providers were asked to select cases randomly, to avoid selection bias."
281,nos_coh_4,ulric063,"2025-09-22 12:34:47","Cases included in this study had a pre-existing I-RMD diagnosis"
281,nos_coh_6,ejholmes,"2025-09-04 15:42:20","Physician reported (voluntary)"
281,rob_screen1,and05081,"2025-09-10 13:47:54","No unvaccinated comparator, but ORs calculated for various factors among the vaccinated group"
282,domain_ae_include_vax,moat0011,"2025-08-06 17:33:53","Pfizer, Sinopharm, AstraZeneca, Covishield"
285,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-04 23:02:48","also stroke (cerebrovascular accidents); also myocardial infarctions, pericarditis"
286,ae_vax_type_v3,emeyerowit.montefiore.org,"2025-08-10 15:50:02",mRNA-1010
288,ae_outcome1_vax_y,flemi644,"2025-08-08 17:07:09","Noted that a retrospective analysis revealed that the 1 GBS case for BNT162b2 did not meet BCCD criteria."
289,ve_outcome_two,harleen.k.marwah.gmail.com,"2025-08-05 14:49:19","Endpoint 2 was RSV associated LRTI with severe hypoxemia"
289,ve_vax_type,harleen.k.marwah.gmail.com,"2025-08-05 14:45:05","RSV F protein nanoparticle vaccine"
290,ae_outcome,emeyerowit.montefiore.org,"2025-08-10 16:06:38","There was no significant between-group difference in the key sec­ondary endpoint of MACE (CV death, myocardial infarction and stroke) at 45 days (WR: 0.82; 95 % CI: 0.48---1.39; P = 0.46). Time-to-first event analysis for MACE showed similar results to those of the 
win ratio analysis (HR: 1.22; 95 % CI: 0.72---2.07; P = 0.47). 

At 45 days, all-cause deaths occurred in 30 (3.3 %) subjects of double-dose group and 25 (2.8 %) of the standard-dose group (HR: 1.22; 
95 % CI: 0.72---2.07; P = 0.47) and CV death had occurred in 20 (2.2%) subjects of double-dose and 14 (1.5 %) in standard-dose (HR: 1.45; 
95 % CI: 0.73---2.87; P = 0.29) (Fig. 3. c,d). 

Acute myocardial infarction occurred in 0.8 % of pa­
tients of the double-dose group and in 0.9 % of those in the late standard- 
dose group (HR: 1.16; 95 % CI: 0.42---3.19; P = 0.78); stroke had 
occurred in 0.4 % of patients of double-dose and in 0.4 % of those in the 
standard-dose group (HR: 1.01; 95 % CI: 0.25---4.04; P = 0.99"
290,rob_outcome_ae,mehr0035,"2025-09-07 14:51:32","Primary endpoints: all-cause death, MI, stroke, hospitalization for unstable angina, hospitalization for heart failure, urgent coronary revascularization, and hospitalization for respiratory infections"
290,rob_screen1,mehr0035,"2025-09-07 14:52:41","""double-dose influ-
enza vaccine at hospitalization, as early as possible after randomization,
vs. standard-dose vaccine 30 days after randomization"""
290,rob2_interv1,ulric063,"2025-09-20 15:47:10","open-label trial with blinded
endpoint adjudication."
290,rob2_interv2,ulric063,"2025-09-20 15:48:25","open-label trial with blinded
endpoint adjudication."
290,rob2_interv6,ulric063,"2025-09-20 15:50:18","The authors state: "" the present results should be considered secondary and exploratory,"" because it was not powered for this specific analysis but the analysis was pre-specified."
290,rob2_random1,mehr0035,"2025-09-07 14:58:32","Processes not specified in the article nor supplementary table, so while assume yes, marked as 'probably yes'"
292,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-08-10 16:24:49","Total of 27,062 hospitalizations or deaths from COVID during the season (not broken down by number who received booster)"
293,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-10 16:32:24","1707 GBS reports, but no total number of BNT162b2 vaccines given during the time period in the EU"
293,ae_incidence_yn_v2,emeyerowit.montefiore.org,"2025-08-10 16:33:05","596 GBS reports for mRNA-1273, but no total number of mRNA-1273 vaccines given in the EU during the study period"
293,ae_incidence_yn_v3,emeyerowit.montefiore.org,"2025-08-10 16:33:50","551 GBS reports following Ad26.Co2.S, but no denominator"
293,nos_cc_2,flemi644,"2025-09-03 09:57:21","Spontaneous reporting with substantial under-reporting likely."
293,nos_cc_3,flemi644,"2025-09-03 09:58:24","other ICSRs. not clearly defined as community or hospital."
293,nos_cc_5,flemi644,"2025-09-03 09:59:27","No multivariable control for age/sex/time/region; only limited stratifications"
293,nos_cc_8,flemi644,"2025-09-03 10:00:38","no description."
293,rob_screen1,flemi644,"2025-09-03 09:44:13","Compared to other COVID vaccines"
293,rob_screen1,flemi644,"2025-09-03 09:46:20","also case/non-case disproportionality."
293,rob_screen1,nebasta,"2025-09-22 18:00:50","ICSR (indiv case safety reports): Cases only - disproportionality analysis among cases"
294,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-10 16:37:16","1 mild case reported, but no denominator can be reliably generated from this study"
295,nos_cc_5,flemi644,"2025-09-03 10:20:34","Controls not consistent across networks."
295,nos_cc_6,flemi644,"2025-09-03 10:22:53","Note; Secure records where available, but not all. Some self-report"
296,nos_cc_6,flemi644,"2025-09-03 10:33:22","Secure records where available, with some self report"
297,ae_outcome1_em_ci,harleen.k.marwah.gmail.com,"2025-08-05 15:09:12","Table 3"
297,ae_vax_type,harleen.k.marwah.gmail.com,"2025-08-05 15:06:19",RSVPreF3
297,ae_vax_type_v2,harleen.k.marwah.gmail.com,"2025-08-05 15:09:51",RSVPreF
297,design,harleen.k.marwah.gmail.com,"2025-08-05 15:02:08","a test-negative case-control design  was used to estimate vaccine effectiveness (VE), and a self-controlled case series of vaccine  recipients was included to estimate vaccine-associated adverse events"
297,rob_screen1,flemi644,"2025-09-03 10:39:48","control period (self-controlled) "
297,ve_adult_vax_n,harleen.k.marwah.gmail.com,"2025-08-05 15:16:44","Over 60: 1318/53 963 (2.4)"
297,ve_adult_vax_n_2,harleen.k.marwah.gmail.com,"2025-08-05 15:19:20","> 60: 391/18 831 (2.1)"
297,ve_adult_vax_n_3,harleen.k.marwah.gmail.com,"2025-08-05 15:21:29","60+: 469/22125 (2.1)"
297,ve_elder_em,harleen.k.marwah.gmail.com,"2025-08-05 15:18:22","60-74: 75.2 (73.0-77.2) 
75+: 75.6 (73.7-77.3)"
297,ve_elder_em_2,harleen.k.marwah.gmail.com,"2025-08-05 15:20:34","60-74: 76.9 (72.9-80.3)
75+:  76.2 (72.9-79.2)"
297,ve_elder_em_3,harleen.k.marwah.gmail.com,"2025-08-05 15:22:21","60-74: 75.2 (71.0-78.8) 
75+ 76.1 (73.2-78.7)"
297,ve_elder_vax_n,harleen.k.marwah.gmail.com,"2025-08-05 15:17:38","60-74: 561/27 923 (2.0) 
> 75: 757/26 040 (2.9)"
297,ve_elder_vax_n_2,harleen.k.marwah.gmail.com,"2025-08-05 15:20:15","60-74: 157/10181 (1.5) 
75+: 234/8650 (2.7)"
297,ve_elder_vax_n_3,harleen.k.marwah.gmail.com,"2025-08-05 15:21:57","60-74: 161/9266 (1.7) 
74+: 308/12 859 (2.4)"
298,nos_coh_1,flemi644,"2025-09-03 10:50:39","Single-center outpatient/primary-care setting"
298,nos_coh_6,flemi644,"2025-09-03 10:55:03","Self-reported, but confirmed in the clinic."
298,nos_coh_8,flemi644,"2025-09-03 10:58:24","Missing data ofr < 5% of variables; censoring described; retention and scheduled follow-ups detailed"
298,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-08-10 16:48:42","Increased risk for long covid associated with not being fully vaccinated: (HR: 1·96, 95 % CI: 1·03-3·7, p = 0·03"
298,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-08-10 16:47:59","276 participants with COVID, including 104 with a prior COVID infection (reinfection identified during the study period).

263 were fully vaccinated

Long COVID -  87 (32 %) had symptoms lasting at least a month. A total 
of 57 (21 %) had symptoms lasting at least two months, 41 (15 %) at 
least three months, 26 (9 %) at least six months, 18 (7 %) at least nine 
months, and 15 (5 %) at least twelve months"
299,ve_child_em,stodd046,"2025-08-11 17:23:41","Did the following math to put into a 2x2 table and calculate simple VE: 
Vax(+) = 6334, Vax(-)=9733
UnVax(+) = 38865, UnVax(-)=36477"
299,ve_child_em_adj,stodd046,"2025-08-11 17:08:15","Unadjusted IVE for 7-17 yr: 40.5 (37.1-43.7)
Adjusted IVE for 6 mo - 6 yr: 45.8 (42.6-48.9)

Unadjusted IVE for 6 mo - 6 yr: 35.3 (32.3-38.2)
Adjusted IVE for 7-17 yr: 38.6 (35.7-41.5)"
299,ve_child_em_adj,stodd046,"2025-08-11 17:24:33","Did not calculate CI for our combined age group VE"
299,ve_child_vax_n,stodd046,"2025-08-11 14:12:45","(Table 2) Added 6 mo - 6 yr  test-positive groups (unvaxxed and vaxxed) with 7-17 yr test-positive groups"
300,nos_coh_1,flemi644,"2025-09-03 11:49:53","Recruitment emphasized nursing homes and tertiary-care staff; participation was voluntary via an online, publicly accessible survey. analytic sample excluded respondents without headaches."
300,nos_coh_2,flemi644,"2025-09-03 11:51:01","no respondents without headaches. "
300,nos_coh_4,flemi644,"2025-09-03 11:57:18","post-vac headache already present at time of survey for all respondents."
300,nos_coh_5,flemi644,"2025-09-03 11:58:51","t-tests for non-missing data only. no real control efforts."
300,nos_coh_7,flemi644,"2025-09-03 11:59:09","single questionnaire, no follow-up."
300,rob_screen1,flemi644,"2025-09-03 11:46:46","Compared to other vaccine types."
300,rob_screen2,flemi644,"2025-09-03 11:47:44","descriptive comparisons using T test/anova, but no multivariable adjustment reported."
301,domain_ae_include_list,emeyerowit.montefiore.org,"2025-08-10 17:12:25","VTE occurred within 90 days in 1,498 (0.11%) of the total 1,353,993 vaccinations, including 882 (0.10%) in the COVID-19 vaccination cohort and 616 (0.14%) in the influenza vaccination cohort. The rates of VTE in the three different types of COVID-19 vaccine cohorts were similar, specifically 0.09% with Pfizer, 0.11% with Moderna, and 0.08% with Janssen"
302,population_disagg,abersm.gmail.com,"2025-08-04 13:24:51","In supplement"
302,virus,abersm.gmail.com,"2025-08-04 13:22:33","Data for COVID-19 vaccine are not disaggregated by vaccine type"
303,date_start_month,abersm.gmail.com,"2025-08-04 13:29:51","Month not explicitly stated but implied based on vaccine availability."
304,ae_outcome1_otherinfo_yn,emeyerowit.montefiore.org,"2025-08-10 17:20:17","Info on presentation"
304,ae_outcome1_vax_y,emeyerowit.montefiore.org,"2025-08-10 17:21:13","8 cases of TTS = thrombosis with thrombocytopenia syndrome, of whom 3 had CVST"
306,ve_vax1_other,emeyerowit.montefiore.org,"2025-08-11 10:32:37","""About half of the 
patients were vaccinated against COVID-19 (49.2%), 
mainly with one dose (26.9%)."""
307,nos_cc_4,ulric063,"2025-09-25 22:08:26","Updating to 'no history of disease' to align with guidance"
309,rob_outcome_epi,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-04 23:25:46","also mortality and vaccination rates"
314,rob_outcome_ve,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-05 10:11:38","long COVID"
314,ve_outcome_prime_txt,emeyerowit.montefiore.org,"2025-08-11 11:11:38","""Vaccination prior to first SARS-CoV-2 infection was associated with better physical and mental health outcomes. This builds upon existing observational research demonstrating a potential benefit to vaccination prior to
SARS-CoV-2.34 Subsequently, we observed markedly better physical and mental health among those receiving multiple boosters compared with no vaccination or only
a primary vaccination series before SARS-CoV-2 infection. This supports a key protective effect of vaccination, which is more pronounced among those receiving booster vaccinations"""
317,nos_coh_1,moat0011,"2025-09-10 15:15:03","database covers more than 99% of French residents, upgraded to ""truly representative"""
318,rob_outcome_epi,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-05 14:29:47","neurologic long COVID symptoms"
321,domain_ae_include_vax,moat0011,"2025-08-12 11:10:28","BBIBP-CorV-Sinopharm 
CoronaVac-Sinovac 
BNT162b2 (Pfizer-BioNTech) 
mRNA-1273 (Moderna) 
Gam-COVID-Vac (Sputnik V) 
JNJ-78436735 ( Johnson & Johnson) 
ChAdOx1 (Oxford AstraZeneca) 
Unknown"
321,population,emeyerowit.montefiore.org,"2025-08-11 11:35:55","Not specified whether children were included"
327,nos_coh_1,stodd046,"2025-09-04 08:47:43","All the subjects were recruited after the application of their first dose at the Hospital de la Sociedad Española de Beneficencia, Pachuca, Hidalgo, México"
327,nos_coh_4,stodd046,"2025-09-04 08:49:18","It's reasonable to assume that participants did not have the covid vax before enrollment because they just became available, but authors did not explain this."
327,nos_coh_7,stodd046,"2025-09-04 08:50:26","6 months after each dose"
327,rob_type,stodd046,"2025-09-04 08:58:21","Authors call their participants a ""cohort"" but they use the same participants before vaccination as controls for the outcome, leading me to believe this is actually a self-controlled case series"
329,domain_ae_include_vax,moat0011,"2025-08-12 11:07:06","Pfizer, Moderna, AZ"
330,population,emeyerowit.montefiore.org,"2025-08-11 20:23:38","Does not specifically state, assume all ages"
330,rob_domain_aensi_other,stodd046,"2025-09-04 09:36:46","including retinal artery occlusion (RAO), retinal vein occlusion (RVO), noninfectious uveitis (NIU), noninfectious scleritis (NIS), optic neuritis (ON), ischemic optic neuropathy (ION), and ocular motor cranial nerve palsy (OMCNP)"
331,nos_xs_1,ejholmes,"2025-09-05 09:56:45","WHO multi-country, different methods across countries on reporting requirements, mostly voluntary"
331,nos_xs_2,ejholmes,"2025-09-05 09:56:57","Large sample"
331,nos_xs_3,ejholmes,"2025-09-05 09:58:09","Researchers make attempts to weed out unrelated reports, but still significant opportunities for misclassification without ability to verify with a health record uniformly"
331,population,emeyerowit.montefiore.org,"2025-08-11 20:26:10","Assume all ages"
331,rob_type,ejholmes,"2025-09-05 09:55:29","Compares rates over time, but no concurrent data points on individuals, exposure/outcome assessed simultaneously"
332,nos_coh_1,calba1.mgh.harvard.edu,"2025-09-12 10:22:53","Representative group was eligible but ultimately only 37% completed survey - classifying as self-selected group/volunteers. JLL agreed with change."
332,rob_outcome_ve,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-05 14:46:34","post-COVID-19 condition -- ""26 physical, mental, and cognitive symptoms
that emerged during or after the first SARS-COV-2 infection"""
332,rob_outcome_ve,calba1.mgh.harvard.edu,"2025-09-12 10:05:46","Referred to as ""post-COVID-19 condition"" which was defined as specific sx persisting for >2 months after infection onset."
332,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-08-11 20:34:13","Table 4"
332,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-08-11 20:34:03","Table 1"
333,nos_xs_1,ejholmes,"2025-09-05 10:05:21","Med students at one institution; convenience sample"
333,nos_xs_2,ejholmes,"2025-09-05 10:05:48","Justified with sample size calc, but very small"
333,nos_xs_3,ejholmes,"2025-09-05 10:06:00",Self-report
335,ae_outcome1_em_ci_4,emeyerowit.montefiore.org,"2025-08-14 11:55:05","supplementary table 24 - BNT boost of any primary series"
335,ae_outcome1_em_ci_v2,emeyerowit.montefiore.org,"2025-08-13 19:59:35","aHR for myocarditis only - may need to sum myocarditis and pericarditis"
335,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-13 09:52:58","Age and sex adjusted hazard ratio for week 1 after either second or booster dose"
335,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-14 11:53:31","supplementary table 24 - BNT booster after any primary series"
335,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-08-13 09:54:22","adjusted hazard ratio for BNT162b2 boost of any primary series at 1 week from booster dose"
335,ae_outcome1_em_type_2_v2,emeyerowit.montefiore.org,"2025-08-13 10:08:39","Used supplementary table 23 - booster with mRNA-1273 after any primary course adjusted hazard ratio"
335,ae_outcome1_em_type_3,emeyerowit.montefiore.org,"2025-08-13 09:54:55","adjusted hazard ratio as above"
335,ae_outcome1_em_type_3_v2,emeyerowit.montefiore.org,"2025-08-13 10:02:26","Age and sex adjusted HR, for week 1 after vaccine"
335,ae_outcome1_em_type_4,emeyerowit.montefiore.org,"2025-08-14 11:55:12","age and sex adjusted HR"
335,ae_outcome1_em_type_4_v2,emeyerowit.montefiore.org,"2025-08-13 10:09:58","Age and sex adjusted HR, using supplementary table 23 as above"
335,ae_outcome1_em_type_5,emeyerowit.montefiore.org,"2025-08-13 09:56:30","adjusted hazard ratio"
335,ae_outcome1_em_type_5_v2,emeyerowit.montefiore.org,"2025-08-13 10:03:24","age and sex adjusted HR, for weeks 0-4 after second dose"
335,ae_outcome1_em_type_6,emeyerowit.montefiore.org,"2025-08-13 09:57:11","adjusted hazard ratio, supplementary table 24"
335,ae_outcome1_em_type_6_v2,emeyerowit.montefiore.org,"2025-08-13 10:10:32","Age and sex adjusted"
335,ae_outcome1_em_type_6_v2,emeyerowit.montefiore.org,"2025-08-14 11:51:42","Supplementary table 23 as above"
335,ae_outcome1_em_type_7,emeyerowit.montefiore.org,"2025-08-13 09:58:13","adjusted hazard ratio"
335,ae_outcome1_em_type_8,emeyerowit.montefiore.org,"2025-08-13 09:57:41","adjusted hazard ratio"
335,ae_outcome1_em_type_8,emeyerowit.montefiore.org,"2025-08-14 11:56:03","supplementary table 24"
335,ae_outcome1_em_type_8_v2,emeyerowit.montefiore.org,"2025-08-13 10:11:10","age and sex adjusted"
335,ae_outcome1_em_type_8_v2,emeyerowit.montefiore.org,"2025-08-14 11:53:00","supplementary table 23 as above"
335,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-13 10:00:48","adjusted, - just reporting value for myocarditis here. May need to calculate myocarditis + pericarditis as composite outcome, supplementary table 13"
335,ae_outcome1_em_value,emeyerowit.montefiore.org,"2025-08-13 18:12:11","for ""myocarditis"" only - may need to calculate composite of ""myocarditis"" + ""pericarditis"""
335,ae_outcome1_em_value_2,emeyerowit.montefiore.org,"2025-08-13 18:12:23","for ""myocarditis"" only - may need to calculate composite of ""myocarditis"" + ""pericarditis"""
335,ae_outcome1_em_value_2,emeyerowit.montefiore.org,"2025-08-14 11:54:29","supplementary table 24 - BNT booster after any primary series"
335,ae_outcome1_em_value_2_v2,emeyerowit.montefiore.org,"2025-08-13 10:08:59","Weeks 0-4 after booster"
335,ae_outcome1_em_value_2_v2,emeyerowit.montefiore.org,"2025-08-13 10:09:25","just reporting myocarditis, may need to use composite of myocarditis + pericarditis"
335,ae_outcome1_em_value_3,emeyerowit.montefiore.org,"2025-08-13 09:55:50","Supplementary Table 12"
335,ae_outcome1_em_value_4_v2,emeyerowit.montefiore.org,"2025-08-13 10:10:16","Risk at 1 week after booster"
335,ae_outcome1_em_value_6_v2,emeyerowit.montefiore.org,"2025-08-13 10:10:56","week 1 after booster"
335,ae_outcome1_em_value_7_v2,emeyerowit.montefiore.org,"2025-08-13 10:04:37","unable to run model"
335,ae_outcome1_em_value_8_v2,emeyerowit.montefiore.org,"2025-08-13 10:11:16","weeks 0-4 after booster"
335,ae_outcome1_em_value_v2,emeyerowit.montefiore.org,"2025-08-13 10:01:27","Collapsed time period for weeks 0-4 after second dose"
335,ae_outcome1_unvax_y_2,emeyerowit.montefiore.org,"2025-08-13 10:24:18","I don't think we have this number for booster cohort"
335,ae_outcome1_unvax_y_2_v2,emeyerowit.montefiore.org,"2025-08-13 10:21:15","I don't think we have this number for the booster cohort"
335,ae_outcome1_unvax_y_3_v2,emeyerowit.montefiore.org,"2025-08-13 10:22:18","supplmentary table 4 - ""no vaccine"""
335,ae_outcome1_unvax_y_4_v2,emeyerowit.montefiore.org,"2025-08-13 10:22:52","I don't think this number is available in the data provided"
335,ae_outcome1_unvax_y_v2,emeyerowit.montefiore.org,"2025-08-13 10:18:46","supplementary table 4 - ""no vaccine"""
335,ae_outcome1_unvax_y_v2,emeyerowit.montefiore.org,"2025-08-13 19:59:10","sum myocarditis + pericarditis"
335,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-08-13 09:50:05","Used total n from supplementary tables 1 and 2"
335,ae_outcome1_vax_y_v2,emeyerowit.montefiore.org,"2025-08-13 10:17:50","summing doses 1+2 totals at bottom of supplementary table 4"
335,nos_coh_1,ejholmes,"2025-09-05 10:17:53","Large, natl datasetl may overrepresnt LTC; may not capture events that don't require medical encounter"
335,nos_coh_8,ejholmes,"2025-09-05 10:24:51","No statement, but nature of dataset leads to few potential LTFU"
336,nos_coh_score,calba1.mgh.harvard.edu,"2025-09-12 10:56:49","I believe this was not complete follow-up but remains >80% (415/500 not refused, LTFU, or deviated from protocol). Since this has no effect on score, leaving as is."
338,ae_incidence_yn_v2,emeyerowit.montefiore.org,"2025-08-12 20:28:12","SAE8 in Table S12 - man in his 20s, symptoms started 4 days after second dose, 2 doses were spaced 1 month apart"
338,design,emeyerowit.montefiore.org,"2025-08-12 20:22:38","28 days after last administration of October 26, 2021"
338,nos_coh_1,ejholmes,"2025-09-05 11:36:29","Very large national sample; mRNA vaccines rely more heavily on subpops (HCWs, essential workers)"
338,nos_coh_2,ejholmes,"2025-09-05 11:45:51","Descriptive within each cohort, but comparison between vaccines limited due to sample source"
338,nos_coh_5,ejholmes,"2025-09-05 11:42:50","Attempts to control for numerous factors; however, populations of each cohort aren't entirely comparable (noted as limitation by researchers)"
338,nos_coh_6,ejholmes,"2025-09-05 11:40:55","Structured diary; given axillary thermometer"
338,nos_coh_8,ejholmes,"2025-09-05 11:44:26","only 3 ppts LTFU"
338,rob_outcome_ae,ejholmes,"2025-09-05 11:33:07","Primarily assessed reactogenicity"
338,rob_screen1,ejholmes,"2025-09-05 11:39:47","Comparisons between vaccine type and SEs; no unvaccinated comparison"
339,date_start_year,abersm.gmail.com,"2025-08-03 17:23:26","Specifically for COVID-19 vaccination subgroup"
343,domain_ae_include_list,scottja.stanford.edu,"2025-08-11 23:41:45","This French pharmacovigilance study and nationwide survey found a reporting rate (RR) for new-onset polymyalgia rheumatica (PMR) of 7.1 cases per 1,000,000 vaccinated persons aged >50 (179 cases total). The RR for giant cell arteritis (GCA) was 2.1 cases per 1,000,000 persons (54 cases total). The median time from vaccination to symptom onset was 10 days for PMR and 7 days for GCA."
343,domain_ae_include_vax,moat0011,"2025-08-15 11:43:17","Also AZ"
343,population,moat0011,"2025-08-15 11:44:13",52-94
344,domain_ae_include_vax,moat0011,"2025-08-07 11:41:00","Ad26.RSV.preF/RSV preF protein vaccine; not approved for use in the US"
346,ae_comparator1_other,emeyerowit.montefiore.org,"2025-08-13 20:30:57","Study uses reporting odds ratio (ROR): ""OR was calculated using the following formula: ROR = (a/b)/(c/d), where ""a"" represents the number of reports for a certain adverse drug reaction, ""b"" is the number of reports for all other ADRs with a specific drug, ""c"" is the number of all reports for certain 
ADRs not related to a specific drug, and ""d"" is the number of all reports not related to both specific ADRs and drugs."""
346,ae_incidence_yn,emeyerowit.montefiore.org,"2025-08-13 20:32:54","Influenza vaccines had the highest association with GBS (ROR, 77.91 [95% CI, 75.30-80.62]"
346,rob_screen1,ejholmes,"2025-09-12 15:02:51","ROR for pharmacovigilance"
351,ve_overall_vax_n,emeyerowit.montefiore.org,"2025-08-13 20:52:09","those who received 4 vaccines"
351,ve_overall_vax_n_2,emeyerowit.montefiore.org,"2025-08-13 20:53:58","those who received 4 (reference group), table 4"
352,ae_outcome_5,emeyerowit.montefiore.org,"2025-08-07 20:31:22","NOT STRICTLY MI"
352,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-05 14:56:13","also: placental abruption; also: gestational hypertensive disorders, gestational diabetes, hemorrhage (ante-,intra-, and postpartum), preterm premature rupture of membranes, chorioamnionitis, deep vein thrombosis, maternal cardiovascular or neonatal outcomes"
355,domain_ae_include_vax,moat0011,"2025-08-07 12:17:12","MVA-BN-RSV vaccine"
357,nos_coh_2,moat0011,"2025-09-11 11:55:23","Sera from age and sex matched health care workers (HW) of nursing
homes, collected in the context of the COV-RISK study, carried out by
the Institute for Research in Biomedicine and the Universit`a della
Svizzera Italiana, were used as healthy controls."
357,nos_coh_4,ulric063,"2025-09-21 18:03:24","Serum samples for exposed and unexposed not consistent time periods: Pre-vaccination sample, as close as possible to the vaccination date for exposed; taken within 3 months before vaccination for unexposed"
357,nos_coh_5,ulric063,"2025-09-21 21:54:31","Sera from age and sex matched health care workers (HW) of nursing homes used as healthy controls, but Table 1 shows imbalances in age, sex, vaccine type;"
359,nos_coh_1,nebasta,"2025-09-05 16:27:11","people undergoing surgery diagnosed with COVID-19 in the 30 days before"
359,nos_coh_2,nebasta,"2025-09-05 16:29:19","Because the cohort is defined as COVID-19 infected people undergoing surgery, then subset by vaccination status, it's not really a vaccinated and unvaccinated cohort. Regardless, we can't say which source the vaccinated vs unvaccinated were drawn from"
359,nos_coh_5,nebasta,"2025-09-05 16:31:45","Based on the study design and our interest in covid-19 vaccination, the study does not adequately control for the reasons one would have/would not have gotten vaccinated which certainly could be associated with the outcome of interest"
359,nos_coh_7,nebasta,"2025-09-05 16:33:00","I marked ""no"" because based on this design, the follow up is too long - we don't know the timing of vaccination prior to COVID-19 diagnosis and/or prior to surgery. Outcomes occurred 30/90/etc days after surgery"
359,rob_outcome_other,nebasta,"2025-09-05 16:17:00","COVID-Myocarditis was chosen in the data extraction phase, but this is not mentioned in the article. The ORs reported in the data extraction phase are for myocardial infarction only."
370,date_end_year,stodd046,"2025-08-15 16:03:17","study end date"
370,nos_coh_5,and05081,"2025-09-04 13:16:52","Did not control for important characteristics of uveitis (time since initial diagnosis, frequency of recurrence, severity, treatment status, etc.)"
373,nos_cc_8,ejholmes,"2025-08-29 15:21:44","Non-response not really an option given cohort/medical abstraction"
373,rob_outcome_ae,ejholmes,"2025-08-29 15:10:09","multiple AESIs of pregnancy (pre-term, LBW, maternal hospitalization)"
373,rob_type,ejholmes,"2025-08-29 15:15:06","Matched case-control study nested in a retrospective cohort"
375,ve_adult_vax_n,stodd046,"2025-08-21 15:12:43","""Within those in a clinical risk group aged 18-64 years"""
377,nos_cc_4,ulric063,"2025-09-25 22:10:18","Updating to 'no history of disease' to align with guidance"
378,domain_ae_include_vax,stodd046,"2025-08-21 14:16:18","Other: ChAdOx1"
378,population_disagg,stodd046,"2025-08-21 14:17:55","18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+"
380,nos_xs_1,nebasta,"2025-09-05 17:00:26","The target population is people with Noninfectious Uveitis because the outcome is ""recurrence"""
382,nos_cc_4,ulric063,"2025-09-25 22:12:04","Updating to 'no history of disease' to align with guidance"
383,rob_screen1,nebasta,"2025-09-05 17:07:34","The WHO pharmacovigilance database has no comparator group. It is only reports of potential AEs. The comparison of AEs between vaccines reported in this article is an inappropriate use of this database, as noted on the database website: https://www.vigiaccess.org/"
385,domain_ae_include_vax,moat0011,"2025-08-21 10:28:14","Also AZ and Novavax"
385,rob_screen1,nebasta,"2025-09-06 15:06:25","Would consider these EudraVigilance/VAERS/other AE-case report-only database analyses not to have a comparator group because there is no [valid] comparator group, even if they compare between two vaccines within the AE database. 
It could also be valid to choose ""yes"" to comparison group, to list study type  as ""case series with comparator group"" and fill in cross-sectional checklist. Both paths lead to the same high risk of bias assessment."
387,nos_coh_1,nebasta,"2025-09-01 18:58:19","Only those who chose to get vaccinated were included in the retrospective analysis"
387,nos_coh_2,nebasta,"2025-09-01 18:59:03","The comparison cohort is those who received a different vaccine type. There is no ""non-exposed"" group. All were vaccinated in this study"
387,rob_screen1,nebasta,"2025-09-01 18:55:20","Descriptive retrospective analysis among vaccinated individuals, comparison group-AEs by vaccine type"
388,ae_outcome,stodd046,"2025-08-21 15:48:40","""Apart from the expected AEs, the following serious unexpected AEs were reported within 6 weeks of vaccination: 1 cerebral sinus thrombosis"
390,nos_xs_2,stodd046,"2025-09-05 12:17:06","not justified and dont report any stats on differences between groups"
392,rob_screen1,nebasta,"2025-09-06 15:10:39","Would consider these Vigibase/EudraVigilance/VAERS/other AE-case report-only database analyses not to have a comparator group because there is no [valid] comparator group, even if they compare between two vaccines within the AE database. 
It could also be valid to choose ""yes"" to comparison group, to list study type  as ""case series with comparator group"" and fill in cross-sectional checklist. Both paths lead to the same high risk of bias assessment."
394,nos_xs_2,stodd046,"2025-09-05 12:22:46","very large dataset"
394,nos_xs_3,stodd046,"2025-09-05 12:25:07","Given the heterogeneity of this large system, there are probably several measurement tools/classifications across the 156 contributing countries"
396,nos_xs_3,stodd046,"2025-09-05 12:33:08","No single measurement tool for outcome assessment described other than ""individual case safety reports"""
398,ve_adult_em_adj,stodd046,"2025-08-21 14:00:44","50-64 year old"
399,ve_adult_vax_n,emeyerowit.montefiore.org,"2025-08-13 21:08:32","ages 3-9 years"
399,ve_adult_vax_n_2,emeyerowit.montefiore.org,"2025-08-13 21:11:52","60-69 years"
399,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-13 21:07:52","6 months to 2 years"
399,ve_child_vax_n_2,emeyerowit.montefiore.org,"2025-08-13 21:11:01","18-59 years"
399,ve_elder_vax_n,emeyerowit.montefiore.org,"2025-08-13 21:09:13","ages 10-17 years"
399,ve_elder_vax_n_2,emeyerowit.montefiore.org,"2025-08-13 21:12:22","70+ years"
400,domain_ae_include_list,stodd046,"2025-08-21 14:04:59","self-reported reactogenicity reports in Table 2"
400,nos_coh_8,ulric063,"2025-09-21 16:11:08","Response rate of 51%"
400,population,emeyerowit.montefiore.org,"2025-08-13 21:15:51","Not specified whether children were included"
401,ae_incidence_yn,stodd046,"2025-08-12 13:32:52","The authors report the number of events and the relative incidence of GBS in 1-42 days of exposure (Figure 1)."
401,ae_incidence_yn,stodd046,"2025-08-12 13:35:22","Dose 1: 93 events, RI=1.1 (0.91,1.4)
Dose 2: 107 events, RI=1.0 (0.83,1.3) 
Dose 3: 78 events, RI= 0.92 (0.70,1.2)"
401,ae_incidence_yn_v2,stodd046,"2025-08-12 13:38:21","Dose 1: 14 events, RI=1.2 (0.68,2.1)
Dose 2: 25 events, RI=1.3 (0.84,2.0)
Dose 3: 35 events, RI= 0.98 (0.64,1.5)"
401,ae_incidence_yn_v3,stodd046,"2025-08-12 13:39:20","Dose 1: 10 events, RI=2.4 (1.2,5.0)*"
402,ae_outcome,emeyerowit.montefiore.org,"2025-08-14 17:13:56","Risk following dose 1"
402,ae_outcome1_describe_4,emeyerowit.montefiore.org,"2025-08-14 20:41:56","supplementary table 2"
402,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-14 17:16:06","Adjusted odds ratio"
402,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-08-14 20:08:55",adjusted
402,ae_outcome1_em_type_2_v2,emeyerowit.montefiore.org,"2025-08-14 20:27:32",adjusted
402,ae_outcome1_em_type_3,emeyerowit.montefiore.org,"2025-08-14 20:15:32",adjusted
402,ae_outcome1_em_type_3_v2,emeyerowit.montefiore.org,"2025-08-14 20:35:49","adjusted odds ratio"
402,ae_outcome1_em_type_4,emeyerowit.montefiore.org,"2025-08-14 20:42:56",adjusted
402,ae_outcome1_em_type_4_v2,emeyerowit.montefiore.org,"2025-08-14 20:48:50",adjusted
402,ae_outcome1_em_type_5_v2,emeyerowit.montefiore.org,"2025-08-14 20:49:55",adjusted
402,ae_outcome1_em_type_6,emeyerowit.montefiore.org,"2025-08-14 20:21:04",adjusted
402,ae_outcome1_em_type_6_v2,emeyerowit.montefiore.org,"2025-08-14 20:51:25",adjusted
402,ae_outcome1_em_type_8,emeyerowit.montefiore.org,"2025-08-14 20:23:33",adjusted
402,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-14 20:26:25",adjusted
402,ae_outcome1_unvax_y_5,emeyerowit.montefiore.org,"2025-08-14 20:44:08",adjusted
402,ae_outcome1_vax_y,emeyerowit.montefiore.org,"2025-08-14 20:00:13","Supplementary Table 3"
402,ae_outcome1_vax_y_6,emeyerowit.montefiore.org,"2025-08-14 20:46:44",males
402,ae_outcome1_vax_y_6_v2,emeyerowit.montefiore.org,"2025-08-14 20:50:49",males
402,date_end_month,flemi644,"2025-08-15 17:49:23","changed to November (Results -> vaccines received)"
405,epi_hospitalization_covid,flemi644,"2025-08-12 10:50:04","Note that I decided to exclude ED since data on whether those ended up being outpatient or hospitalized was not provided. Data pulled from Supp figure (table) 3"
405,epi_sample_covid,flemi644,"2025-08-12 10:51:17","ED visits excluded. See comment on hospitalization rate."
406,ve_adult_em,scottja.stanford.edu,"2025-08-15 02:00:24","The study reports VE for 18-49 and 50-64 year olds separately, but not for the combined 18-64 group."
406,ve_adult_em_ci,scottja.stanford.edu,"2025-08-15 02:00:50","The study reports the following separately:
VE for 18-49 years: 53% (95% CI, 34%-67%)
VE for 50-64 years: 47% (95% CI, 31%-60%)"
406,ve_adult_unvax_n,scottja.stanford.edu,"2025-08-15 01:59:54","(This is 1389 controls from the 18-49 group + 1748 from the 50-64 group)"
406,ve_adult_unvax_y,scottja.stanford.edu,"2025-08-15 02:00:07","(This is 364 vaccinated controls from the 18-49 group + 653 from the 50-64 group)"
406,ve_adult_vax_n,scottja.stanford.edu,"2025-08-15 01:59:31","(This is 314 cases from the 18-49 group + 351 cases from the 50-64 group)."
406,ve_adult_vax_y,scottja.stanford.edu,"2025-08-15 01:59:42","(This is 52 vaccinated cases from the 18-49 group + 96 from the 50-64 group)."
406,ve_vax_type,scottja.stanford.edu,"2025-08-15 01:55:14","data on the type of influenza vaccine received were not collected, precluding comparative effectiveness analyses by vaccine type"
407,epi_sample_covid,emeyerowit.montefiore.org,"2025-08-16 20:44:29","3080 BA.2.86 lineage (eg JN.1) and 4614 non-BA.2.76 lineage infections"
409,ae_outcome,stodd046,"2025-08-20 14:48:04","26 cases, not disaggregated by vaccine type."
409,ae_outcome_v2,stodd046,"2025-08-20 14:48:12","26 cases, not disaggregated by vaccine type."
409,domain_ae_inc_other_txt,stodd046,"2025-08-20 14:43:07","""Among the SAE reports, a total of 8,723 non-unique AEs and 1,907 unique AEs were identified. The most commonly reported AEs included death (N = (250)), dyspnoea (N = 115), and COVID-19 (N = 107)."""
410,rob_outcome_ae,ejholmes,"2025-08-29 15:28:27","Reports other AESIs (death, pregnancy (preterm birth))"
412,exclude,flemi644,"2025-08-13 10:44:45","no negative controls and only comparing to non-US licensed vaccines for AEs not of special interest. May consider excluding. Leaving for second reviewer opinion."
412,population,flemi644,"2025-08-13 10:34:34","All adults 18+"
414,population_other,flemi644,"2025-08-13 17:28:06","Note that VE is not disaggregated by 1-64 and 65+ even though some numbers are given. Not enough to calculate ve"
414,ve_adult_em_adj,flemi644,"2025-08-13 17:16:08","reported as ""similar to overall"""
414,ve_adult_em_adj_2,flemi644,"2025-08-13 17:22:20","only 7-59d post vaccine"
414,ve_elder_em_adj,flemi644,"2025-08-13 17:17:07","Reported as ""similar to overall"""
414,ve_elder_em_adj_2,flemi644,"2025-08-13 17:26:41","7-59d post-vaccine only"
416,ae_outcome,flemi644,"2025-08-15 11:00:56","Myocard and perar is pooled"
416,domain_ae_include_vax,stodd046,"2025-08-20 14:53:37","Other = ChAdOx1 nCoV-19"
417,nos_coh_3,ulric063,"2025-09-07 22:27:57","""have documentation of a previous nonsevere
COVID-19 infection"""
417,population,flemi644,"2025-08-15 15:32:55","Adults 60+ years"
417,ve_em_type,stodd046,"2025-08-20 15:13:23","IRR by wave is reported in the supplementary but uses wave 10 as the reference group."
417,ve_overall_em,flemi644,"2025-08-15 15:52:46","Hybrid vs VUPI"
417,ve_overall_em,flemi644,"2025-08-15 15:56:59","calculated using person-days at risk."
417,ve_overall_unvax_n,flemi644,"2025-08-15 15:55:03","# VUPI patients with severe disease"
417,ve_overall_vax_n,flemi644,"2025-08-15 15:54:46","# hybrid patients with severe disease"
417,ve_overall_vax_n,stodd046,"2025-08-20 15:11:50","For the total study period, not just wave 10 which spans into 2024. They have graphs depicting the disaggregated age and wave date but do not report the numbers."
418,ae_vax_type,flemi644,"2025-08-15 16:59:00","Extracting the pooled pfizer/moderna data due to lack incidence rate data"
419,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-16 13:48:31","Table 3 has IRR"
419,ae_outcome1_em_value,stodd046,"2025-08-21 10:15:53","This is the IRR for GBS among Medicare FFS population."
419,ae_outcome1_unvax_n,emeyerowit.montefiore.org,"2025-08-16 13:44:56","adjusted person years - 1,463,721.80"
419,ae_outcome1_unvax_n_2,emeyerowit.montefiore.org,"2025-08-16 13:52:53","adjusted person years:  1,448,623.87"
419,ae_outcome1_unvax_n_3,emeyerowit.montefiore.org,"2025-08-16 15:01:52","1,467,906.74"
419,ae_outcome1_unvax_n_4,emeyerowit.montefiore.org,"2025-08-16 15:03:50","1,467,984.36"
419,ae_outcome1_unvax_n_5,emeyerowit.montefiore.org,"2025-08-16 15:06:09","1,480,427.42"
419,ae_outcome1_vax_n,emeyerowit.montefiore.org,"2025-08-16 13:44:36","adjusted person years -   1,318,301.10"
419,ae_outcome1_vax_n_2,emeyerowit.montefiore.org,"2025-08-16 13:52:18","adjusted person-years: 1,306,238.98"
419,ae_outcome1_vax_n_3,emeyerowit.montefiore.org,"2025-08-16 15:01:57","1,322,518.91"
419,ae_outcome1_vax_n_4,emeyerowit.montefiore.org,"2025-08-16 15:03:45","1,322,453.20"
419,ae_outcome1_vax_n_5,emeyerowit.montefiore.org,"2025-08-16 15:05:50","1,331,496.86"
419,nos_xs_1,nebasta,"2025-09-27 21:58:29","medical claims data"
419,rob_screen1,nebasta,"2025-09-27 21:57:52","comparison group is historical controls"
419,rob_screen2,nebasta,"2025-09-27 22:05:07","Cannot identify any control for confounding - AEs reported are descriptive. Some analyses compare to historical controls, but no clear explanation of attempt to control for the considerable confounding that would entail"
421,population,emeyerowit.montefiore.org,"2025-08-16 20:16:26","Does not specify whether children were included"
421,rob_outcome_ae,mehr0035,"2025-09-06 14:27:54","Also GBS, stroke, and numerous others (e.g., arrhythmia, heart failure, coronary artery disease, encephalitis, hearing loss, facial palsy, dizziness, pneumonia, local cellulitis)"
422,rob_type,ejholmes,"2025-09-05 12:18:48",SCCS
423,ae_outcome,abersm.gmail.com,"2025-07-30 13:00:42","Non-hemorrhagic stroke"
423,ae_outcome_2,abersm.gmail.com,"2025-07-30 13:05:39",TIA
423,ae_outcome_2_v2,abersm.gmail.com,"2025-07-30 13:12:29",TIA
423,ae_outcome_3_v2,abersm.gmail.com,"2025-07-30 13:12:48","Non-hemorrhagic stroke"
423,ae_outcome_4,abersm.gmail.com,"2025-07-30 13:07:39","TIA or non-hemorrhagic stroke"
423,ae_outcome_4_v2,abersm.gmail.com,"2025-07-30 13:13:11","Non-hemorrhagic stroke or TIA"
423,ae_outcome_v2,abersm.gmail.com,"2025-07-30 13:12:14","Hemorrhagic stroke"
423,ae_outcome1_describe_3,abersm.gmail.com,"2025-07-30 13:07:06","Non-hemorrhagic stroke"
423,ae_vax_type,abersm.gmail.com,"2025-07-30 13:10:48","Bivalent Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5"
423,ae_vax_type_v2,abersm.gmail.com,"2025-07-30 13:11:40","Bivalent Moderna mRNA-1273.222"
423,domain,abersm.gmail.com,"2025-07-30 13:47:10","Not formally a co-administration study but analyses are stratified by whether patient received influenza vaccine (see raw data in supplement)"
423,domain_ae_include_yn,abersm.gmail.com,"2025-07-30 12:48:09","Data in article/supplement are disaggregated by type of stroke"
426,domain_ae_include_list,stodd046,"2025-08-21 10:39:17","""There was one serious AEFI (angina pectoris), and all other AEFI were non-serious"""
427,nos_xs_1,ejholmes,"2025-09-05 12:30:01","Not all reporting is mandatory/uniform across database; some self-report"
427,nos_xs_2,ejholmes,"2025-09-05 12:30:11","Large sample, not justified in text"
427,nos_xs_3,ejholmes,"2025-09-05 12:30:56","Some self-report; not verifiable"
427,rob_screen1,ejholmes,"2025-09-05 12:26:50","Comparison of vaccine type"
427,rob_screen2,ejholmes,"2025-09-05 12:29:08","stratified analysis; exclusion criteria"
427,rob_screen2,nebasta,"2025-09-27 13:05:56","No attempt to control for confounding in the estimates reported"
428,ae_outcome1_em_type_2,ncmccann.bu.edu,"2025-08-07 20:33:47","Not sure why they give a RR for preterm birth but not weight"
430,date_start_year,abersm.gmail.com,"2025-08-03 18:06:13","Date of vaccination"
430,setting,abersm.gmail.com,"2025-08-03 18:06:16","Date of vaccination"
435,nos_cc_4,ulric063,"2025-09-25 22:00:53","Updating to 'no history of disease' to align with guidance"
436,study_label,stodd046,"2025-08-21 16:38:44","EXCLUDED FROM FURTHER REVIEW"
439,nos_cc_4,ulric063,"2025-09-25 21:58:54","Updating to 'no history of disease' to align with guidance"
440,rob_domain_aensi_other,mehr0035,"2025-09-07 16:19:25","Fatigue, Myalgia, Arthralgia, Nausea/Vomiting, Fever, Headache, Pain, Swelling"
440,rob_screen1,mehr0035,"2025-09-07 16:19:55","50 μg vs 30 μg mRNA-1345"
440,rob_screen2,mehr0035,"2025-09-07 16:22:54","From supplementary data: ""Enrollment was structured to achieve an approximate distribution of 30% of participants with CAD/CHF, 30% with chronic lung diseases, and 40% with DM as the risk group. Participants were randomized to each dose group based on their risk group to ensure a similar representation of these conditions increasing the risk of RSV-LRTD across both groups. Selection of the risk group for each participant was at the discretion of the Investigators and based on clinical judgment."""
440,rob2_msmt3,mehr0035,"2025-09-07 16:28:14","From supplementary info: ""This study design included blinding of the participant, sponsor, Investigator, and clinical staff responsible for study assessments/safety."""
440,rob2_random1,mehr0035,"2025-09-07 16:24:21","From supplementary info: ""Enrollment was structured to achieve an approximate distribution of 30% of participants with CAD/CHF, 30% with chronic lung diseases, and 40% with DM as the risk group. Participants were randomized to each dose group based on their risk group to ensure a similar representation of these conditions increasing the risk of RSV-LRTD across both groups. Selection of the risk group for each participant was at the discretion of the Investigators and based on clinical judgment."""
441,rob2_interv1,mehr0035,"2025-09-08 07:06:04","single-blind parallel group RCT; randomized to Moderna or Novavax; also a self-select 3rd group who chose not to be vaccinated, choosing ""no"" here due to Moderna / Novavax randomization"
441,rob2_interv2,mehr0035,"2025-09-08 07:33:22","""An unblinded study staff administered the vaccine, while study staff evaluating reactogenicity were blinded during the first week post-vaccination when assessing symptoms and study participants were unblinded after seven days upon completion of the reactogenicity diary card."""
441,rob2_msmt3,mehr0035,"2025-09-08 07:31:51","Outcome assessors and participants were unblinded after 7 days post-vaccination. However, the study focuses on AEs during the first 7 days post-vaccination (i.e., the time used for the diary card).

""An unblinded study staff administered the vaccine, while study staff evaluating reactogenicity were blinded during the first week post-vaccination when assessing symptoms and study participants were unblinded after seven days upon completion of the reactogenicity diary card.""

Note also: ""Overall, 17 AE/SAEs were reported (Appendix Table 5) among participants up to day 28 post vaccination, predominantly classified as unrelated or possibly related to the study intervention and were all classified as mild in severity (grade 1). Most of these events re-solved quickly. """
441,rob2_random1,mehr0035,"2025-09-08 07:06:55","Participants were randomised 1:1 to receive either the bivalent mRNA Moderna (mRNA-1273.214, later replaced by mRNA-1273.222) or protein Novavax vaccine (NVX-COV2373) and with randomisation stratified by age (< 50 and ≥50 years). An independent statistician from the Melbourne Children's Trial Centre at the Murdoch Children's Research Institute provided a secure, password-
protected web-based randomisation schedule using random blocks of permuted length""

""The control group was not randomised, but were frequency matched by age to the vaccine groups where possible (18-29 years, 30-49 years, 50-59 years)"""
442,rob2_random1,mehr0035,"2025-09-08 10:30:48","Core protocol available at: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-023-07225-z"
444,nos_cc_4,ulric063,"2025-09-25 21:57:47","Updating to 'no history of disease' to align with guidance"
446,rob_screen2,nebasta,"2025-09-01 19:24:50","authors note they only used ""binary"" logistic regression, which seems to refer to ""univariate"" logistic regression (given the sample size, it would not be possible to include all of the covariates they listed in a single model). Univariate models so not control for confounding."
448,rob_screen1,mehr0035,"2025-09-08 07:49:28","Spikevax (n=70) vs Comirnaty (n=59)"
449,domain_ae_include_vax,scottja.stanford.edu,"2025-08-15 02:59:52","Standard-dose (VaxigripTetra), MF59-adjuvanted (Fluad), High-dose (Fluzone-HD)"
449,ve_overall_vax_n,scottja.stanford.edu,"2025-08-15 03:07:43","This is the total number of participants who received a vaccine across all three groups"
449,ve_overall_vax_y,scottja.stanford.edu,"2025-08-15 03:07:59","This is the total number of PCR-confirmed influenza cases across all three vaccine groups combined"
449,ve_vax_type_v2,scottja.stanford.edu,"2025-08-15 03:09:39","MF59-adjuvanted (Fluad)."
454,date_end_month,flemi644,"2025-08-22 12:29:32","Edited date based on section 2.3"
455,nos_coh_6,mehr0035,"2025-09-06 06:52:47","not sure if this or 'record linkage' would be more appropriate for the study's antibody titer comparisons"
456,study_label,stodd046,"2025-08-21 16:44:17","EXCLUDED FROM FURTHER REVIEW"
457,population,emeyerowit.montefiore.org,"2025-08-20 14:26:56","Age range not mentioned but appears to be only adults"
458,coadmin_sero,emeyerowit.montefiore.org,"2025-08-22 12:42:58","Model-adjusted GMRs (95% CI) for coad-
ministration to separate-administration were
0.83 (0.77, 0.89) for full-length S-binding IgG
levels and 0.89 (0.77, 1.04), 0.95 (0.83, 1.09),
0.96 (0.85, 1.09), and 1.00 (0.89, 1.13) for the
four strain-specific HAI titers (Fig. 3). The pre-
specified noninferiority criterion was met for
full-length S-binding IgG levels and HAI titers
for each of the four influenza assay strains
(lower bound 95% CI [0.67)"
458,rob2_random3,ulric063,"2025-09-08 17:46:51","The median (range) number of days from the previous
(third dose) BNT162b2 vaccination to the
BNT162b2 vaccination received during the
study was 129 (87-204) and 165 (117-259) in
the coadministration and separate-administration groups, respectively, differing primarily
because those in the separate-administration
group received BNT162b2 as their visit 2
vaccination."
461,date_end_year,flemi644,"2025-08-14 16:08:48","Vaccine product and lab assay timing indicate the 2020/21 influenza season; Results section says ""between November and December 2021,"" which is almost certainly a typographical error given invitations in Nov-Dec 2020 and assays in March 2021."
462,rob_screen1,nebasta,"2025-09-06 18:59:58","Survey of vaccinated participants-all but 6 had gotten 3 doses. No comparison group. Analysis compares AEs after each dose but methods are not described, but it seems like participants reported AEs once (after the 3rd dose) about prior doses."
464,ae_outcome,emeyerowit.montefiore.org,"2025-08-22 13:02:15","Level of Certainty 1-2"
464,ae_outcome_2,emeyerowit.montefiore.org,"2025-08-22 13:03:10","Level of confidence 1-4"
464,ae_outcome_2_v2,emeyerowit.montefiore.org,"2025-08-22 13:12:10","LOC 1-4"
464,ae_outcome_2_v3,emeyerowit.montefiore.org,"2025-08-22 13:14:54","LOC 1-4"
464,ae_outcome_v2,emeyerowit.montefiore.org,"2025-08-22 13:11:38","LOC 1-2"
464,ae_outcome_v3,emeyerowit.montefiore.org,"2025-08-22 13:14:10","LOC 1-2"
464,ae_outcome1_em_type,emeyerowit.montefiore.org,"2025-08-22 13:02:38","Relative incidence"
464,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-08-22 13:03:21","Relative incidence"
464,ae_outcome1_em_type_2_v2,emeyerowit.montefiore.org,"2025-08-22 13:12:28","Relative incidence"
464,ae_outcome1_em_type_2_v3,emeyerowit.montefiore.org,"2025-08-22 13:15:12","Relative incidence"
464,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-22 13:11:30","Relative incidence"
464,ae_outcome1_em_type_v3,emeyerowit.montefiore.org,"2025-08-22 13:14:27","Relative incidence"
465,ae_outcome1_em_type_2_v3,emeyerowit.montefiore.org,"2025-08-24 16:19:27","frequency per million doses"
465,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-24 16:16:24","frequency per million doses"
465,ae_outcome1_em_type_v3,emeyerowit.montefiore.org,"2025-08-24 16:18:24","frequency per million doses"
465,ae_outcome1_em_value,emeyerowit.montefiore.org,"2025-08-24 16:11:37","per million"
465,rob_screen1,nebasta,"2025-09-02 13:03:18","Frequency of AEs by vaccine type were compared to one another in this retrospective cross-sectional study"
466,ae_outcome1_em_type_2,emeyerowit.montefiore.org,"2025-08-24 16:36:16","Rate per million doses"
466,ae_outcome1_em_type_2_v2,emeyerowit.montefiore.org,"2025-08-24 16:41:40","rate per million doses"
466,ae_outcome1_em_type_2_v3,emeyerowit.montefiore.org,"2025-08-24 16:48:45","rate per million doses"
466,ae_outcome1_em_type_3,emeyerowit.montefiore.org,"2025-08-24 16:36:48","rate per million doses"
466,ae_outcome1_em_type_3_v2,emeyerowit.montefiore.org,"2025-08-24 16:42:30","rate per million doses"
466,ae_outcome1_em_type_3_v3,emeyerowit.montefiore.org,"2025-08-24 16:49:26","rate per million doses"
466,ae_outcome1_em_type_4,emeyerowit.montefiore.org,"2025-08-24 16:37:34","rate per million doses"
466,ae_outcome1_em_type_4_v2,emeyerowit.montefiore.org,"2025-08-24 16:43:14","rate per million doses"
466,ae_outcome1_em_type_4_v3,emeyerowit.montefiore.org,"2025-08-24 16:50:16","rate per million doses"
466,ae_outcome1_em_type_5,emeyerowit.montefiore.org,"2025-08-24 16:38:31","Per million doses"
466,ae_outcome1_em_type_5_v2,emeyerowit.montefiore.org,"2025-08-24 16:44:08","rate per million doses"
466,ae_outcome1_em_type_5_v3,emeyerowit.montefiore.org,"2025-08-24 16:51:10","rate per million doses"
466,ae_outcome1_em_type_v2,emeyerowit.montefiore.org,"2025-08-24 16:40:15","Myopericarditis per million doses"
466,ae_outcome1_em_type_v3,emeyerowit.montefiore.org,"2025-08-24 16:45:30","rate per million doses"
466,ae_outcome1_em_value,emeyerowit.montefiore.org,"2025-08-24 16:35:10","Rate of myopericarditis per million doses"
467,domain_ae_include_list,flemi644,"2025-08-12 16:44:01","DVT and/or PE"
467,population,calba1.mgh.harvard.edu,"2025-08-12 18:33:24","Immunocompromised adults are also 18-64 and adults >=65 years"
468,rob2_data1,mehr0035,"2025-09-08 11:25:44","1083 randomized into 7 groups; 1061 completed the study"
468,rob2_interv2,mehr0035,"2025-09-08 11:14:41",""" Study staff receiving, storing, dispensing, preparing, and administering study interventions were unblinded. All other study and site personnel, including investigators and individuals evaluating participant safety, were blinded."""
468,rob2_random1,mehr0035,"2025-09-08 11:16:42","""Participants were randomized using interactive response technology to 1 of 7 study groups"""
469,population_disagg,stodd046,"2025-08-12 16:20:23","Below 40 group, 40+ group"
470,nos_cc_4,ulric063,"2025-09-25 21:55:22","Updating to 'no history of disease' to align with guidance"
470,population,flemi644,"2025-08-18 11:12:36","Adults 18-64 = All adults 18+"
472,nos_cc_4,ulric063,"2025-09-25 21:54:15","Updated to 'no history of disease' to align with guidance"
473,nos_xs_1,nebasta,"2025-09-27 22:30:47","participants were drawn from a COVID-19 registry, no info about how recruited"
473,nos_xs_3,nebasta,"2025-09-08 17:48:33","Self-report was used, no standardized definition of a ""flare"" was established"
474,nos_coh_8,calba1.mgh.harvard.edu,"2025-09-15 09:38:27","This uses EHR-based data. The authors do not seem to explicitly address follow-up rate. In appendix, it does mention people were excluded if there were missing vaccine data (but don't give #s). Given study design, I would consider ""b) Subjects LTFU unlikely to introduce bias"" but this does not change the overall RoB assessment so leaving as is."
474,population,flemi644,"2025-08-18 12:23:30","adults 65+ = adults 65-79"
474,ve_elder_unvax_n,flemi644,"2025-08-18 12:33:28","unvaccinated, person-months at risk"
474,ve_elder_unvax_n_2,flemi644,"2025-08-18 12:40:07","unvaccinated; person months at risk"
474,ve_elder_unvax_y,flemi644,"2025-08-18 12:33:44","unvaccinated events"
474,ve_elder_unvax_y_2,flemi644,"2025-08-18 12:40:15","unvaccinated cases"
474,ve_elder_vax_n,flemi644,"2025-08-18 12:34:24","vaccinated, person-months at risk"
474,ve_elder_vax_n_2,flemi644,"2025-08-18 12:39:49","vaccinated; person months at risk"
474,ve_elder_vax_y,flemi644,"2025-08-18 12:34:35","vaccinated events"
474,ve_elder_vax_y_2,flemi644,"2025-08-18 12:39:56","vaccinated cases"
474,ve_other_unvax_n,flemi644,"2025-08-18 12:37:51","unvaccinated; person months at risk"
474,ve_other_unvax_n_2,flemi644,"2025-08-18 12:40:46","unvaccinated; person months at risk"
474,ve_other_unvax_y,flemi644,"2025-08-18 12:38:00","unvaccinated cases"
474,ve_other_unvax_y_2,flemi644,"2025-08-18 12:40:52","unvaccinated cases"
474,ve_other_vax_n,flemi644,"2025-08-18 12:36:46","vaccinated; person months at risk"
474,ve_other_vax_n_2,flemi644,"2025-08-18 12:40:29","vaccinated; ; person months at risk"
474,ve_other_vax_y,flemi644,"2025-08-18 12:37:05","vaccinated cases"
474,ve_other_vax_y_2,flemi644,"2025-08-18 12:40:38","vaccinated cases"
475,nos_coh_1,moat0011,"2025-09-08 10:22:43","cohort came from Yale New Haven CHildrens Hospital, but no description of how the 20 cases were selected from that facility"
475,nos_coh_3,moat0011,"2025-09-08 10:23:20","exposure= myopericarditis after mRNA vaccination"
475,nos_coh_3,moat0011,"2025-09-08 10:25:22","Chose a low score here because case definition was probably and did not require confirmatory MRI findings"
475,nos_coh_3,ejholmes,"2025-09-12 16:55:04","In discussion, confirmed/probable cases compared and ~50% pts did not meet dx criteria"
475,nos_coh_5,moat0011,"2025-09-08 10:26:16","comparisons made for same cases at different time points"
475,rob_outcome_ae,moat0011,"2025-09-08 10:21:09","*left ventricular longitudianal strain among cases of myocarditis"
475,rob_screen1,moat0011,"2025-09-08 10:11:52","Same case, different time points"
475,rob_screen2,moat0011,"2025-09-08 10:11:37","Lon-
gitudinal analysis of echocardiographic parameters strati-
fied by treatment group was completed using mixed linear
regression."
477,population_disagg,abersm.gmail.com,"2025-08-02 12:56:04","Individual patient data provided"
478,ae_outcome,emeyerowit.montefiore.org,"2025-08-24 19:35:05","Note composite outcome of neurologic outcomes other than epilepsy"
479,date_start_year,stodd046,"2025-08-12 16:08:19","When Vigilbase was started"
479,design,stodd046,"2025-08-12 16:10:07",Pharmacovigilance
479,domain_ae_include_vax,scottja.stanford.edu,"2025-08-24 23:22:27","The study disaggregates reports for COVID-19 mRNA, Ad5-vectored COVID-19, and inactivated whole-virus COVID-19 vaccines. It also investigates Influenza vaccines."
479,nos_xs_1,ejholmes,"2025-09-05 13:25:09","Vigibase not representative (see WhatsApp thread)"
479,nos_xs_2,ejholmes,"2025-09-05 13:25:22","Large dataset"
479,nos_xs_3,ejholmes,"2025-09-05 13:27:16","Not all data verifiable (self-report)"
480,population,arpey001,"2025-08-08 14:11:16","Adults >=60 years"
481,coadmin_ae_yn,stodd046,"2025-08-20 11:42:27","no difference - number of vaccine-related AEs was 171 in concomitant group and 170 in sequential group"
481,coadmin_pop1_n_2,stodd046,"2025-08-20 11:40:07","In the PCV15 concomitant group, one participant of the 210 that received a COVID shot (errantly?) received the PPSV23 vaccine, so number of participants in this group reduced to 209"
481,coadmin_vax2_type,flemi644,"2025-08-18 15:40:57","Concomitant arm (Day 1): mRNA-1273 + PPSV23; placebo on Day 30.

Sequential arm: mRNA-1273 + placebo on Day 1; PPSV23 on Day 30."
481,coadmin_vax2_type_2,flemi644,"2025-08-18 15:41:58","Concomitant arm (Day 1): mRNA-1273 + PCV15; placebo on Day 30.

Sequential arm: mRNA-1273 + placebo on Day 1; PCV15 on Day 30."
481,rob2_data1,mehr0035,"2025-09-08 08:47:53","""A total of 850 participants were randomized: 212 participants in the PPSV23 sequential group, 210 participants in the PCV15 sequential group, and 214 participants in each of the PPSV23 and PCV15 concomitant groups (Figure 2). Most randomized participants received at least one dose of study vaccine and completed the study (≥93.9%). The most common reasons for discontinuing the study across all groups were participant withdrawal (2.4%) and loss to follow-up (1.9%). Most randomized participants were included in the immunogenicity analyses; in the PPSV23 sequential and PCV15 sequential groups, ≥87.3%
and ≥87.6% were included at one or more timepoints, respectively. In addition, ≥85.8%
and ≥87.6% were included for both baseline and post-vaccination timepoints, respectively"""
481,rob2_interv1,mehr0035,"2025-09-08 08:45:34","""The participant, investigator, and other personnel involved in study conduct or clinical evaluation were blinded."""
481,rob2_interv2,mehr0035,"2025-09-08 08:43:22","""PPSV23, PCV15, and placebo were prepared and administered by an unblinded pharmacist or qualified personnel. The participant, investigator, and other personnel involved in study conduct or clinical evaluation were blinded. mRNA-1273 was provided open-label and was also prepared and administered by unblinded personnel"""
481,rob2_msmt3,mehr0035,"2025-09-08 08:51:29","""The participant, investigator, and other personnel involved in study conduct or clinical evaluation were blinded."""
481,rob2_random1,mehr0035,"2025-09-08 08:41:36","""Participants were randomly assigned in a 1:1:1:1 ratio via a centralized interactive response technology system"""
482,ae_comparator,stodd046,"2025-08-20 11:51:01","Of the 19 cases, 16 had received mRNA vaccines and 3 had not. So the unvaccinated cases are the comparator group."
482,ae_outcome1_otherinfo_yn,stodd046,"2025-08-20 11:58:30","for each case the following are reported: age, sex, stroke diagnosis, tissue sample origin, history of previous covid infection, history of mRNA vaccination, number of vaccines, time from last vaccination to surgery, and the immunostaining profile for spike protein/nucleocapsid"
482,ae_outcome1_unvax_y,flemi644,"2025-08-18 16:21:56","positive spike protein/nucleocapsid IHC = COVID-related"
482,ae_outcome1_vax_y,flemi644,"2025-08-18 16:18:00","positive spike protein/nucleocapsid IHC = COVID-related"
482,ae_vax_type,stodd046,"2025-08-20 11:48:37","mRNA vaccines for SARS-CoV-2, such as BNT162b2 (BioNTech-Pfizer) and
mRNA-1273 (Moderna)"
483,rob_screen1,mehr0035,"2025-09-08 12:46:11","89 vaccinated; comparison for those who received aflibercept (n=49) vs. ranibizumab (n=40)"
486,population,abersm.gmail.com,"2025-08-03 17:43:36","Study states ""adults"" were included (age criteria not specified)"
488,domain_ae_include_yn,flemi644,"2025-08-20 18:15:35","ITP reported, but not by vaccine brand (study includes non-U.S. products)"
488,nos_xs_1,ejholmes,"2025-09-05 13:36:32","Would not capture those who don't have med encounter for AE"
488,nos_xs_3,ejholmes,"2025-09-05 13:33:24","Non-serious AEs are voluntarily reported and not always verified"
488,population,flemi644,"2025-08-20 18:09:54","Children 5-17"
489,nos_coh_1,ejholmes,"2025-09-05 13:59:41","Pts from one region of Pakistan, but unclear where/how they were recruited; small sample"
489,nos_coh_3,ejholmes,"2025-09-05 13:59:58","Some via email report, others via interview"
489,nos_coh_5,ejholmes,"2025-09-05 14:02:05","Statistical controls somewhat unclear, but reference associations by multiple factors"
489,nos_coh_7,ejholmes,"2025-09-05 13:49:16","Only followed 2 months"
492,nos_xs_1,ejholmes,"2025-09-05 14:08:01","VAERS voluntary, not verified reports"
492,nos_xs_2,ejholmes,"2025-09-05 14:08:39","Not justified, large n for VAERS overall"
493,coadmin_pop1_n,emeyerowit.montefiore.org,"2025-08-24 19:55:27","35 received ipsilateral and 81 contralateral vaccination"
494,nos_cc_4,ulric063,"2025-09-25 21:52:51","Updating to 'no history of disease' to align with guidance"
495,ve_adult_vax_n_5,flemi644,"2025-08-12 17:52:45","For thrombolytic events, 18-64 = all adults (no age disaggregation)"
496,population_disagg,abersm.gmail.com,"2025-08-03 17:33:24","Individual patient data provided"
496,rob_screen1,nebasta,"2025-09-03 21:42:25","The authors note that this is a ""case series"" examining reported AE. They compare rates of adverse events for two vaccinations, but this does not provide insight into whether these rates are higher than they would be in the absence of vaccination. They also note that: ""In comparison to the mRNA vaccines, the reporting incidence rates for the non‐mRNA vaccines were much higher, likely due to selection bias, as non‐mRNA vaccines were administered to at‐risk patients who had allergic reactions to prior COVID‐19 vaccines."""
497,population_disagg,abersm.gmail.com,"2025-08-03 17:36:47","Individual patient data provided"
498,comments,calba1.mgh.harvard.edu,"2025-08-12 19:11:51","Counts and other AEs reported in Table S2 (added file to Covidence). Ns suggest denominator is 108. Also reports fatigue (n = 15, 13.9%), headache (4, 3.7%), chills and shivers (2, 1.9%), increased body temp (2, 1.9%), diarrhea (1, 0.9%), N/V (1, 0.9%), and arthralgias/back pain (1, 0.9%)."
498,date_end_year,calba1.mgh.harvard.edu,"2025-08-12 19:05:04","Enrollment was between 10/2021 and 12/2021 but AE data was collected at 2-4 weeks post-vaccination - so could extend into 1/2022"
498,date_end_year,flemi644,"2025-08-12 19:54:10",adjusted
498,population,calba1.mgh.harvard.edu,"2025-08-12 19:06:05","Also includes adults >65 (although not stratified data is not presented). IQR is 49-68 so majority are in the 18-64 bucket - I think okay as is extracted."
498,population,flemi644,"2025-08-12 19:53:40",fixed
499,rob_screen1,mehr0035,"2025-09-08 08:57:24","CoronaVac v. BNT162b2 b. ChAdOx1"
500,population_disagg,abersm.gmail.com,"2025-08-03 17:29:39","Individual patient data provided"
501,rob_screen1,mehr0035,"2025-09-08 11:38:43","""MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4) with that of a licensed, standard-dose quadrivalent inactivated influenza vaccine (IIV4)"""
501,rob2_data1,mehr0035,"2025-09-08 12:20:55","""The solicited safety set included all exposed subjects with any solicited AE data, including body temperature measurements or use of
analgesics/antipyretics, and the unsolicited safety set included all exposed subjects who provided unsolicited AE data. The overall safety set included all subjects in the solicited safety set and/or unsolicited safety set.""

2044 subjects enrolled/randomized, 2043 received vaccines. 

""The solicited safety set included 1020 and 1008 subjects from the aIIV4 and IIV4 groups, respectively (Supplementary Figure S1), and the unsolicited safety set and overall safety set included 1027 subjects exposed to aIIV4 and 1016 subjects exposed to IIV4."""
501,rob2_interv2,mehr0035,"2025-09-08 12:10:18","""observer-blind"""
501,rob2_random1,mehr0035,"2025-09-08 12:11:22","""An interactive response technology system was used to randomly assign subjects to receive either aIIV4 or IIV4 in a 1:1 ratio, stratified by age (50 to ≤59 years and 60 to ≤64 years) and whether or not the subject had received any influenza vaccination within the previous 3 influenza seasons"""
502,nos_xs_1,moat0011,"2025-09-08 10:40:39","All samples submitted to a lab were used (perhaps not representative of underlying pop'n but given all samples were used, reasonable representation)"
502,nos_xs_2,moat0011,"2025-09-08 10:41:24","No mention of sample size calculation"
503,population_disagg,abersm.gmail.com,"2025-08-02 12:35:54","Individual patient data provided in article."
504,nos_cc_4,ulric063,"2025-09-25 21:51:38","Updating to 'no history of disease' to align with guidance"
504,ve_adult_vax_n,scottja.stanford.edu,"2025-08-15 02:47:42","The paper does not provide the raw numbers of cases and controls stratified by both age group and vaccination status."
504,ve_ic_vax_n,scottja.stanford.edu,"2025-08-15 02:51:40","The entire study population consists of immunocompromised individuals (solid organ transplant recipients). Therefore, the data for the ""immunocompromised"" group is the same as the data for the ""overall"" population."
506,domain,harleen.k.marwah.gmail.com,"2025-08-12 10:33:35","non-US epi"
510,coadmin_vax_prime_other,stodd046,"2025-08-22 11:27:57","Both Pfizer and Moderna are approved in Italy (study location)"
511,nos_coh_4,ejholmes,"2025-09-05 14:29:13","No evidence on medical record, but also not tested specifically for outcome independently"
511,nos_coh_7,ejholmes,"2025-09-05 14:27:44","3 months"
512,design,stodd046,"2025-08-26 13:46:29","""Briefly, three of the multicentre studies (EU-H, EU-PC and UK-PC) used prospective patient recruitment, while five studies used electronic database linkage (DK-H, DK-PC, EN-H, NI-H, SC-H)."""
512,domain_ve_num,stodd046,"2025-08-26 13:41:34","This study pools 8 different studies across 17 countries and reports the vaccine types used nationally or in the study for each, sometimes dependent on age,. These include QIV (plus variations aQIV, QIV-HD, QIVc), LIAV, and TIV but VE estimates are not disaggregated by type."
512,nos_cc_4,ulric063,"2025-09-25 21:49:47","Updating to 'no history of disease' to align with guidance"
512,ve_child_vax_n,stodd046,"2025-08-26 14:18:55","0-17 years"
512,ve_child_vax_n_2,stodd046,"2025-08-26 14:25:05","6 mo -17 years"
512,ve_child_vax_n_3,stodd046,"2025-08-26 14:32:26","2-17 years"
512,ve_child_vax_n_4,stodd046,"2025-08-26 14:37:33","Age group not included here"
512,ve_child_vax_n_5,stodd046,"2025-08-26 14:40:56","2-17 years"
512,ve_child_vax_n_6,stodd046,"2025-08-26 14:46:00","0-17 years"
512,ve_child_vax_n_7,stodd046,"2025-08-26 14:49:30","Pediatric data not reported for this study"
512,ve_child_vax_n_8,stodd046,"2025-08-26 14:52:19","2-17 years"
512,ve_outcome_eight,stodd046,"2025-08-26 14:51:45","Scotland Hospital (SC-H)"
512,ve_outcome_five,stodd046,"2025-08-26 14:40:26","England Hospital (EN-H)"
512,ve_outcome_four,stodd046,"2025-08-26 14:37:13","Denmark Hospital (DK-H)"
512,ve_outcome_prime,stodd046,"2025-08-26 14:18:44","Denmark Primary Care (DK-PC)"
512,ve_outcome_seven,stodd046,"2025-08-26 14:49:03","Northern Ireland Hospital (NI-H)"
512,ve_outcome_six,stodd046,"2025-08-26 14:44:10","European Union Hospital (EU-H)"
512,ve_outcome_six,stodd046,"2025-08-26 14:45:20","EU VEBIS multicountry hospital network (EU-H: six of 10 countries contributing to the interim analysis)"
512,ve_outcome_three,stodd046,"2025-08-26 14:31:54","United Kingdom (UK) Primary Care (UK-PC:
four countries)"
512,ve_outcome_two,stodd046,"2025-08-26 14:23:50","European Union (EU) Vaccine Effectiveness, Burden and Impact Studies (VEBIS) multi-country primary care network (EU-PC: eight of 10 countries contributing to the interim analysis)"
513,nos_coh_1,ejholmes,"2025-09-05 14:35:13","Single-center study, high-income"
513,nos_coh_3,ulric063,"2025-09-22 12:41:39","questionnaires concerning SARS-CoV-2 vaccination status and experienced post-vaccination side effects were
handed out to all IBD patients presenting for their follow-up appointments."
513,nos_coh_4,ulric063,"2025-09-22 12:44:47","Study is among patients with established IBD diagnosis presenting for care at the Crohn-Colitis center"
513,nos_coh_8,ejholmes,"2025-09-05 14:38:51","Minimal LTFU"
514,nos_xs_1,ejholmes,"2025-09-05 14:44:48","One Canadian province"
514,nos_xs_1,nebasta,"2025-09-27 19:36:39","passive surveillance within that province, unknown representativeness"
514,nos_xs_2,ejholmes,"2025-09-05 14:43:38","Large natl dataset"
514,nos_xs_3,ejholmes,"2025-09-05 14:44:04","Legally required AE reporting (by HCW) with validation"
515,nos_coh_1,mehr0035,"2025-09-08 09:14:13","""...the study enrolled working adults aged 18 to < 65 years in the US and Canada who voluntarily received an authorized/approved primary series or booster dose of a COVID-19 vaccine"""
515,nos_coh_3,mehr0035,"2025-09-08 09:19:38","Selecting ""secure record"" because of the following language in the referenced paper that gives more info on participants: 

""Participants voluntarily seeking the COVID-19 vaccine were recruited from primary care or specialty care clinics. Eligible participants were aged ≥18 to ≤65 years, receiving a first, second, or booster dose of a COVID-19 vaccine (US: BNT162b2, mRNA-1273, Ad26.COV2.S, NVX-CoV2373; Canada: BNT162b2, mRNA-1273, Ad26.COV2.S, NVX-CoV2373, AZD1222, CoVLP), were employed (working for pay) for ≥20 h per week, were scheduled to work ≥3 days in the 6 days post-dose, and had access to a smartphone, tablet, or computer (to complete the daily study diary). ""

From: https://www.mdpi.com/2076-393X/12/1/83"
515,rob_screen1,mehr0035,"2025-09-08 09:09:22","""...determine the difference in local or systemic reactogenicity events occurring within the first 2 days after the receipt of an NVX-CoV2373 vaccine versus an mRNA COVID-19 vaccine, administered after completion of any primary vaccination series."""
515,rob_screen2,mehr0035,"2025-09-08 09:11:58","""... each participant was assigned a propensity score based on a select group of demographic and clinical characteristics identified using standardized differences. The present analysis used the following covariates in the IPTW model: country (US vs. Canada), prior COVID-19 diagnosis (yes vs. no), race (Asian, White), job category (professional), work at home (yes, no, or prefer not to answer), gender identity (male, female), and scheduled to work in the next 24 h (yes vs. no)."""
516,ve_outcome_num,scottja.stanford.edu,"2025-08-25 01:14:17","combined event of ICU admission/mortality"
516,ve_overall_em,scottja.stanford.edu,"2025-08-25 01:17:06","The study reports a hazard ratio"
516,ve_overall_em_ci,ejholmes,"2025-08-25 10:21:05","p = 0.017"
516,ve_overall_vax_n,scottja.stanford.edu,"2025-08-25 01:16:00","It's a retrospective observational cohort study"
517,ae_incidence_yn,flemi644,"2025-08-14 17:46:01","denominator for IRR calculations appears to be person-days outside of the determined post-vaccine risk-window for the same patients."
517,ae_incidence_yn_2,flemi644,"2025-08-14 17:46:09","denominator for IRR calculations appears to be person-days outside of the determined post-vaccine risk-window for the same patients."
517,ae_outcome1_otherinfo_yn,flemi644,"2025-08-14 17:44:14","IRR rates"
517,ae_outcome1_otherinfo_yn_2,flemi644,"2025-08-14 17:44:21","IRR rates"
517,ae_vax_type,flemi644,"2025-08-14 17:27:36","Pooled Pfizer and Moderna"
517,nos_xs_1,mehr0035,"2025-09-10 10:29:07","cancer patients 12+ years with cardiovascular outcomes (4,754 for study out of 318,105 total 12+ yrs with cancer)"
517,population,flemi644,"2025-08-14 17:12:12","children 12-17"
517,rob_outcome_ae,mehr0035,"2025-09-06 13:31:31","Study looked at multiple cardiovascular outcomes, including multiple AESIs.

""Cardiovascular outcomes of interest were prespecified as myocardial infarction, stroke
including ischemic stroke and hemorrhagic stroke, venous thromboembolism (VTE)
including deep vein thrombosis (DVT), pulmonary embolism (PE), and cerebral venous sinus
thrombosis (CVST), myocarditis, and pericarditis and any of these cardiovascular outcomes."""
518,nos_xs_1,ejholmes,"2025-09-05 16:08:03","Passive, voluntary surveillance system may result in selection bias"
518,nos_xs_3,ejholmes,"2025-09-05 16:08:35","Self-report; not entirely verifiable"
519,nos_coh_1,ejholmes,"2025-09-05 16:15:15","Small sample, one IVF clinic"
519,nos_coh_2,ulric063,"2025-09-22 12:49:37","Non-exposed included November 2017 - September 2021, before vaccination was available"
519,nos_coh_4,ejholmes,"2025-09-05 16:18:26","IVF indications matched w/o a significant difference between cohorts"
519,nos_coh_7,ejholmes,"2025-09-05 16:20:43","Only followed one cycle post-vaccination"
519,nos_coh_8,ejholmes,"2025-09-05 16:21:45",retrospective
520,nos_xs_1,moat0011,"2025-09-08 11:57:35","linkable admin health databases from Lombardy region on 10 million residents (16% of Italian pop'n) who receive NHS assistance"
524,nos_coh_3,mehr0035,"2025-09-06 13:13:48","not stated how vaccination status was identified; presumably chart linkage but not clear"
524,nos_coh_3,moat0011,"2025-09-12 16:05:12","Changed to secure record- found language saying they used the French national COVID19 vaccination database"
524,rob_outcome_ae,mehr0035,"2025-09-06 13:06:51","counting myopericarditis as myocarditis based on previous WhatsApp discussion that the former can be counted"
525,nos_cc_4,ulric063,"2025-09-25 21:47:02","Updating to 'no history of disease' to align with guidance"
525,ve_elder_vax_n,abersm.gmail.com,"2025-08-02 12:01:00","Data from table 2"
525,ve_elder_vax_n_2,abersm.gmail.com,"2025-08-02 12:06:40","Data from table 2"
525,ve_other_vax_n,abersm.gmail.com,"2025-08-02 12:01:06","Data from table 2"
525,ve_other_vax_n_2,abersm.gmail.com,"2025-08-02 12:06:45","Data from table 2"
525,ve_overall_vax_n,abersm.gmail.com,"2025-08-02 12:08:31","Data from table 2"
525,ve_overall_vax_n_2,abersm.gmail.com,"2025-08-02 12:10:37","Data from table 2"
525,ve_overall_vax_n_3,abersm.gmail.com,"2025-08-02 12:11:52","Data from table 2"
527,domain_ae_include_vax,moat0011,"2025-08-12 10:31:19","Pfizer, AZ, Sinovac"
528,population,moat0011,"2025-08-12 10:18:24",">12 yo"
530,ae_outcome1_vax_y,stodd046,"2025-08-22 13:01:58","I think this is 65+ only ""When we restricted the analysis to patients 65 years and older who
received the bivalent Pfizer vaccine-based on the VSD's RCA signal
detection- we identified 12 cases with an ICD-10-CM in the primary
position and all were confirmed: PPV = 100 % (95 % CI, 73.5-100)."""
530,ae_outcome1_vax_y_v2,stodd046,"2025-08-22 13:15:25","was co-administered with high-dose flu vaccine same day"
531,rob2_interv6,ulric063,"2025-09-20 16:12:18",". Safety
analyses were descriptive and presented by treatment group"
532,rob2_data1,flemi644,"2025-09-15 15:18:00","changed to probably no. 88% completion."
532,rob2_data1,corey.watts.pennmedicine.upenn.edu,"2025-09-16 09:35:51","Agreed -- keep as probably no"
532,rob2_data2,flemi644,"2025-09-15 15:18:21","Discontinuations due to LTFU/withdrawal and not due to AEs/death; AESIs collected throughout study, with zero AESIs shown across all groups"
532,rob2_data2,corey.watts.pennmedicine.upenn.edu,"2025-09-16 09:36:01","Agreed -- keep as probably yes"
534,rob_screen1,nebasta,"2025-09-08 17:40:02","All participants in this follow up study received a booster dose, the comparison groups were defined based on past vaccination history in the parent trial"
535,design,moat0011,"2025-08-22 12:29:08","""self controlled case series"""
537,ve_overall_em_2,flemi644,"2025-08-20 19:07:41","calculated by modelling infections over time (Cox model; Simon-Makuch plot)"
537,ve_overall_em_3,flemi644,"2025-08-20 19:07:48","calculated by modelling infections over time (Cox model; Simon-Makuch plot)"
537,ve_overall_vax_n,flemi644,"2025-08-20 18:59:33","Total number of employees vaccinated: 7978
Not vaccinated: 40323"
539,nos_cc_4,ulric063,"2025-09-25 21:06:30","Updating to 'no history of disease' to align with guidance"
541,nos_cc_4,ulric063,"2025-09-08 16:01:58","Explored in sensitivity analyses"
541,ve_adult_vax_n,emeyerowit.montefiore.org,"2025-08-21 15:23:47",20-64
541,ve_adult_vax_n_2,emeyerowit.montefiore.org,"2025-08-21 15:28:40","Ages 20-64"
541,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-21 15:22:12","Ages 1-19"
541,ve_child_vax_n_2,emeyerowit.montefiore.org,"2025-08-21 15:27:57","Ages 1-19"
541,ve_em_type,emeyerowit.montefiore.org,"2025-08-21 15:20:25","Specified in Table S5"
543,ae_outcome1_disagg,abersm.gmail.com,"2025-07-31 11:48:43","Not for BNT162b2 specifically"
543,ae_outcome1_disagg_v2,abersm.gmail.com,"2025-07-31 11:49:34","Not for mRNA1273 specifically"
543,ae_outcome1_otherinfo_yn,abersm.gmail.com,"2025-07-31 11:48:18","Not for BNT162b2 specifically"
543,ae_outcome1_otherinfo_yn_v2,abersm.gmail.com,"2025-07-31 11:49:30","Not for mRNA1273 specifically"
543,design,abersm.gmail.com,"2025-07-31 11:45:23","Title says cross-sectional but actually a retrospective cohort study"
543,population_disagg,abersm.gmail.com,"2025-07-31 11:47:23","Age not disaggregated by specific vaccine"
544,nos_cc_1,ulric063,"2025-09-05 11:37:52","Additional study details in cited protocol: https://bmjopen-bmj-com.ezp3.lib.umn.edu/content/9/9/e029708.long"
544,ve_adult_em,scottja.stanford.edu,"2025-08-26 00:16:05","For the 20-64 year old group"
544,ve_adult_unvax_n,scottja.stanford.edu,"2025-08-26 00:11:11","The study reports that of the 11679 test-negative cases in the 20-64 years group, 16% were vaccinated. This means that 84% were not vaccinated, which is approximately 9,810 individuals."
544,ve_adult_unvax_y,scottja.stanford.edu,"2025-08-26 00:15:31","For the 20-64 years age group, there were 11,679 test-negative cases. Of these, 16% were vaccinated. This calculates to approximately 1,869 individuals."
544,ve_adult_vax_n,scottja.stanford.edu,"2025-08-26 00:09:20","Of the 4,079 test-positive cases in the 20-64 years group, 8% were vaccinated. This =  approximately 326 individuals"
544,ve_child_em,scottja.stanford.edu,"2025-08-25 02:23:31","The article provides separate adjusted VE estimates for two subgroups within this age range:


74% for the 6 months-9 years age group.
62% for the 10-19 years age group."
544,ve_child_em_adj,scottja.stanford.edu,"2025-08-25 02:24:04","74% for the 6 months-9 years age group.
62% for the 10-19 years age group"
544,ve_child_em_ci,scottja.stanford.edu,"2025-08-25 02:24:48","For the  6 months-9 years group, the 95% CI is 66-79.
For the 10-19 years group, the 95% CI is 32-78"
544,ve_child_unvax_n,scottja.stanford.edu,"2025-08-25 02:22:19","6 months-9 years: The total number of individuals who tested negative for influenza was 3,032. Of these, 15% were vaccinated, which means 85% were unvaccinated. That equals approximately 2,577 unvaccinated individuals who tested negative.
10-19 years: The total number of individuals who tested negative was 1,134. Of these, 7% were vaccinated, which means 93% were unvaccinated. That equals approximately 1,055 unvaccinated individuals who tested negative."
544,ve_child_unvax_n,scottja.stanford.edu,"2025-08-26 00:02:31","This number is a sum of the unvaccinated, test-negative individuals from the two subgroups: 2,577 (6 months-9 years) + 1,055 (10-19 years)"
544,ve_child_unvax_y,scottja.stanford.edu,"2025-08-26 00:02:53","This number is a sum of the vaccinated, test-negative individuals from the two subgroups: 455 (6 months-9 years) + 79 (10-19 years)."
544,ve_child_vax_n,scottja.stanford.edu,"2025-08-25 02:20:13","The study does not provide a single, combined number for this entire age range, but provides disaggregated data for two subgroups: 6 months-9 years and 10-19 years."
544,ve_child_vax_y,scottja.stanford.edu,"2025-08-26 00:02:08","This number is a sum of the vaccinated, test-positive individuals from the two subgroups: 92 (6 months-9 years) + 14 (10-19 years)."
544,ve_elder_unvax_y,scottja.stanford.edu,"2025-08-26 00:17:35","Of the 13,350 test-negative individuals, 43% were vaccinated, which is roughly 5,741 individuals."
544,ve_elder_vax_y,scottja.stanford.edu,"2025-08-26 00:16:58","Of the 1,952 test-positive cases, 30% were vaccinated, which is approximately 586 individuals."
544,ve_ic_unvax_y,scottja.stanford.edu,"2025-08-26 00:20:08","For the influenza A(H1N1) strain, 74% of the test-negative individuals in the comorbidity group were vaccinated, which = 15,953 individuals."
544,ve_ic_vax_y,scottja.stanford.edu,"2025-08-26 00:19:13","For the influenza A(H1N1 strain, 58% of the test-positive cases in the comorbidity group were vaccinated, which is approximately 2,822 individuals."
545,rob_screen1,flemi644,"2025-09-15 15:26:59","passive surveillance summaries only."
546,nos_coh_1,calba1.mgh.harvard.edu,"2025-09-15 11:14:35","Changed from somewhat representative after discussion with JLL. Participants self-enrolled into study by responding to survey link."
546,nos_coh_3,calba1.mgh.harvard.edu,"2025-09-15 11:16:04","Used structured survey as well as EHR data. Maintaining as self report as there is no explanation for how prevalent self report was among the included population."
546,nos_coh_8,calba1.mgh.harvard.edu,"2025-09-15 11:15:27","According to Fig 1A, only 92,457/184,073 (~50%) of people vaccinated in study completed the 7-month follow-up survey without comparison of those followed vs LTFU. No such breakdown presented for unvaccinated cohort."
548,rob_screen1,mehr0035,"2025-09-08 09:31:06","compared vaccines (e.g., Moderna, AstraZeneca)"
548,rob_screen2,flemi644,"2025-09-15 16:48:26","no adjusted models for AE outcomes"
549,nos_cc_2,moat0011,"2025-09-04 15:49:51","""To ensure
balanced ILI selection, approximately five patients are
recruited daily per sentinel hospital, with sampling dis-
tributed throughout the day whenever possible.""... not a random sample or all presenting with ILI, which introduces potential for bias"
549,nos_cc_4,ulric063,"2025-09-25 21:03:46","Updating to 'no history of disease' to align with guidance"
549,nos_cc_5,moat0011,"2025-09-04 15:56:17","Age, comorbidities, current/previous season vaccination"
549,ve_adult_vax_n,flemi644,"2025-08-25 10:59:05","18-59 y"
549,ve_child_vax_n,flemi644,"2025-08-25 10:57:45","6-17 years"
549,ve_elder_vax_n,flemi644,"2025-08-25 11:00:05","60 + years"
549,ve_infant_vax_n,flemi644,"2025-08-25 10:54:10","Children 0-5 years"
549,ve_vax_type,flemi644,"2025-08-25 10:52:36","influenza vaccinations in Beijing during the 2024/25 season 
are inactivated influenza vaccines, with 87.1% being trivalent and 12.9% quadrivalent."
550,ae_outcome_4,flemi644,"2025-08-25 11:44:39","Hemorrhagic stroke"
550,ae_outcome_5,flemi644,"2025-08-25 11:46:46","Ischemic Stroke"
550,ae_outcome1_unvax_n,flemi644,"2025-08-25 11:39:44","control period"
550,design,flemi644,"2025-08-25 11:10:07","Observational, self-controlled risk interval study comparing AESI incidence in a pre-specified risk window after vaccination vs a control window after a 30-day washout"
550,nos_coh_1,moat0011,"2025-09-08 17:29:44","commercially-insured individuals in the US"
550,nos_coh_2,moat0011,"2025-09-08 17:28:25","since the ""controls"" are those with AESIs in the ""control period"", they could not have also had AESIs in the ""risk period"" (cases), therefore are from a different pop'n"
550,nos_coh_4,flemi644,"2025-09-15 17:04:50","356-day clean window prior to vaccination. Would change to yes?"
551,nos_cc_4,ulric063,"2025-09-25 21:01:43","Updating to 'no history of disease' to align with guidance"
551,population,abersm.gmail.com,"2025-07-30 14:52:17","Actual age criteria: age >= 60"
551,population_disagg,abersm.gmail.com,"2025-07-30 15:23:20","Data re disaggregated by 60-74, 75+"
551,ve_em_type,abersm.gmail.com,"2025-07-30 14:55:52","(1 - adjusted OR)*100"
551,ve_outcome_prime,abersm.gmail.com,"2025-07-30 15:00:17","RSV-associated hospitalization"
551,ve_overall_em,abersm.gmail.com,"2025-07-30 15:22:01","Unweighted (not inverse probability weighted)"
551,ve_overall_em_adj,abersm.gmail.com,"2025-07-30 15:22:14","Unweighted (not inverse probability weighted)"
551,ve_overall_em_ci,abersm.gmail.com,"2025-07-30 15:22:18","Unweighted (not inverse probability weighted)"
552,epi_ifr_rsv,stodd046,"2025-08-06 15:20:51","Authors group death with invasive mechanical ventilation"
553,epi_hospitalization_covid,flemi644,"2025-08-25 12:10:48","Vaccination = any U.S. licensed MRNA vaccine. Others excluded."
553,epi_medical_covid,flemi644,"2025-08-25 12:10:53","Vaccination = any U.S. licensed MRNA vaccine. Others excluded."
554,ae_outcome_v2,abersm.gmail.com,"2025-07-30 15:58:44","Adverse events were defined as ""myocarditis"" and  ""pericarditis ""using preferred terms in MedDRA. We defined vaccine-induced myocarditis/pericarditis as adverse event reports within the  ""narrow""  range. Furthermore, if  myocarditis/pericarditis was not described in the adverse event report, we defined the
adverse event as out of scope such as myocarditis/pericarditis."
554,ae_outcome1_longterm_yn,abersm.gmail.com,"2025-07-30 15:41:06","Death reported"
554,ae_outcome1_longterm_yn_v2,abersm.gmail.com,"2025-07-30 15:57:22",Death
554,ae_outcome1_otherinfo_yn,abersm.gmail.com,"2025-07-30 15:41:39","Time to onset following vaccination, sex"
554,ae_outcome1_otherinfo_yn_v2,abersm.gmail.com,"2025-07-30 15:57:36","Time to onset after vaccination, sex"
555,ae_outcome1_longterm_yn,abersm.gmail.com,"2025-07-30 16:08:39","Death, imaging abnormalities (cardiac MRI), persistent symptoms"
555,ae_outcome1_longterm_yn_v2,abersm.gmail.com,"2025-07-30 16:09:14","Death, imaging abnormalities (cardiac MRI), persistent symptoms"
555,design,abersm.gmail.com,"2025-07-30 16:06:13","Retrospective cohort"
556,ae_outcome1_em_value,stodd046,"2025-08-07 15:16:28","Authors merely say that acute MI was observed in 0.1% of vaccinated group, 0% of placebo group"
557,ae_outcome1_unvax_y,flemi644,"2025-08-25 12:43:14","38126 stroke events total - 1309 that occurred within 30 days of vaccination."
557,ae_outcome1_unvax_y,scottja.stanford.edu,"2025-08-26 00:41:21","The total number of stroke events was 38,126. Subtracting the 1,309 stroke events that occurred within 30 days of vaccination gives 38,126 - 1,309 = 36,817"
557,ae_outcome1_vax_n,flemi644,"2025-08-25 12:40:18","ever vaccinated during study window"
557,ae_outcome1_vax_y,flemi644,"2025-08-25 12:40:54","within 30 days of vaccination"
557,ae_outcome1_vax_y,flemi644,"2025-08-25 12:48:01","Table 1 lists ""Within 30 days: 16,004 events"" alongside HR 0.66 (0.65-0.68) with the footnote ""time windows are not mutually exclusive."" Given earlier text (1,309 strokes within 30 days of vaccination) and the step-up pattern 284→601→905→1286, ""16,004"" is likely an error. Abstract and text both list as 1309."
560,population,flemi644,"2025-08-12 12:55:47","All adults 18+ with cute respiratory infection "
560,ve_overall_em_adj,flemi644,"2025-08-12 13:19:31","Overall VE not reported"
560,ve_overall_vax_y_2,flemi644,"2025-08-12 13:14:42","from Figure s1"
561,nos_cc_4,ulric063,"2025-09-25 21:00:27","Updating to 'no history of disease' to align with guidance"
565,design,abersm.gmail.com,"2025-07-31 10:11:30","Data provided to calculate incidence of events but study is primarily a case series"
566,nos_coh_1,moat0011,"2025-09-08 15:16:00","conducted on all students who had COVID-19 vaccine
from July 12, 2021 to March 23, 2022, at Gifu University - a national
general university in Japan."
566,nos_coh_8,moat0011,"2025-09-08 15:18:21","only included individuals in analysis that had complete data for annual health checkups"
567,design,moat0011,"2025-08-25 09:05:31","Used a cross-sectional design to obtain incidence info, later paired case/controls."
567,domain_ae_include_vax,moat0011,"2025-08-25 09:01:57","CoronaVac, AZD1222, or BNT162b2 COVID-19 vaccines"
567,population_disagg,moat0011,"2025-08-25 09:06:01","Only age < 60"
568,rob2_data1,mehr0035,"2025-09-07 13:19:08","118 of 124 overall; 59 of 64 for SD and 59 of 60 for HD"
568,rob2_random1,mehr0035,"2025-09-07 13:16:03","Study protocol available for reference: https://cdn.clinicaltrials.gov/large-docs/61/NCT03179761/Prot_SAP_000.pdf"
569,ve_vax_type,flemi644,"2025-08-25 15:00:10","Commercial QIV, Not U.S. Licensed, but comparable (Shenzhen Sanofi Pasteur Biological Products Co., Ltd.)"
570,ae_outcome1_vax_n,ejholmes,"2025-08-25 14:55:01","Dose 2, Pfizer"
570,ae_outcome1_vax_n_2,ejholmes,"2025-08-25 14:59:08","Dose 2"
570,domain_ae_include_vax,ejholmes,"2025-08-25 14:38:23","AZD, Pfizer, Moderna"
570,nos_cc_1,moat0011,"2025-09-08 14:25:16","Self report"
570,nos_cc_2,moat0011,"2025-09-08 14:26:20","CANVAS uses participant-based surveillance, data collected from surveys"
572,population_disagg,abersm.gmail.com,"2025-07-31 10:16:46","Individual patient data provided"
574,ae_outcome1_disagg,abersm.gmail.com,"2025-07-31 10:48:19","But raw data are publicly available."
574,ae_outcome1_disagg_2,abersm.gmail.com,"2025-07-31 10:49:23","But raw data are publicly available."
574,ae_outcome1_longterm_yn_2,abersm.gmail.com,"2025-07-31 10:49:37","But raw data are publicly available."
574,ae_outcome1_otherinfo_yn_2,abersm.gmail.com,"2025-07-31 10:49:32","But raw data are publicly available."
574,date_end_year,abersm.gmail.com,"2025-07-31 10:37:18","Methods section states 10/2022 was cutoff. Figure 1 shows data up to 10/2021 but only includes 69 of 86 total cases"
576,nos_coh_1,mehr0035,"2025-09-05 16:20:48","HCWs part of the BRACE trial"
576,rob_domain_aensi_other,mehr0035,"2025-09-05 16:18:34","Also: local other than pain (i.e., redness, swelling, tender, itch, regional lymphadenopathy), systemic (headache, fatigue, muscle ache, joint ache, fever, chill, vomiting, diarrhea), and allergic (uticaria, swollen lips, cough/wheeze)"
576,rob_type,mehr0035,"2025-09-05 16:19:30","nested cohort study among HCWs in Australia and Brazil"
579,rob2_interv6,ulric063,"2025-09-20 16:18:09","Safety data are
presented descriptively in the safety population (all randomized
participants who received RSVpreF or placebo)."
580,domain,flemi644,"2025-08-26 12:58:26","VE is out of range"
580,rob_outcome_ve,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-07 21:45:08","from the paper: ""COVID-19 infection, determined by a positive PCR or RAT result; (2) 28-day
hospitalization after COVID-19 infection, determined by admission
to a hospital within 28 days after COVID-19 infection; (3) severe
COVID-19, which was defined as an ICU admission or use of ventilatory support within 7 days after COVID-19 infection; and (4) 28-
day mortality after COVID-19 infection, which was defined as death
within 28 days after COVID-19 infection"""
580,ve_outcome_two,scottja.stanford.edu,"2025-08-26 01:16:03","VE vs severe COVID-19, which was defined as ""an ICU admission or use of ventilatory support"
580,ve_overall_em_adj_2,scottja.stanford.edu,"2025-08-26 01:19:00","2-dose comparison"
580,ve_overall_em_adj_3,scottja.stanford.edu,"2025-08-26 01:24:02","3-dose comparison HR was 0.457."
580,ve_overall_em_ci_3,scottja.stanford.edu,"2025-08-26 01:24:23","3-dose comparison CI was 0.372-0.561"
581,design,abersm.gmail.com,"2025-07-31 10:56:57","Study also includes a cross-sectional analysis of survey data but less useful than VAERS data"
581,population_disagg,abersm.gmail.com,"2025-07-31 10:58:14","Not disaggregated by specific vaccine"
583,rob_screen1,mehr0035,"2025-09-06 10:10:50","ancestral monovalent vs. bivalent vaccines"
583,ve_adult_em_adj_2,emeyerowit.montefiore.org,"2025-08-27 19:36:19","Supplementary Table 1"
583,ve_adult_em_ci,emeyerowit.montefiore.org,"2025-08-27 19:34:36","SI Table 1 (Supplementary)"
583,ve_adult_vax_n,emeyerowit.montefiore.org,"2025-08-27 19:34:00","< 60"
583,ve_adult_vax_n_2,emeyerowit.montefiore.org,"2025-08-27 19:36:01","< 60"
583,ve_elder_vax_n,emeyerowit.montefiore.org,"2025-08-27 19:34:43",">60 years"
583,ve_elder_vax_n_2,emeyerowit.montefiore.org,"2025-08-27 19:36:23",>60
583,ve_overall_em_adj,emeyerowit.montefiore.org,"2025-08-27 19:35:25","Table 2"
583,ve_overall_em_adj_2,emeyerowit.montefiore.org,"2025-08-27 19:37:02","Table 2"
584,domain_ae_include_vax,ejholmes,"2025-08-25 13:39:20","BNT162b2, mRNA-1273, ChAdOx1, and
Ad26.COV2.S,"
585,domain,moat0011,"2025-08-25 15:15:39","This article presents data for 3 different studies- results are separated by study"
585,nos_cc_4,ulric063,"2025-09-25 20:58:58","Updating to 'no history of disease' to align with guidance"
585,population,moat0011,"2025-08-25 15:16:06","2-17y, 18-64y, 65+y"
585,ve_child_vax_n,moat0011,"2025-08-25 15:35:13",2y-17y
585,ve_child_vax_n_v2,moat0011,"2025-08-25 16:10:30",2y-17y
585,ve_child_vax_n_v2_v3,moat0011,"2025-08-25 16:20:57",2y-17y
585,ve_vax_type,moat0011,"2025-08-25 15:34:40","GB-PC Study Results"
585,ve_vax_type_v2,moat0011,"2025-08-25 15:39:17","Results for EN-H study"
585,ve_vax_type_v2_v3,moat0011,"2025-08-25 16:19:52","Results from SC-H study"
586,ae_outcome1_unvax_n,sundaram.maria.marshfieldresearch.org,"2025-08-06 13:45:09","Number of people vaccinated *separately* (i.e., not coadministered, but received 2 vaccines 28 days apart)"
586,ae_outcome1_vax_n,sundaram.maria.marshfieldresearch.org,"2025-08-06 13:44:34","Number of people in *coadministration* group"
589,ae_outcome1_em_ci,ulric063,"2025-08-25 17:44:00","Not estimable"
589,ae_outcome1_em_value,ulric063,"2025-08-25 17:43:46","Not estimable"
589,ae_outcome1_unvax_n,ulric063,"2025-08-25 17:42:45","Number with sequential vaccination"
589,ae_outcome1_vax_n,ulric063,"2025-08-25 17:42:32","Number with concomitant vaccination with PPSV-23"
589,coadmin_ae_describe,ulric063,"2025-08-25 17:33:51","Adjusted IRR compared to sequential administration"
590,population,abersm.gmail.com,"2025-08-02 10:55:45","Age criteria (for study inclusion) not mentioned. Age range of patients in study 2-41 years"
591,domain_ae_include_vax,abersm.gmail.com,"2025-08-02 10:48:34","Ad26.COV2.S and NVX-CoV2373 also included in study but no IRR calculated for these vaccines (0 PMR cases for these vaccines. Total number who received these vaccines not mentioned)."
591,population,abersm.gmail.com,"2025-08-02 10:50:13","Age >= 50"
591,population_disagg,abersm.gmail.com,"2025-08-02 10:50:54","Age not disaggregated by vaccine type."
594,rob_outcome_ve,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-07 22:13:27","long COVID"
595,rob_outcome_epi,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-09-07 22:25:47","death while hospitalized for COVID or influenza"
598,rob_outcome_ae,joseph.ladines-lim.pennmedicine.upenn.edu,"2025-08-29 16:04:50","I selected myocarditis but stroke was also evaluated"
601,immunocomp_describe,stodd046,"2025-08-22 14:14:24",""" These underlying
medical conditions included diabetes, hypertension, heart disease, chronic
pulmonary conditions, weakened immune system, cancer, kidney failure,
and a body mass index (BMI) >30"""
601,nos_coh_1,ulric063,"2025-09-21 16:24:18","a cohort of 5079 participants from a
prospective observational trial of individuals in the PerMed study +anonymized EHRs of 250,000 randomly selected members of MHS who were members throughout the entire period"
602,nos_xs_3,ejholmes,"2025-08-29 12:34:45","VSD verification acceptable"
605,date_end_year,abersm.gmail.com,"2025-07-31 11:03:14","This is the end date for Bell's palsy diagnosis. End date for vaccination is 3/1/2022"
607,design,abersm.gmail.com,"2025-07-31 11:14:42",Survey
610,ae_outcome1_otherinfo_yn,abersm.gmail.com,"2025-08-02 11:12:48","Age, sex, time to onset (after vaccination), whether MRI/echo abnormal, whether troponin elevated"
610,ae_outcome1_otherinfo_yn_v2,abersm.gmail.com,"2025-08-02 11:16:32","Age, sex, time to onset (after vaccination), whether MRI/echo abnormal, whether troponin elevated"
610,design,abersm.gmail.com,"2025-08-02 11:09:06","Retrospective study of myopericarditis, myocarditis, and pericarditis"
610,population_disagg,abersm.gmail.com,"2025-08-02 11:11:26","Individual patient data provided"
612,nos_coh_1,calba1.mgh.harvard.edu,"2025-09-16 08:39:39","Exposed cohort self-selected into the study: ""...based on their willingness to be vaccinated..."""
612,nos_coh_5,scottja.stanford.edu,"2025-09-16 01:25:00","study controls for sex the most"
612,nos_coh_6,calba1.mgh.harvard.edu,"2025-09-16 08:36:28","This is for primary AE outcome as defined on previous page. Independent blind assessment for other outcomes like kidney graft function."
612,nos_coh_8,calba1.mgh.harvard.edu,"2025-09-16 08:38:15","For study diary component, ~86% (79/91 among vaccinated and 31/36 unvaccinated) completed diaries."
613,nos_cc_4,ulric063,"2025-09-25 20:54:15","Updating to 'no history of disease' to align with guidance"
614,population_disagg,abersm.gmail.com,"2025-07-31 11:22:49","Not disaggregated by specific vaccine"
615,nos_cc_2,moat0011,"2025-09-04 17:00:57","ntinel hospitals were
requested to collect pharyngeal swabs each week from ≥20 patients
with ILI who visited the outpatient clinic within 3 days of illness onset."
615,nos_cc_4,ulric063,"2025-09-25 20:52:37","Updating to 'no history of disease' to align with guidance"
615,population,moat0011,"2025-08-25 13:28:31","0-5y
6-18y
19-59y
>=60y"
615,ve_adult_vax_n,moat0011,"2025-08-25 14:02:01",19y-59y
615,ve_child_vax_n,moat0011,"2025-08-25 13:44:20",6y-18y
615,ve_elder_vax_n,moat0011,"2025-08-25 14:03:13",>=60y
615,ve_infant_vax_n,moat0011,"2025-08-25 13:40:12",0-5y
616,coadmin_vax_prime,flemi644,"2025-08-25 15:34:22","Non U.S. licensed, but comparable"
616,population,flemi644,"2025-08-25 15:33:25","Adults 60+"
617,ve_adult_em,ulric063,"2025-08-25 16:33:09","stratified into 2 age groups: 
18-49: 39 (36-41)
50-64: 27 (23-30)"
617,ve_adult_em_adj,ulric063,"2025-08-25 16:33:13","stratified into 2 age groups:
18-49: 36
50-64: 30"
617,ve_adult_em_ci,ulric063,"2025-08-25 16:33:17","stratified into 2 age groups:
18-49: 46-50
50-64: 33-39"
617,ve_adult_unvax_n,ulric063,"2025-08-25 16:33:00","stratified into 2 age groups: 
18-49: 189129
50-64: 96148"
617,ve_adult_unvax_y,ulric063,"2025-08-25 16:33:04","stratified into 2 age groups: 
18-49: 36171
50-64: 28579"
617,ve_adult_vax_n,ulric063,"2025-08-25 16:31:42","stratified into 2 age groups: 
18-49: 26435
50-64: 10861"
617,ve_adult_vax_y,ulric063,"2025-08-25 16:31:48","stratified into 2 age groups: 
18-49: 3334
50-64: 2575"
618,ve_adult_em,moat0011,"2025-08-25 17:19:41","VE 18-49y: 42 (41-44)
VE 50-64y: 30(27-32)"
618,ve_adult_vax_n,moat0011,"2025-08-25 17:17:22","Combined the 18-49 and 50-64 subgroups here"
619,ve_child_em,ejholmes,"2025-08-25 16:28:18","For 2023-24 season; Flu A&B"
619,ve_child_vax_n,moat0011,"2025-08-25 14:56:21","3-9y; VE= 41% (95% CI: 34-47)
9-< 18; VE= 23% (-3-43)"
619,ve_infant_vax_n,moat0011,"2025-08-25 14:54:01","0.5-< 3y"
619,ve_overall_em,ejholmes,"2025-08-25 16:29:50","Across all flu seasons (2021-2024); Flu A&B"
620,nos_xs_1,ejholmes,"2025-09-06 15:50:13","Voluntary parent recruitment via text message; selection bias likely high"
620,nos_xs_2,ejholmes,"2025-09-06 15:50:21","~20% response rate"
620,nos_xs_3,ejholmes,"2025-09-06 15:50:41","Parent self-report"
621,ve_comparator1,scottja.stanford.edu,"2025-08-26 01:55:30","The study compared those who received an updated dose to a group of patients who did not receive an updated dose. This group included both patients who had received previous COVID-19 vaccine doses and those who had never received a dose."
621,ve_outcome_num,scottja.stanford.edu,"2025-08-26 02:07:10","The study evaluated a composite outcome of invasive mechanical ventilation or death. However, the results presented for this outcome are adjusted odds ratios comparing the JN lineage to the XBB lineage, not a direct VE against an unvaccinated group."
621,ve_overall_em_adj,scottja.stanford.edu,"2025-08-26 02:02:09","The study also provides data for the JN lineage. The adjusted VE against JN lineage hospitalization was 32.7% (95% CI, 1.9-53.8%). The number of vaccinated cases was 38, and the number of vaccinated controls was 844."
621,ve_overall_vax_n,scottja.stanford.edu,"2025-08-26 02:01:00","XBB lineage"
623,nos_xs_1,ejholmes,"2025-09-06 15:53:50","VAERS - voluntary reporting, not independently verified"
623,nos_xs_3,ejholmes,"2025-09-06 15:54:24","Outcomes not verified by HC provider or considered causal"
627,ve_child_vax_n,emeyerowit.montefiore.org,"2025-08-11 21:09:38","Total ""catch up"" cohort, including premies"
627,ve_infant_vax_n,emeyerowit.montefiore.org,"2025-08-11 21:09:20","""total ""born during season"" cohort"" including premies"
628,population,moat0011,"2025-08-25 13:12:35",">=80 years"
628,ve_elder_vax_n_2,arpey001,"2025-08-26 10:59:59","Only full vaccine, not partial"
628,ve_elder_vax_y_2,arpey001,"2025-08-26 11:05:57","Only full vaccine group"
629,ve_overall_em,ncmccann.bu.edu,"2025-08-11 22:00:37",adjusted
629,ve_overall_em_2,ncmccann.bu.edu,"2025-08-11 22:02:22",adjusted
629,ve_timeline,scottja.stanford.edu,"2025-08-11 23:52:33","""Eligible infants could therefore be aged between0 and 5 months."" ""This study evaluating the effectiveness of RSVpreF
maternal vaccination within the first 5 months of
national implementation indicated that vaccination was
effective against RSV-associated ALRI leading to hospitalisation. """
630,epi_hospitalization_rsv,ncmccann.bu.edu,"2025-08-12 10:55:51","hospitalizations / infections; summed table 1 numbers to get overall %"
630,epi_hospitalization_rsv,flemi644,"2025-08-12 11:24:54","added per 100K rates"
630,epi_ifr_rsv,ncmccann.bu.edu,"2025-08-12 10:58:27","in-hospital mortality / total infections (would miss mortality outside of hospital)"
630,epi_ifr_rsv,flemi644,"2025-08-12 11:25:07","added per 100k rates"
630,epi_sample_rsv,ncmccann.bu.edu,"2025-08-12 10:53:37","1660 total identified with infections (CD+ALF+SNF); incidence rates are calculated from broader population data"
631,ve_adult_em,ncmccann.bu.edu,"2025-08-11 22:28:44",adjusted
631,ve_overall_unvax_n_3,scottja.stanford.edu,"2025-08-12 00:28:57","2,506 pregnant + 43,671 non-pregnant"
631,ve_overall_unvax_y_3,scottja.stanford.edu,"2025-08-12 00:29:06","862 pregnant + 11,769 non-pregnant"
631,ve_overall_vax_n_3,scottja.stanford.edu,"2025-08-12 00:28:20","1,033 pregnant + 14,038 non-pregnant"
631,ve_overall_vax_y_3,scottja.stanford.edu,"2025-08-12 00:28:35","249 pregnant + 2,114 non-pregnant"
631,ve_overall_yn_3,ncmccann.bu.edu,"2025-08-11 22:34:46","Added this under its own outcome for combined urgent care and ED visits b/c the overall population estimate for non preg + preg women is not stratified by visit type"
633,ae_incidence_yn,stodd046,"2025-08-25 11:42:29","Events/person days = 34/14930"
633,ae_incidence_yn_2,stodd046,"2025-08-25 11:42:51","Events/person days = 71/40130"
633,ae_incidence_yn_2_v2,stodd046,"2025-08-25 11:48:42","Events/person days = 51/26093"
633,ae_incidence_yn_3,stodd046,"2025-08-25 11:43:20","Events/person days = < 20/7897"
633,ae_incidence_yn_3_v2,stodd046,"2025-08-25 11:49:56","Events/person days = 0/784"
633,ae_incidence_yn_4,stodd046,"2025-08-25 11:46:35","Events/person days = < 20/3047"
633,ae_incidence_yn_4_v2,stodd046,"2025-08-25 11:51:48","Events/person days = < 20/1475"
633,ae_incidence_yn_v2,stodd046,"2025-08-25 11:48:02","Events/person days = < 20/7897"
633,ae_outcome_4,stodd046,"2025-08-25 11:44:47",Myo/pericarditis
633,date_start_month,stodd046,"2025-08-25 11:39:44","study start date, patient selection occurred 9/23-6/24"
633,nos_xs_1,moat0011,"2025-09-08 11:49:09","National COVID Cohort Collaborative"
633,nos_xs_2,ulric063,"2025-09-13 16:08:48","""Furthermore, our study leveraged the N3C database, which
includes data from over 2 million patients across more than 70 institutions nationwide, to construct a cohort of over 240,000 patients-
ensuring a sufficient sample size to detect rare vaccine-associated adverse events. """
633,nos_xs_3,moat0011,"2025-09-08 11:51:02","No description of outcome evaluation"
633,nos_xs_3,nebasta,"2025-09-27 23:01:15","""We identified these events using standard concept IDs for specific disease codes (see Supplementary Table 1)"" and ""Records of specific outcomes from outpatient, inpatient, and emergency department settings were all retrieved from the dataset."""
634,nos_xs_1,moat0011,"2025-09-08 11:23:13","Volunteers; no further description of where found/sourced"
634,nos_xs_2,moat0011,"2025-09-08 11:23:31","No justification"
634,nos_xs_3,ulric063,"2025-09-13 15:52:24","Did not assess outcome among people who became infected with COVID-19 during the study

Outcome measurement not consistent time frame: ""The examination data of the patients within nearly one week before the vaccination as a control group and the data within the earliest 2 months after the second dose of vaccination were evaluated and compared."""
634,rob_type,ulric063,"2025-09-13 15:49:11","Pre- and post-vaccination measurements. Cases serve as their own controls"
635,nos_xs_1,ejholmes,"2025-09-06 19:44:36","Vigibase - WHO pharmacovigilance; mix of voluntary reporting w/o verification"
635,nos_xs_2,ejholmes,"2025-09-06 19:44:59","Large dataset, but sample unjustified"
635,nos_xs_3,ejholmes,"2025-09-06 19:45:18","Not independently verified clinical outcome"
635,virus,scottja.stanford.edu,"2025-08-14 23:12:03","The covid vaccine data wasn't disaggregated and the highest signal was for flu vaccines, which I entered as a comment."
636,exclude,scottja.stanford.edu,"2025-08-12 00:49:02","This meets our protocol criteria, in my opinion."
636,exclude,emeyerowit.montefiore.org,"2025-08-12 06:35:07",Agree
636,rob_type,nebasta,"2025-09-09 10:41:41","Contacted Caitlin to mark this high risk of bias - case series without a comparator"
637,rob2_data1,nebasta,"2025-09-07 19:34:18","Fig 2 shows more participants were lacking outcomes in the sequential group"
637,rob2_interv6,nebasta,"2025-09-07 19:30:42","""Immunogenicity analyses were conducted on the ""per protocol"" population, which consisted of all randomized participants without protocol deviations that may substantially affect results of the immunogenicity endpoints."""
638,date_end_month,flemi644,"2025-08-15 17:34:28","Date cutoff October 2024 (methods->assessments)"
638,domain_ae_include_list,flemi644,"2025-08-15 17:35:47","Myocarditis/pericarditis was monitored as an AESI; none reported"
638,rob_screen1,nebasta,"2025-09-06 18:14:04","""single-arm study"" - follow-up to an RCT but enrolled only a subset of previous participants and all got same intervention. No attempt to control of confounding for the AE assessments, either"
639,domain_ae_include_yn,ulric063,"2025-08-20 13:19:49","19 participants excluded for severe adverse events leading to hospitalization within 7 days of vaccination. Not disaggregated by vaccine type. (respiratory distress (n=4), kidney failure (n=2), chest pain & cardiac problem (n=7), severe anaphylactic shock (n=5))."
639,nos_coh_1,ejholmes,"2025-09-06 21:21:49",HCWs
639,nos_coh_7,ejholmes,"2025-09-06 21:32:45","7 days"
639,population,ulric063,"2025-08-20 13:10:26","Adults over the age of 18; unclear if/how many participants were >65"
640,coadmin_ae_describe,ulric063,"2025-08-20 14:23:42","Authors report: Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/
RZV alone), showing no elevated risks."
640,coadmin_ae_yn,ulric063,"2025-08-20 14:34:45","No statistical test of the association, so selecting ""yes"" here to provide detailed count data aon each outcome below. Authors report: Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/
RZV alone), showing no elevated risks."
640,coadmin_outcome_other,ulric063,"2025-08-20 14:26:57","Authors report: Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/
RZV alone), showing no elevated risks."
640,design,ulric063,"2025-08-20 13:58:26","Data mining using VAERS reports"
640,rob_outcome_ae,ejholmes,"2025-08-29 12:49:15","myocarditis also included"
640,rob_screen2,ejholmes,"2025-08-29 12:54:49","Some results stratified"
641,ae_outcome,ulric063,"2025-08-21 17:37:20","Pericarditis was presented as a separate outcome:
8 events /77,417 PY with JN1
338 events /1,310,773 PY without JN1
IRR: 0.42 (0.20-0.89)"
641,ae_outcome1_unvax_n_2,ulric063,"2025-08-21 17:39:10","denominator is person-years"
641,ae_outcome1_unvax_n_3,ulric063,"2025-08-21 17:41:34","denominator is person-years"
641,ae_outcome1_vax_n,ulric063,"2025-08-21 17:32:57","Denominator is 77,489 person-years"
641,ae_outcome1_vax_n_2,ulric063,"2025-08-21 17:38:45","denominator is person-years"
641,ae_outcome1_vax_n_3,ulric063,"2025-08-21 17:40:58","denominator is person-years"
641,ae_vax_type,ulric063,"2025-08-21 17:51:24","JN.1-containing vaccines"
641,domain_ae_num,ulric063,"2025-08-21 17:08:10","Vaccinated with a primary course and one booster Covid-19 vaccine, defined as registered three previous Covid-19 vaccines received with the BNT162b2 and/or mRNA-1273 as well
as and/or AZD1222 vaccine (the latter as part of the primary vaccination course only). Other vaccine types were rare within our source population and were treated as censoring events."
641,nos_coh_4,nebasta,"2025-09-06 18:07:02","""Adverse events were  identified as the first hospital contact with a recorded outcome diagnosis"""
642,ae_incidence_yn_v2,ejholmes,"2025-08-25 14:25:22","0 CVST cases found with mRNA COVID vaccination"
642,ae_incidence_yn_v3,ejholmes,"2025-08-25 14:26:05","0 CVST cases found with mRNA COVID vaccination"
642,ae_outcome,ejholmes,"2025-08-25 14:24:11","0 CVST cases found with J&J vaccination"
642,rob_screen1,nebasta,"2025-09-06 17:58:40","Analysis of a registry of patients with any thrombotic event - case series with no comparator group"
643,coadmin_vax2_type,emeyerowit.montefiore.org,"2025-08-14 12:21:41","COVID vaccines not disaggregated. Only Moderna and Pfizer allowed"
643,nos_xs_2,nebasta,"2025-09-06 17:53:57","Used all eligible participants with tinnitus, which is the AE outcome, sample size not discussed"
644,ae_outcome1_em_type,cdugdale.mgh.harvard.edu,"2025-09-26 14:50:19","Adjusted OR"
644,nos_cc_3,ulric063,"2025-09-27 06:43:31","""We matched 75 cases who delivered preterm with 519 controls who delivered at term, with matching performed based on estimated due date within 14 days.""
AKU: potential for mis-classification of unvaccinated controls: ""After matching, any controls who received RSVpreF vaccination after the delivery date of their matched case were classified as unvaccinated"". This should result in a more conservative estimate."
644,nos_cc_5,ulric063,"2025-09-27 06:46:48","Conducted a ""multivariable conditional logistic regression model adjusting for relevant covariates"""
644,rob_type,ulric063,"2025-09-27 06:36:01","Nested case control study of pre-term delivery (< 37 weeks vs >=37 weeks)"
